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Biocatalysis is a green and useful tool for chemical production, especially for 
the production of enantiopure fine chemicals and pharmaceutical intermediates, with 
wide industrial application and huge market. Nevertheless, many biocatalytic reactions 
are still not efficient for practical application, and most of industrial biotransformations 
are mainly based on one-step biocatalysis. To address some of these problems in this 
Ph. D. thesis, I aim 1) to engineer a recombinant whole-cell biocatalyst expressing an 
epoxide hydrolase for green and efficient production of enantiopure epoxides and 
vicinal diols, 2) to develop novel whole-cell based cascade biocatalysis for asymmetric 
dihydroxylation of alkenes to practically prepare both enantiomers of the 
corresponding vicinal diols in high ee and yield, and 3) to develop novel and efficient 
one-pot multi-step cascade biocatalysis to prepare enantiopure hydroxy acid, amino 
alcohol, and amino acid from styrene or bio-based L-phenylalanine.    
Firstly, a unique epoxide hydrolase (SpEH) from Sphingomonas sp. HXN-200 
was successfully identified and cloned based on genome sequencing for 
enantioselective hydrolysis of racemic and meso-epoxides to prepare the corresponding 
(S)-epoxides and (R, R)-vicinal diols, respectively. The engineered E. coli (SpEH) 
highly expressed SpEH and gave 172 times higher cell-based activity for the hydrolysis 
of styrene oxide than that of Sphingomonas sp. HXN-200. Kinetic resolution of several 
selected racemic styrene oxides with the rest cells of E. coli (SpEH) produced the 
corresponding (S)-styrene oxides in 98.0-99.5% ee and 35.1-46.5% yield. Hydrolysis 
of three cyclic meso-epoxides afforded the corresponding (R, R)-vicinal diols in 86-93% 
ee and 90-99% yield. Biotransformation at higher substrate concentration produced (S)-
styrene oxide in 430 mM (51 g/Lorg) and (1R, 2R)-cyclohexene diol in 500 mM (58 
g/L). The E. coli (SpEH) cells are highly active and easily available biocatalysts for the 
practical production of these useful and valuable enantiopure epoxides and vicinal diols.  
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Next, an intracellular epoxidation-hydrolysis cascade was developed for 
efficient asymmetric trans-dihydroxylation of aryl olefins to produce chiral vicinal 
diols by combining styrene monooxygenase (SMO) and epoxide hydrolase. E. coli 
(SSP1) was engineered to coexpress SMO and SpEH for efficient S-enantioselective 
dihydroxylation. On the other hand, for R-enantioselective dihydroxylation, E. coli 
(SST1) was engineered to coexpress SMO and the epoxide hydrolase from Solanum 
tuberosum (StEH), which has a complementary regioselectivity to SpEH. 
Biotransformation of 15 terminal aryl olefins with E. coli (SSP1) and E. coli (SST1), 
respectively, produced the corresponding 15 (S)-vicinal diols and 15 (R)-vicinal diols 
in high ee (99-84%) and high yield (>65%), respectively. The trans-dihydroxylation 
was also demonstrated on several non-terminal and cyclic aryl olefins to give diols in 
high ee and de, and the process was easily scaled up by using growing cells in a 
bioreactor. The cascade biocatalysis provides a green and useful synthetic tool to 
produce chiral vicinal diols, complementary to Sharpless cis-dihydroxylation.  
Finally, a modular approach was applied for one-pot multi-step cascade 
biocatalysis to achieve asymmetric oxy- and amino-functionalization of terminal 
alkene to produce chiral hydroxy acid, amino alcohol, and amino acid. The following 
enzyme modules were designed, constructed, and tested: (1) SMO-SpEH for 
converting alkene to 1,2-diol; (2) alcohol dehydrogenase-aldehyde dehydrogenase for 
converting 1,2-diol to α-hydroxy acid; (3) alcohol dehydrogenase-ω-transaminase for 
converting 1,2-diol to 1,2-amino alcohol; (4) hydroxy acid oxidase-α-transaminase for 
converting α-hydroxy acid to α-amino acid. Assembly of different modules in E. coli 
provided several whole-cell biocatalysts to convert styrene to (S)-mandelic acid, (S)-
phenylethanolamine, and (S)-phenylglycine in high ee and yield, respectively. In this 
work, cascade biocatalysis was harnessed to achieve asymmetric one-pot multi-step 
oxy- and amino-functionalization of hydrocarbons, which is useful but challenging in 
chemistry. The cascade transformation represents a novel artificial pathway, with no 
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natural counterparts. Furthermore, with one additional enzyme module (ammonia 
lyase-decarboxylase), enantiopure (S)-mandelic acid, (S)-phenylethanolamine, and (S)-
phenylglycine were also directly produced from bio-based L-phenylalanine. This 
provides the opportunity to produce these useful and valuable enantiopure chemicals 
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Chapter 1. Introduction 
This chapter provides the background, objectives, and organization of this thesis.  
1.1 Chiral Chemicals 
The word “Chirality” was derived from the Greek word meaning handedness. 
In chemistry, chiral chemicals are a huge group of asymmetric molecules with non-
superposable mirror image, which are similar to the left and right hands.[1] In biology, 
chirality is the key intrinsic feature of many macromolecules (e.g. proteins, DNAs), 
which serve as basis of life. The asymmetric molecular recognition and interaction 
between small chiral molecules and complex macromolecules in living organisms is 
the scientific base for the increasing industrial demand of enantiopure chiral 
chemicals.[1-3] For example, increasing numbers of active pharmaceutical ingredients 
were manufactured as single enantiomer forms, because different enantiomers of the 
drug have different interactions with the targeted receptor site in human body, resulting 
in different biological activities.[4, 5] 4 out of 5 best-selling drugs in US 2012 are 
enantiopure chiral drugs (Figure 1.1).[6] In addition, many agrochemicals and fragrance 
are also produced in enantiopure forms, due to the different effects on plants and 
phytopathogens and different odors of different enantiomers.[7-9] Therefore, it is gaining 
importance to develop technologies to produce chiral chemicals in high enantiopurities 
in an efficient, environmentally friendly, and sustainable way.  
Figure 1.1. Enantiopure chiral drugs in top 5 best-selling drugs in US 2012 (Adapted with 
permission, Copyright © American Chemical Society and Njardarson Group).[6] 
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1.2 Production of Chiral Chemicals 
Except for some naturally occurring chiral compounds (e.g. amino acids, 
carbohydrates) which were isolated directly, the majority of non-natural chiral 
chemicals were obtained by costly and cumbersome traditional technologies, such as 
physical separation (chiral chromatography, diastereomeric crystallization) from 
racemic compounds and chemical derivation (chiral pool synthesis) from enantiopure 
natural chemicals before early 1990s.[2-4] Recently, due to the rapid progress in 
stereoselective chemical transformation, more enantiopure chiral compounds were 
produced by kinetic resolution of racemic substrates and asymmetric synthesis from 
achiral substrates via chemocatalysis (organometallic catalysis and organocatalysis) 
and biocatalysis.[10-14] An example for production of chiral epoxide is shown Figure 1.2.  
Figure 1.2. Production of chiral epoxides by kinetic resolution (hydrolysis of racemic epoxide) 
or asymmetric synthesis (epoxidation of achiral alkene) via organometallic catalysis, 
organocatalysis, or biocatalysis. 
 
1.3 Biocatalysis 
Biocatalysis is the use of natural catalysts, enzymes, to catalyze chemical 
transformation.[15] The most remarkable feature of biocatalysis is often high to excellent 
selectivity (chemoselectivity, regioselectivity, and enantioselectivity), which is 
prerequisite to produce chiral chemicals in high enantiopurities.[16-27] Besides the high 
selectivity, biocatalysis also provides two important advantages comparing to 
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chemocatalysis in asymmetric organic synthesis. Biocatalysis is environmentally 
benign and less hazardous, because it usually occurs in aqueous buffer (less organic 
solvent used) at moderate temperature and pressure (less energy input), and enzyme is 
generally biodegradable without involving toxic heavy metals (common in 
organometallic catalysis).[16-27] The other advantage is that enzymes are generally 
cheaper than some precious metal catalysts. Thanks to the advance of recombinant 
DNA technology, most of enzymes were available by facile fermentation of 
recombinant microbes growing on inexpensive and renewable resources. Thus, 
biocatalysis is becoming a green and efficient synthetic tool for chiral chemical 
production.[16-27] Although various types of enzymes and biocatalytic processes have 
been explored in laboratory nowadays, many of them are still suffering from low 
efficiency (productivity and product concentration) and limited substrate and product 
scope. Robust enzymes and efficient biocatalytic processes are highly demanded to 
facilitate the translation of academic research into industrial implementations. 
Figure 1.3. Advantages and disadvantages of biocatalysis in general. 
 
1.4 Whole-Cell Biocatalysis  
Biocatalysis could be performed with different forms of biocatalyst, such as 
purified or immobilized enzymes (in vitro) and enzymes inside whole cells. The choice 
of forms often depends on a case-by-case basis. Whole cell is a popular choice because 
of its several advantages over in vitro biocatalysis (Figure 1.4).[28-32] Firstly, enzymes 
in whole cell are readily available from fermentation directly without further 
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downstream processes, e.g. disruption of cells and purification of enzymes. Secondly, 
enzymes would be more active in their natural environment (inside cell, for most 
enzymes), and possibly be more stable due to the protection of the membrane and cell 
walls. In addition, naturally existing cofactors (e.g. NAD(P)H, ATP) could be easily 
regenerated in whole cells, and this is particularly important for enzyme-catalyzed 
oxidoreductions.[28-32] Last but not the least, whole cells provide the context for co-
localization of multiple enzymes and enzyme components, which will increase the local 
concentration of enzymes and reduce the diffusion of intermediates in multistep 
catalysis.[33]  
Figure 1.4. Types of biocatalysis: in vitro biocatalysis and whole-cell biocatalysis. 
 
1.5 Cascade Biocatalysis 
Enzymes are especially suitable for multistep catalysis in one pot or one cell 
(cascade/tandem biocatalysis), because most of enzymes catalyze reactions in similar 
conditions as they occur in cellular metabolism naturally. Thus, performing cascade 
biocatalysis is attractive to circumvent the time-consuming, yield-decreasing, waste-
producing, and labor-demanding intermediate recovery and purification steps in 
traditional multistep synthesis.[34-40] Distinctive from metabolic engineering, cascade 
biocatalysis is designed and engineered in a bottom-up way and largely unlinked to the 
metabolism (except for cofactors).[34-40] It could be performed with different forms of 
biocatalysts, such as in vitro, whole cell, or mixture of in vitro and whole cell. By 
supplying different starting substrates, multistep biocatalysis could generate diverse 
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non-natural chemicals, especially chiral compounds in high enantiopurity (Figure 
1.5).[34-40] Although several interesting prototypes of cascade biocatalysis have been 
developed recently, the majority of them are with low efficiency, limited substrate 
scope, and only one enantiomer produced. Furthermore, novel types of biocatalytic 
cascades are still limited in academia but they are highly demanded for pharmaceutical 
and other chemical industries.  
Figure 1.5. Whole-cell based cascade biocatalysis. 
 
1.6 Thesis Objectives 
i) As mentioned above, many biocatalytic reactions are still not efficient for 
practical application, due to the low activity of biocatalysts and poor performance of 
processes. This problem persists in enantioselective hydrolysis of epoxides to produce 
enantiopure epoxides and vicinal diols. To address this gap, we aim to identify and 
clone a unique epoxide hydrolase (SpEH) from Sphingomonas sp. HXN-200, and 
develop a robust recombinant whole-cell biocatalyst and an efficient process for 
enantioselective hydrolysis of racemic and meso-epoxides to practically produce chiral 
epoxides and diols in high ee and high concentration.       
ii) Another current limitation in biocatalysis is that most of industrial 
biotransformations are mainly based on one-step biocatalysis. Although several types 
of cascade biocatalysis have been recently reported, most of them are still suffering 
from low productivity, limited substrate scope, and no access to multiple enantiomers. 
Thus, we aim to develop a whole-cell based epoxidation-hydrolysis cascade for 
efficient asymmetric trans-dihydroxylation of a range of aryl alkenes to access to both 
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enantiomers of the corresponding vicinal diols in high enantiopurity. The cascade 
biocatalysis process should be robust, scalable, and comparable to chemical 
asymmetric dihydroxylation.        
iii) To further address the gap of multistep biocatalysis and provide very novel 
cascade transformations with no natural or chemical counterparts, we propose to 
develop modular cascade biocatalysis for achieving asymmetric oxy- and amino-
functionalization of easily available alkenes to produce valuable chiral α-hydroxy acids, 
1,2-amino alcohols, and α-amino acids in high enantiopurity. To utilize renewable 
feedstock as starting material, we also aim to extend the cascade reactions to start from 
bio-based phenylalanine. These will serve as potential prototypes for future industrial 
implementation.  
Figure 1.6. Overall diagram summarizing the current works in the PhD thesis. 
1.7 Novelty and Significance of the Thesis  
i) The newly cloned SpEH is highly active and showing the highest S-
enantioselectivity for several epoxides, and thus enables the development of efficient 
biotransformation process to practically produce chiral epoxides and vicinal diols.   
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ii) The novel intracellular epoxidation-hydrolysis cascade provides access to 
both enantiomers of many aromatic vicinal diols in high ee, which is challenging in 
biocatalysis, and the method is much greener than Sharpless dihydroxylation.  
iii) The one-pot functionalization of terminal alkenes to chiral α-hydroxy acids 
and α-amino acids is unique, with no chemical or natural counterpart. The one-pot 
functionalization of terminal alkenes to 1,2-amino alcohols represents the first 
biocatalytic aminohydroxylation, being greener than existing chemical methods. 
iv) The cascade biocatalysis for converting L-phenylalanine to several types of 
chiral chemicals provides new opportunities for production of non-natural chemicals 
from renewable bioresource.   
1.8 Thesis Organization 
Chapter 1 briefly describes the introduction, objectives, and organization of 
this thesis.  
Chapter 2 gives an intensive literature review of biocatalysis for chiral 
chemical synthesis, with highlights on enzyme discovery and engineering, several 
classes of enzymes, and cascade biocatalysis.  
Chapter 3 presents the project of cloning a novel epoxide hydrolase and 
applying it for enantioselective hydrolysis of epoxides.  
Chapter 4 describes the work of cascade biocatalysis for asymmetric trans-
dihydroxylation of aryl olefins to vicinal diols.   
Chapter 5 describes the topic of a novel modular cascade biocatalysis to 
achieve asymmetric oxy- and amino-functionalization of aryl alkenes.   
Chapter 6 summarizes the finding and conclusion of this thesis, and gives 
recommendations for future directions.   
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Chapter 2 Literature Review 
This chapter provides a comprehensive review of the biocatalysis field with a 
particular focus on the enzyme discovery, whole-cell biocatalysis, and cascade 
biocatalysis.  
2.1 Biocatalysis in the Context of Biotechnology 
Biotechnology is a broad discipline of application of advances in life science 
for development of commercial products, distinguished from fundamental research. 
According to the application areas, modern biotechnology is divided into three main 
branches (Figure 2.1).[41]  
i) Green biotechnology for application in agriculture. One of the major fields 
is the development of genetic modified crops for better pathogen resistance (e.g. 
transgenic plants expressing insecticidal proteins),[42] better nutrition (e.g. golden rice 
with increased pro-vitamin A content),[43] and other purposes.  
ii) Red biotechnology for application in medicine. A great breakthrough is the 
development of therapeutic monoclonal antibodies (US sale ~$25 billion in 2012)[44] 
produced by cell culture technology. And a recent “hot spot” is regenerative medicine 
by induced pluripotent stem cells.[45]  
iii) White biotechnology (industrial biotechnology) for industrial purposes, e.g. 
production of chemicals, materials, and fuels. Although mankind has used 
bioprocessing such as brewing for thousands of years, it is not until recently that white 
biotechnology starts to attract great interests from both academia and industry, because 
it often utilizes renewable bioresource instead of dwindling fossil feedstock and 
provides green and non-toxic processes with reduced energy consumption and 
greenhouse gas emissions.[46-48]      
 2.1.1 Enzymatic Catalysis in White Biotechnology  
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Enzymatic catalysis (as a broad definition of biocatalysis) is central in white 
biotechnology (Figure 2.1). In some industries, enzymes produced by fermentation of 
microbes are directly used for numerous applications, e.g. for detergent application and 
for processing of food and animal feed.[49] In fermentation process, bio-based feedstock 
is converted to cell mass and metabolites through multiple enzymatic reactions 
(metabolism) of living microorganisms.[50, 51] In biological wastewater treatment, 
various organic pollutants and some inorganic nitrogen and phosphate are degraded to 
CO2 and converted to cell mass with microorganisms through enzyme catalyzed 
metabolism.[52] In biological fuel cell, electrical energy is generated from chemical 
energy via redox reactions catalyzed by enzymes in vitro or in vivo.[53] In this thesis, 
we particularly focus on industrial biotechnology for production of organic chemicals.   
Figure 2.1. Three main parts of Biotechnology, key position of enzymatic catalysis in white 
biotechnology, and biotransformation and fermentation for production of organic chemicals. 
 
2.1.2 Biotechnology for Production of Organic Chemicals  
Organic chemicals were firstly discovered and extracted from living organisms, 
and had been believed to be a privilege of living organisms. After Wöhler's synthesis 
of urea from the inorganic substrates in 1828, [54] researchers started to develop theories 
and methodologies to synthesis various organic compounds (natural or non-natural), 
which have profound impact on human life and the whole world. However, many 
natural organic chemicals are still produced by fermentation of microorganisms, as 
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primary and secondary metabolites, because they are difficult or uneconomical to 
produce by organic synthesis.  
Recently, with the advance in recombinant DNA technology, biotechnological 
production of small organic chemicals has been significantly improved both in 
efficiency and chemical complexity. Two different approaches were actively pursued:   
i) Biotransformation process (narrow meaning of biocatalysis): employ 
enzymes and microbial cells for transformation of natural or non-natural substrates to 
various products with one or several-step conversions.[16-27] This direction is greatly 
enhanced by genetic engineering and protein engineering recently.  
ii) Fermentation process: utilize cellular metabolism to produce organic 
metabolites from simple growth carbon sources (e.g. bio-based glucose). The 
fermentative production is boosted by recent breakthrough in metabolic engineering 
and synthetic biology.[55-58]   
The key difference between the two approaches is the 
independence/dependence of internal metabolism. Yet, in some cases, part of the 
product is from glucose (fermentation) while other part of product is directly provided 
as substrates.[59, 60] We believe that fermentative process is important for production of 
many biofuel, bulk chemicals and certain natural products (e.g. isoprenoids),[55-58] and 
biotransformation (biocatalysis) has great potential in production of many diverse fine 
chemicals and certain biofuels (e.g. biodiesel from oil).[16-27]  
Since the targeted products in this thesis are several groups of non-natural 
chiral chemicals, the following sections will concentrate on enzymes and biocatalysis.    
2.2 Enzyme Discovery, Engineering, and Design  
Because enzymatic catalysis is the center of biocatalysis and white 
biotechnology, it is particularly important to discover and engineer new enzymes and 
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novel enzymatic activities. Theoretically, this will extend the boundary of enzymatic 
catalysis in the chemical space. From a practical point of view, it is the foundation of 
many applications in biocatalysis, metabolic engineering, and some other fields in 
biotechnology. Here, traditional strategies and three modern strategies in enzyme 
discovery and engineering will be briefly reviewed with recent excellent examples. The 
de novo design of enzyme will be concisely discussed as well.   
2.2.1 Traditional Enzyme Discovery  
Figure 2.2. An example of traditional protein purification approach for enzyme discovery. 
Summary of identification of the first fluorination enzyme (Adapted by permission from 
Macmillan Publishers Ltd: Nature,[61] copyright © 2004).   
Traditionally, most of enzymes were discovered by either biochemical 
purification approaches or genetic complementation approaches (disrupt and 
reconstitute the phenotype). In one of the biochemical purification approaches, the 
target enzyme is first purified from a mixture of thousands of intrinsic proteins of the 
microorganism. Some information of the enzyme (e.g. amino acid sequence) could be 
obtained, and then utilized to identify the corresponding gene. This method was clearly 
demonstrated in the identification of the first fluorination enzyme (Figure 2.2).[61] In 
one of the genetic complementation approaches, the genome of the microorganism is 
broken into small pieces of DNAs to construct a genetic library. Next, the library is 
introduced to another microorganism (which cannot catalyze the reaction originally), 
and test the recombinant microbes for the reaction. If one clone of new microbe 
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catalyzes the reaction, the heterogenous DNA fragment will be isolated to identify the 
corresponding gene. These traditional approaches are tedious, troublesome, and with 
serious drawbacks, e.g. protein purification is difficult for enzymes in low abundance, 
and gene expression is unpredictable in heterogenous hosts.  
2.2.2 Sequence-Based Enzyme Discovery  
 Figure 2.3. Sequence-based enzyme discovery using homology method (comparison 
with known enzymes), gene clustering, transcriptomes, comparative genome analysis, etc. 
The situation was drastically changed during the 2000s, due to the great 
advance of DNA sequencing technology. From 1990 to 2003, the human genome 
project cost about US$ 3 billion to complete.[62] But recently, many next-generation 
DNA sequencing technologies could sequence the entire human genome within hours 
at a low cost of several thousand dollars.[63, 64] Nowadays, DNA sequences of genomes 
from various organisms and metagenomes from different environments (containing 
numerous unculturable microbes) are easily available from online database, and these 
will be an excellent source to discover new enzymes and pathways.[65, 66] When a 
microorganism is found for some new enzymatic transformation, it is now a common 
technique to sequence the whole genome to identify the new enzymes and pathways. 
The most straightforward genome mining method to identify putative enzymes is 
comparing putative proteins to the known enzymes for similar chemical reactions. This 
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homology-driven method can be used to identify hundreds of enzymes easily (if the 
enzymes are ubiquitous), but it often gives “me too” or “me better” enzymes.  
 To discover unprecedented novel enzymes, besides the genome sequence itself, 
other information such as gene clustering, transcription profile, and genome of other 
similar organisms could provide great assistance (Figure 2.3). In bacteria and fungi, the 
enzymes for biodegradation or biosynthetic pathways are usually encode by genes 
clustered together on genome, thus the neighborhood of the gene will provide rich 
information about the function. This is particularly useful to identify biosynthetic 
pathways and elucidate the novel enzymatic reactions in natural product research. For 
instance, Prof. Liu’s group recently use this approach to identify the first standalone 
enzyme solely committed to the catalysis of a Diels-Alder reaction ([4+2] 
cycloaddition) in spinosyn A biosynthesis from Saccharopolyspora spinosa.[67] In 
higher organisms (e.g. plant), biochemically related genes are not necessarily clustered 
together, but they are usually co-regulated in transcription. Thus, the transcription 
profile (many cDNA sequences) is the key to identify novel enzymes from higher 
organisms. A recent example is the discovery of a novel iridoid synthase for a new 
route to cyclize a terpene via dialdehyde instead of diphosphates from Catharanthus 
roseus by Prof. O’Connor’s group using feeding studies and transcriptomic data.[68] 
Another great strategy is comparative genome analysis, which was employed to 
discover the alkane synthesis pathway from cyanobacteria.[69] Researchers from LS9 
Company firstly compared and analyzed the genomes of 9 alkane-producing 
cyanobacteria and 1 related non-producing cyanobacterium. And the putative pathway 
was identified and heterogeneously expressed in recombinant E. coli to validate the 
function. To sum up, the fast-growing DNA sequence of various genomes, 
metagenomes, and transcriptomes, together with bioinformatics analysis (e.g. gene 
clustering, comparative genomics) provide precious information for enzyme discovery.            
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2.2.3 Structure-Based Enzyme Discovery and Engineering 
 Protein engineering is a very powerful tool to improve enzyme with better 
properties in activity, selectivity (chemo-, region- and enantio-selectivity), thermo 
stability, substrate/product inhibition etc.[70-75] It is an enabling technology for many 
industrial application of biocatalysis, because many natural enzymes are not evolved 
for performing the desired reactions under the industrial conditions. Enzyme 
engineering could be traditionally achieved with two approaches. Rational design 
approach highly depends on the well understanding of the complex structure-function 
relationship, which is difficult for many enzymes. Directed evolution approach 
utilizing random mutagenesis (e.g. error-prone PCR) could achieve moderate success, 
but it usually gives huge size of libraries which are difficult for screening and selection. 
With a rapidly increasing number of 3D protein structure in the RCDB Protein Data 
Bank, a new semi-rational approach guided by protein structure allows fast engineering 
of enzymes with relatively small libraries. [70-75] For engineering of substrate scope, 
selectivity, and activity, the 3D structure of the enzyme would be used to identify the 
amino acid residues around the catalytic center or substrate binding site, and then a 
random mutagenesis will focus on these hot spots to create small but smart enzyme 
libraries to screen (Figure 2.4). These structure-guided methods, e.g. CASTing,[76] 
ISM,[77, 78] have achieved great success in engineering various types of enzymes for 
biocatalysis applications in the last few years.    
Figure 2.4. A semi-rational approach to engineer enzymes: CASTing method to focus 
engineering of sites around the substrate binding pocket (Adapted with permission, copyright 
© 2011 WILEY-VCH).[73] 
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 A famous case is the engineering of a transaminase for manufacture of the 
chiral drug Sitagliptin by researchers from Codexis (Figure 2.5).[79] The initial 
transaminase was limited to simple ketones with no detectable acitivity on very bulky 
prositagliptin. The engineering was started with expending the active site by 
mutagenesis and screening with increasing bulky substrates, and finally gave an 
engineered transaminase with 27 mutated sites. This engineered transaminase was 
applied to convert 200 g/L prositagliptin to sitagliptin with 99.95% ee and 92% yield. 
In comparison with chemo-catalyzed process, the biocatalysis process clearly 
demonstrates both economic advantage of higher yield, higher enantiopurity, higher 
productivity, and lower cost, and environmental advantage of less waste and no toxic 
heavy metals. It is an excellent example of biocatalysis for production of chiral 
chemicals.     
Figure 2.5. Engineering of transaminase for Sitagliptin manufacture: focus engineering of the 
large and small binding pockets (L, S) for accepting very bulky prositagliptin (Adapted with 
permission, copyright © 2010 The American Association for the Advancement of Science).[79] 
  
2.2.4 Mechanism-Based Enzyme Discovery and Engineering 
 Enzyme promiscuity is the ability of an enzyme to transform different non-
natural substrates (substrate promiscuity), and to catalyze distinctively different 
chemical transformations with different transition states (catalytic promiscuity).[81-83] 
The promiscuity is especially important for evolution of organisms. For biocatalysis, 
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while substrate promiscuity is well conceptually accepted and usually experimentally 
explored, catalytic promiscuity is still rather unexplored though it is more important to 
discover new types of enzymatic transformations. Catalytic promiscuity involves 
breaking/forming different types of chemical bonds with similar or altered catalytic 
mechanism. Thus, the understanding of catalytic mechanism would significantly 
contribute to the discovery and engineering of new enzyme-catalyzed transformations.   
 One of the well-known examples of enzyme catalytic promiscuity is the C-C 
bond formation reaction (aldol addition and Michael addition) catalyzed by versatile 
lipases, which naturally catalyze the hydrolysis of esters.[84, 85] In its native reaction 
mechanism of lipase, an oxyanion hole is formed in the catalytic center to polarize the 
carbonyl bond (C=O) in the ester substrate and assists the nucleophilic attack by a 
serine residue at the active site. In the proposed mechanism for aldol addition, the 
oxyanion hole still functions to polarize the carbonyl group (C=O) of ketone, but a 
histidine residue acts as base to abstract an α-proton to facilitate C-C bond formation 
with a second substrate.[86]  
Figure 2.6. Engineering of P450 monooxygenase for carbene transfer. a) Natural 
epoxidation/hydroxylation reactions via iron-oxene intermediate; b) engineered 
cyclopropanation reaction via iron-carbenoid intermediate (Adapted with permission, copyright 
© 2013 The American Association for the Advancement of Science).[87] 
More recently, Prof. Arnold group provided an excellent example of catalytic 
promiscuity of P450 monooxygenase.[87] P450 monooxygenases are versatile enzymes 
for various oxidative transformations, such as hydroxylation, epoxidation, oxidative 
coupling, and heteroatom oxygenation, and mostly via the reactive high-valent iron-
oxene intermediate (Figure 2.6a). The transferring of oxene to olefins through this 
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intermediate gives epoxides (epoxidation). They proposed to achieve distinctive 
carbene transferring via a similar high-valent iron-carbenoid species (Figure 2.6b). 
Transferring carbene to olefins is a widely used reaction in organic chemistry 
(cyclopropanation), which was unknown in enzyme catalysis before. In their study, 
several P450BM3 variants were tested for cyclopropanation of styrene with diazoester 
carbene precursors, and further mutagenesis of P450BM3 led to good activity (TTN up 
to 300), diastereoselectivity (up to 92:8) and enantioselectivity (up to 97% ee). In a 
follow-up study, rational engineering of P450BM3 gave a new P411BM3, and then a 
very efficient whole-cell biocatalysis process was developed to produce cyclopropanes 
in high enantioselectivity (99% ee), high product titer (27 g/L), and good yield (78%, 
48,800 TTN).[88] These impressive studies not only provided a novel enzymatic 
approach for many carbene transfer reactions, but also demonstrated that the enzyme 
mechanism can be purposely designed and altered for unnatural enzymatic 
transformations.  
2.2.5 Computation-Based de novo Enzyme Design 
Figure 2.7. Key steps of computational de novo enzyme design (Adapted with permission, 
copyright © 2013 WILEY-VCH).[90] 
When discussing about enzyme discovery and engineering, it is impossible not 
to mention computation-based de novo enzyme design.[89, 90] In this approach, quantum 
mechanical calculations are firstly used to generate the three dimensional arrangements 
(theozymes) of amino acid residues to stabilize the transition state of the target reaction. 
Then the theozymes are incorporated into possible protein scaffolds by matching to 
existing protein 3D structures in database with efficient algorithms. The active site 
residues and other residues were further optimized with computational programs, and 
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usually several possible amino acid sequences were generated at the last of the 
computational design. Experiments are carried out to further validate and test these 
possible in silico designed enzymes. Initial successful examples include the design of 
enzymes for Kemp elimination and Diels-Alder cycloaddition by Prof. Baker’s 
group.[91, 92] The work represents a great success of computation-based de novo enzyme 
design for expanding the scope of enzymatic catalysis. Extensive protein engineering 
(directed evolution) was applied to improve the efficiency of the designed enzyme for 
Kemp elimination, resulting in a highly active artificial enzyme with a kcat of 700 s-1 
and a kcat/Km of 230,000 M-1 s-1, which is comparable with the high rates of many natural 
enzymes.[93]  
 As a conclusion of this part, discovery of new enzymes and novel enzymatic 
activities are fundamentally important for biocatalysis. Information from DNA 
sequence, protein structure, and enzyme mechanism is often the basis of enzyme 
discovery and engineering. By combination of knowledge from sequence, structure, 
mechanism, and tools from bioinformatics and computation, we can envision that more 
and more powerful enzymes will be discovered, engineered, and designed for various 
applications in the near future—a booming age of biocatalysis.  
2.3 Enzymes for Biocatalysis   
 Enzymes are typically classified into different categories and subcategories 
according to the types of reaction catalyzed.[94, 95] A numerical classification scheme 
for enzymes is the EC number. Table 2.1 shows the six categories of enzymes with the 
key enzymes in this thesis highlighted in bold.  
Table 2.1. Classification of enzymes.[94]  
Enzyme Group Reaction Catalyzed Examples 
EC 1:  
Oxidoreductases 
Oxidation or reduction reactions: transfer of 
electrons, and H, O atoms  
monooxygenase, 
oxidase, dehydrogenase 
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EC 2:  
Transferases 
Transfer of a functional group, such as 
NH2-, CH3-, RCO-, and -H2PO4 
kinase, transaminase  
EC 3:  
Hydrolases  
Hydrolysis, use water to cleave chemical 
bonds 
lipase, peptidase, 
epoxide hydrolase  
EC 4:  
Lyases 




EC 5:  
Isomerases 
Intramolecule rearrangement mutase, isomerase 
EC6:  
Ligases 
Utilize ATP to join two molecules by 
forming new C-O, C-S, C-N or C-C bonds 
synthetase 
 
In biocatalysis for production of organic chemicals, traditionally most useful 
enzymes are the hydrolytical enzymes (EC 3). More recently, there is a fast progress in 
application of oxidoreductases (EC 1) for more challenging but useful redox reactions. 
And some other subgroups of enzyme such as transaminase (EC 2), and aldolase (EC 
4) are drawing attentions from academia and industry as well.[16-27] Several groups of 
enzymes used in this thesis and their biocatalysis applications are individually reviewed 
in the following sections.   
2.3.1 Epoxide Hydrolases for Enantioselective Hydrolysis 
Scheme 2.1. Enantioselective hydrolysis of epoxides by epoxide hydrolase: a) kinetic resolution 
of racemic epoxides to produce chiral epoxides and diols; b) desymmetrization of meso-
epoxides to produce chiral vicinal diols.   
Epoxide hydrolase (EH, EC 3.3.2.x) is a ubiquitously found enzyme in living 
organisms responsible for the hydrolysis of epoxides. Because of the toxicity of 
 Chapter 2. Literature Review  
20 
 
epoxides, the major physiological role of EH is detoxification, though it has other roles 
in catabolism and regulation of signaling molecules in certain organisms.[96] EH is one 
of the most useful enzymes for production of chiral chemicals, since it often exhibits 
stereoselectivity in hydrolysis of racemic epoxides (kinetic resolution) and meso-
epoxides (desymmetrization) to prepare chiral epoxides and vicinal diols (Scheme 
2.1).[97-104] Chiral epoxides are very useful synthetic synthons, because they could easily 
react with different nucleophiles to offer various other chiral compounds (Scheme 
2.2).[105] EH also has other advantages for industrial application: only use water as co-
substrates; independent from cofactors; relatively stable; and often with broad substrate 
scope (this feature is important for a detoxification enzyme).   
 
Scheme 2.2. Various chiral compounds could be derived from chiral epoxides.[105]  
 
2.3.1.1 Structure and Mechanism of Epoxide Hydrolase  
The majority of EHs (except for several EHs, such as limonene EH) belong to 
the α/β-hydrolase fold proteins. The 3D structure of EH has a relatively conserved core 
domain containing eight stranded β-sheets surrounded by α-helices, a less conserved 
lid domain, and a flexible loop connecting both domains (Figure 2.8).[102]  
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Figure 2.8. 3D structure of α/β-hydrolase fold EH from Aspergillus niger (PDB 1QO7). 
The reaction mechanism of EH resembles to that of other hydrolases in the α/β-
hydrolase fold family (Figure 2.9). The first step of mechanism involves a nucleophilic 
attack of an Asp residue on the carbon of epoxide ring, giving a covalently bound ester 
intermediate. In the second step, the intermediate is hydrolyzed by an activated water 
molecule in which proton is abstracted by a charge relay system (His-Asp/Glu). The 
catalytic trial (Asp-His-Asp/Glu) is on the core domain. Other key residues are two Tyr 
groups from lid domain, which provide hydrogen bonding and protonating of the 
oxygen of epoxide. These two Tyr residues in the catalytic center also distinguish EH 
from other members of the α/β-hydrolase fold family.  
Figure 2.9. Mechanism of α/β-hydrolase fold EH (Adapted with permission, copyright © 2010 
Elsevier).[103] 
 
2.3.1.2 Well-Studied Epoxide Hydrolases  
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 Prof. Furstoss’ group initiated the study of EH from fungus Aspergillus niger 
(AnEH) for kinetic resolution of racemic epoxides to prepare enantiopure epoxides in 
early 1990s.[106,107] AnEH was found to exhibit high R-enantioselectivity (E > 30) for 
kinetic resolution of para-substituted styrene oxides,[108] but it showed low to moderate 
R-enantioselectivity (E < 30) for other substituted styrene oxides.[109] High 
concentration biotransformation (substrate concentration > 50 g/L) was achieved with 
AnEH for hydrolysis of para-chlorostyrene oxide,[110] and several other useful 
epoxides.[111-113] The 3D structure of AnEH was determined in 2000,[114] and Prof. Reetz 
group performed protein engineering to improve the enantioselectivity for hydrolysis 
of phenyl glycidyl ethers.[115, 116]    
 Another famous EH, ArEH was initially purified from epichlorohydrin 
degrading bacterium Agrobacterium radiobacter AD1 by Prof. Janssen’s group in early 
1990s.[117] Then the cloning and heterogeneous expression of ArEH facilitated the 
detailed biochemical characterization and elucidation of the reaction mechanism.[118] 
The native ArEH showed a moderate R-enantioselectivity (E = 10-20) for kinetic 
resolution of racemic styrene oxides and derivatives,[119] but a good selectivity in 
desymmetrization of meso-cyclohexene oxide to give (1R, 2R)-cyclohexane-diol.[120] 
The elucidation of 3D structure of ArEH in 1999[121] significantly contributed to the 
further protein engineering to improve activity and selectivity.[122-124] However, there is 
no report of application of ArEH for biotransformation in high concentration (possibly 
due to substrate/product inhibition).       
2.3.1.3 Epoxide Hydrolase from Sphingomonas sp. HXN-200 
Previously, our group has discovered that an alkane degrading bacterial strain 
Sphingomonas sp. HXN-200 catalyzed the enantioselective hydrolysis of meso-N-
protected-3, 4-epoxy-pyrrolidine  and meso-cyclohexene oxide to give corresponding 
(R, R)-vicinal diols in high ee (desymmetrization, Scheme 2.3).[125] Another study 
showed that it hydrolyzed racemic N-protected-3,4-epoxy-piperidine to yield 
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corresponding  enantiopure (−)-epoxide via kinetic resolution.[126] The cell and CFE 
(cell free extract) of Sphingomonas sp. HXN-200 were also found to have moderate to 
high R-enantioselectivity towards styrene oxide and chlorostyrene oxides.[127, 128] 
Especially for meta-chlorostyrene oxide, the R-selectivity (E = 41) is the highest among 
all of the EHs. And for styrene oxide, the R-selectivity (E = 26-29) is the highest among 
all of the native EHs at that time. The high R-selectivity enables the production of 
valuable (S)-styrene oxides via kinetic resolution (Scheme 2.3). Starting from 320 mM 
racemic styrene oxide, 129 mM (15 g/Lorg) enantiopure (S)-styrene oxide was produced 
with 60 g/L CFE of Sphingomonas sp. HXN-200.[127] Obviously, the loading of 
biocatalyst is too high and the product concentration is still low for practical application.     
Scheme 2.3. Enantioselective hydrolysis of meso and racemic epoxides with Sphingomonas sp. 
HXN-200.[125-128]  
However, the EH form Sphingomonas sp. HXN-200 has not been identified 
yet. The identification and cloning of the EH will contribute to 1) much more efficient 
biocatalysis by highly heterogeneously expressing the EH in E. coli; 2) biochemical 
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characterization of the enzyme; 3) further 3D structure elucidation and protein 
engineering; 4) other biocatalytic applications, such as enzyme immobilization and 
cascade biocatalysis. It was unsuccessful to identify the EH using a biochemical 
purification method (unpublished results from previous group members), probably due 
to the very low abundance (< 1%) of the EH in the native Sphingomonas sp. HXN-200.     
2.3.2 Monooxygenases for Asymmetric Epoxidation 
Although EH is a facile biocatalyst to produce valuable chiral epoxides, the 
drawback is the maximum 50% yield in kinetic resolution. Another potential approach 
is direct asymmetric epoxidation of prochiral alkene to give chiral epoxide in maximum 
100% yield (Scheme 2.4).[105, 129] In the early studies, chloroperoxidase (EC 1.11.1.10) 
was found to be a great biocatalyst for highly enantioselective epoxidation of aliphatic 
cis-alkenes and 1,1-disubstituted  terminal  alkenes.[130, 131] However, it only showed 
low to moderate selectivity for mono-substituted terminal alkenes and styrene 
derivatives.[132] Recently, there is a growing interest to use ubiquitous O2 instead of 
H2O2 as a green and cheap oxidant.[133] And monooxygenases (EC 1.13.x.x and EC 
1.14.x.x) are the enzymes catalyzing the insertion of one oxygen atom of O2 into 
organic substrates (hydroxylation: insert O into C-H bond; epoxidation: insert O into 
C=C bond).[134]  
Scheme 2.4. Two approaches to produce chiral enantiopure epoxides a) kinetic resolution of 
racemic epoxides by EH, maximum yield: 50%; b) Asymmetric epoxidation of alkenes by 
peroxidation or monooxygenase, maximum yield: 100%.  




2.3.2.1 Styrene Monooxygenase  
Figure 2.10. a) Genetic organization of styrene degradation pathway in Pseudomonas; b) 
styrene degradation pathway in Pseudomonas; c) function and electron transfer of the two 
component SMO.   
One of the most famous monooxygenases for enantioselective epoxidation is 
the styrene monooxygenase (SMO, EC 1.14.14.11), a two component flavin-dependent 
monooxygenase.[135,136] The SMO was first discovered in the styrene degrading 
pathway from several Pseudomonas species (Figure 2.10).[137-140] It comprises two 
components: StyA consumes O2 and FADH2 for epoxidation of styrene, and StyB 
utilizes NADH to reduce FAD to FADH2.[141] One component SMO (fused StyA and 
StyB) was later discovered from a Rhodococcus species.[142]   
All the discovered SMOs catalyze highly enantioselective epoxidation of 
styrene to produce enantiopure (S)-styrene oxide (ee > 99%). Further exploration of the 
substrate scope found that SMO accepts various styrene analogues to give S-epoxides 
in very high enantiopurity (most ee > 95%) and relatively good product concentration 
(Scheme 2.5).[143-145] Because SMO consumes stoichiometric cofactor FADH2 or 
NADH for the epoxidation, various methods have been developed to regenerate the 
cofactors for the epoxidation in vitro, including: enzyme method using a formate 
dehydrogenase,[146] chemical method using a transition metal complex,[147] and 
electrochemical method directly using cathode.[148] However, using recombinant whole 
cells with cofactor regenerated by cell metabolism seems a more efficient and 
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economical option for SMO-catalyzed epoxidation. After about one decade’s 
development from Prof. Witholt’s and Prof. Schmid’s groups,[149-152] the epoxidation of 
styrene by recombinant whole cells expressing SMO was improved to be one of most 
productive biocatalytic oxyfunctionalization processes: (S)-styrene oxide was 
produced at 72.6 g/Lorg from styrene and glucose in 8 h.[152] In a detailed environmental 
and economic assessment, the biocatalytic process is comparable or better than other 
chemical processes, demonstrating the great potential of biocatalysis in epoxidation 
and other oxyfunctionalization.     
Scheme 2.5. SMO-catalyzed highly selective epoxidation of styrene and analogues. 
Recently, the 3D structures of StyA and StyB were reported,[153, 154] which 
enable detailed characterization of reaction mechanism and structure-guided protein 
engineering of SMO. Initial attempt to change the enantioselectivity of SMO was rather 
unsuccessful.[155] This led to a hypothesis that enantioselectivity of SMO is controlled 
by the overall shape of the binding site, and thus simply mutating one or two residues 
could not alter the selectivity. It will be interesting to engineer existing SMOs or to 
bioprospect new enzymes for epoxidation with a reversed R-selectivity.          
2.3.2.2 P450 Monooxygenases  
 Cytochrome P450 monooxygenases (EC 1.14.13.x, EC 1.14.14.x and EC 
1.14.15.x) are heme-dependent enzymes that are ubiquitously found. They are versatile 
biocatalysts for a variety of chemical transformations, such as hydroxylation, 
epoxidation, dealkylation, and heteroatom oxygenation.[156-159] The monooxygenation 
reactions (e.g. hydroxylation and epoxidation) utilize O2 and depend on the electron 
transfer between heme and NAD(P)H via electron partner proteins.  
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 Many native P450 monooxygenases are responsible for epoxidation in some 
natural product biosynthesis.[160] Importantly, because of the promiscuous nature of 
P450 enzymes, P450s responsible for hydroxylation are usually also capable of 
performing epoxidation, and some P450 variants (mutants) could have altered 
selectivity for epoxidation.[161] One of the most famous P450s is P450BM3, a native 
fatty acid hydrolase from Bacillus megaterium.[162] For epoxidation of styrenes, 
P450BM3 is not a good choice: native P450BM3 gave (R)-styrene oxide in low ee of 
20%,[163] and several mutants produced the reverse enantiomer (S)-styrene oxide but in 
low ee.[164]  
Scheme 2.6. Highly R-selective epoxidation of substituted styrenes with P450pyrTM and 
P450tol.  
In search of new enzymes for epoxidation with high R-selectivity, the P450pyr 
from Sphingomonas sp. HXN-200, which has been investigated for selective 
hydroxylation in our group previously,[165-168] was found to catalyze epoxidation of 
styrenes.[169] More importantly, a triple mutant, P450pyrTM showed significant 
improvement in R-selectivity for epoxidation of para- substituted styrenes, giving the 
corresponding (R)-styrene oxides in 97-99% ee (Scheme 2.6).[169] A novel P450tol 
responsible for toluene hydroxylation in Rhodococcus coprophilus TC-2, was recently 
discovered in our lab for epoxidation of meta- and ortho- substituted styrenes to 
produce the corresponding (R)-styrene oxides in 91-99% ee.[170] The high R-selectivity 
of P450pyrTM and P450tol makes them special, and complementary to the S-selective 
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SMO. However, the activity and efficiency of epoxidation by P450 monooxygenase 
are rather low, which require intensive development for future application. 
2.3.3 Dehydrogenases and Oxidases for Selective Alcohol Oxidation 
 Oxidation of alcohols to produce carbonyl compounds (ketones, aldehydes, 
acids) is an important and useful oxidative chemical transformation. However, 
traditional chemocatalysis approaches often involve toxic metal agents and/or 
problematic oxidants with low regioselectivity. Alternatively, several types of enzymes, 
such as dehydrogenase and oxidase, have been developed as a green method for alcohol 
oxidation with appropriate selectivity.[171-174] Depending on enzymes and substrates, the 
oxidation could convert secondary alcohols to ketones or convert primary alcohols to 
aldehydes and acids. In this thesis, we are particularly interested in regioselective 
oxidation of the primary alcohol group in diols to produce α-hydroxy acids, and 
oxidation of α-hydroxy acids to α-keto acids (Scheme 2.7).      
Scheme 2.7. Alcohol oxidation by dehydrogenase or oxidase a) oxidation of secondary alcohol 
to ketone; b) terminal oxidation of diol to hydroxy acid; c) oxidation of α-hydroxy acid to α-
keto acids.  
 
2.3.3.1 Alcohol Dehydrogenases  
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 Alcohol dehydrogenases (ADHs, mainly EC 1.1.1.x) are distributed in a wide 
range of organisms and responsible for reversible oxidation of alcohols mainly using 
nicotinamide cofactors NAD(P)+.[175] Although the majority of ADHs show preference 
for oxidation of secondary alcohols, there are several exceptions which prefer oxidizing 
primary alcohols to aldehydes and acids.[176, 177] ADH from horse liver (HLADH) was 
reported to oxidize several small aliphatic 1,2-diols and amino alcohols to hydroxy 
aldehydes and amino aldehydes.[178] But transformation of bulky diols (such as 
aromatic diols) has not been reported. Similar to HLADH, a thermophilic ADH from 
Bacillus stearothermophilus also oxidizes primary alcohols, but with rather unexplored 
substrate scope.[179, 180]  
Some non-canonical ADHs are independent of nicotinamide cofactors. The 
membrane-bound ADH (mADH, EC 1.1.5.x) using pyrroquinoline quinone cofactor is 
the key enzyme for terminal oxidation in acetic bacteria (Acetobacter or Gluconobacter 
species).[181-183] Acetic bacteria could catalyze the incomplete oxidation of 
carbohydrates and alcohols to organic acids, which is distinguished from the complete 
oxidation to carbon dioxide and water by other aerobic microorganisms.[184, 185] 
However, because of the nature of mADH (membrane-bounded, using pyrroquinoline 
quinone cofactor), heterogenous expression of functional mADH has not been reported 
and further application is rather limited. Another non-canonical ADH is FAD 
dependent AlkJ, which is responsible for aliphatic alcohol oxidation in the well-studied 
alkane-metabolizing Pseudomonas putida GPo1.[186, 187] The alkane degradation 
pathway involves hydroxylation of alkane to alcohol by AlkBGT, oxidation of alcohol 
to aldehyde by AlkJ, oxidation of aldehyde to acid by AlkH, and activation of acid to 
acyl-CoA by AlkK (Scheme 2.8). AlkJ is initially classified as a member of glucose-
methanol-choline (GMC) oxidoreductase family according to its sequence.[188] 
Recently, the detailed biochemical characterization of AlkJ evidenced that it is an 
FAD-dependent membrane-associated dehydrogenase coupling to the bacterial 
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respiratory chain.[189] However, only several n-alkanol and derivatives were tested as 
substrates of AlkJ, leaving other potential substrates unexplored. It will be interesting 
to further explore these ADHs for terminal oxidation of diols.   
Scheme 2.8. Alkane (n-octane) degradation pathway in Pseudomonas putida GPo1. AlkJ is the 
key enzyme in oxidation of terminal alcohol to aldehyde.        
2.3.3.2 Alcohol Oxidases  
 Alcohol oxidases (EC 1.1.3.x) provide a facile tool for alcohol oxidation, 
because they directly utilize the most economical and greenest oxidant, O2, and give 
nontoxic H2O2 or H2O as byproduct.[171-174]  These oxidases employ tightly bound 
redox-active prostetic groups (e.g. FAD) instead of diffusible and sensitive 
nicotinamide cofactor, which makes them suitable for many in vitro applications. The 
majority of alcohol oxidases contain a flavin cofactor (FAD or FMN), thus they are 
often referred as flavoprotein oxidases.[190, 191] In comparison with reversible 
oxidation/reduction by most of dehydrogenases, oxidation by oxidases is irreversible, 
which provides strength in certain biocatalysis applications.  
We are interested in oxidation of α-hydroxy acids to α-keto acids, which is 
catalyzed by FMN-dependent 2-hydroxyacid oxidase family. Two well-known 
enzymes in this family are lactate oxidase[192] and glycolate oxidase.[193] However, their 
good substrates are short- and medium-chain 2-hydroxy acids, but not more bulky 
aromatic acids. On the other hand, a hydroxymandelate oxidase (HMO) was identified 
in the biosynthesis pathway of vancomycin group of antibiotics.[194, 195] The 
enantioselectivity of HMO was found to be highly S-selective, leaving (R)-mandelic 
acid unreacted. HMO could be a very efficient enzyme in oxidation of (S)-mandelic 
acid and its analogues to the corresponding α-keto acids.  
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2.3.4 Amino Transferases for Reductive Amination 
 Amino group is one of most important functional groups in bioactive 
compounds, due to its distinct electrostatic and hydrogen bonding interactions with 
other molecules. The formation of amino group was usually achieved via amination of 
carbonyl group (ketones and aldehydes) by chemical catalysts or enzymes, mainly 
transaminases (EC 2.6.1.x).[196, 197] In fact, transaminases are the key enzymes for 
nitrogen metabolism in living organisms, maintaining the synthesis/degradation of 
amino acids. In biocatalysis, two types of transaminases have been applied for synthesis 
of chiral amino acids and amines.    
2.3.4.1 α-Transaminases  
α-Transaminases (α-TAs) catalyze the reversible transferring of amino groups 
between α-amino acids (amine donor) and α-keto acids (amine acceptor) using 
pyridoxal 5’-phosphate as a prosthetic group (Scheme 2.9a). L-selective α-TAs are 
ubiquitously found for the synthesis of proteinogenic amino acids, and D-selective α-
TAs were discovered in many bacterial species (e.g. Bacilli) to produce D-amino acids 
for peptidoglycan and secondary metabolite biosynthesis.[198] Many of these α-TAs 
accept a range of α-keto acids, thus they are valuable for production of various natural 
and unnatural amino acids, especially D-amino acids.[199, 200]  
Scheme 2.9. Transferring of amino group catalyzed by a) α-transaminase and b) ω-transaminase. 
 
2.3.4.2 ω-Transaminases  
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 Chiral amines are indispensable structure components in many chiral 
pharmaceuticals,[201] but they are inaccessible with native α-TAs, which require acid 
groups in substrates. To achieve green and efficient production of these chiral amines, 
ω-transaminases (ω-TAs) were recently discovered and developed as promising 
enzymes, and plenty of papers were published during the last few years.[202-206] 
Distinguished from the limited scope of α-TAs, ω-TAs could use amines (without acid 
group) as donor and ketones/aldehydes (without acid group) as acceptor for 
transamination (Scheme 2.9b), and thus with great potential for synthetic application. 
The ω-TA from Vibrio fluvialis is the first reported enzyme for asymmetric reductive 
amination (S-selective) with relatively broad substrate scope.[207] Another similar ω-TA 
from Chromobacterium violaceum catalyzes S-selective amination of even more 
diverse substrates, including aliphatic and aromatic keto acids, aldehydes, and 
ketones.[208] On the other hand, a group of useful R-selective ω-TAs were discovered 
by Prof. Bornscheuer’s group via structure-guided in silico enzyme mining.[80] Further 
study of these enzymes provides a versatile toolbox for R-amine synthesis, and two 
representative examples are from Aspergillus terreus and Aspergillus fumigatus.[209]  
Scheme 2.10. An elegant strategy to overcome equilibrant problem in transamination.[210]  
One common problem of using ω-TAs is the equilibrant reaction, which often 
requires a large excess of amine donor to achieve high yield of amine products.[202-206] 
Many strategies have been developed to overcome this issue, mainly through removing 
of the co-product (ketone/aldehyde/keto acid). The most elegant strategy is using L-
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alanine dehydrogenase (L-AlaDH) to regenerate L-alanine (amine donor) from 
pyruvate (co-product) and ammonia (Scheme 2.10).[210] The resulting net reaction is 
reductive amination of ketones with stoichiometric consumption of ammonia and easily 
available reducing agents (glucose or formate). This regeneration strategy is generally 
applicable in other systems, e.g. cascade biocatalysis containing ω-TAs.  
 
2.4 Whole-Cell Biocatalysis and its Applications   
Enzymes in purified form are suitable for accurate scientific characterization 
and medical application. For synthesis application, it depends on many factors to 
choose the forms of biocatalyst.  Relatively simple and stable enzymes in the class of 
hydrolases (e.g. lipase) and in the class of transferases (e.g. transaminase) are usually 
applied in isolated or immobilized forms, because those could offer clean reaction 
system without cell mass, give few byproducts produced by other enzymes in cells, and 
eliminate the potential diffusion limit of cell membranes. Nevertheless, as for many 
complex or unstable redox enzymes, it is generally better to apply microbial cells 
containing the enzymes as biocatalysts.  
2.4.1 Advantages of Whole-Cell Biocatalysis  
Whole-cell biocatalysis offers several advantages over in vitro biocatalysis 
(Figure 2.11).[28-33]  
i) Many oxidoreductases, such as alcohol dehydrogenase, ene-reductase, 
monooxygenase, consume stoichiometric cofactors, such as NAD(P)H. The 
regeneration of these cofactors by another enzyme or cell metabolism inside the 
microbial cell is an efficient and economical way,[211-213] whereas in vitro regeneration 
of the cofactors is less efficient and more expensive. An excellent example is the 
biocatalytic epoxidation of styrene by SMO: the recombinant whole-cell process[149-152] 
is more efficient than several other processes with cell-free systems.[146-148]    
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ii) Whole cells provide a natural environment for enzymes. For example, many 
membrane-bound enzymes are inactive without the membrane environment of cells, 
and some complex enzymes involve electrons transfer in several components (e.g. 
P450 monooxygenase) which is easy to achieve within cell as it does naturally, but it 
is difficult or inefficient to reconstitute in vitro. A number of synthetically useful 
enzymes are membrane bounded or integrated, such as alkane monooxygenase AlkB[214] 
and xylene monooxygenase XylM.[215]    
iii) The cell membrane, though poses some diffusion limitations, could protect 
fragile enzymes from harsh conditions of the process, such as organic solvents[216, 217] 
or ionic liquids.[218, 219] These water immiscible solvents are sometimes applied in 
biocatalytic processes to increase substrate solubility, reduce substrate/product 
inhibition, and facilitate product recovery.  
iv) Because most enzymes are initially produced in recombinant microbial 
cells through fermentation, enzyme in the microbial cells is the most inexpensive form 
of biocatalysts without further processing, such as breaking cells by homogenization 
and purifying enzyme by chromatography.  
Figure 2.11. Four advantages of whole-cell biocatalysis: a) easy cofactor regeneration in cells; 
b) cells provide the natural environment for enzymes; c) cell membrane protect enzymes; d) 
cells are cheap without further processing. 
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Therefore, whole-cell biocatalysis is a common choice of many biocatalysis 
laboratories in both academia and industry.       
2.4.2 Categories of Whole-Cell Biocatalysts  
Depending on the status of cells performing reactions, whole-cell biocatalysts 
can be grouped into growing cells, resting cells, or dead cells.  
i) Applying growing cells allows continuous generating enzymes when 
performing reactions, and this is particularly suitable for less stable enzymes. The use 
of growing cells has other advantages. For instance, growing cells could adapt for 
chemical reactions and manage the related stress (e.g. from organic solvents and 
reactive oxygen species). Cells cultured by high density cultivation techniques[220-222] 
could be directly employed for biotransformations in the same bioreactor without 
isolating the cell mass by centrifugation or filtration. But growing cells will generate 
extra cell mass as waste, and sometimes trend to degrade the substrates and products 
to something else during the reaction.  
ii) Resting cells are not active in dividing themselves (increasing cell mass), 
but still metabolically active (still live). They are usually obtained by limitation of the 
certain nutrition, such as nitrogen or phosphate. Resting cells could be able to provide 
higher efficiency than growing cells during the reaction in terms of energy sources, 
since energy is not used for growth in resting cells theoretically. The maximum NADH 
regeneration rate of 367 U/g cdw was estimated for resting E. coli cells metabolizing 
glucose based on a flux balance analysis of the metabolic network.[223] A recent 
investigation of epoxidation by recombinant E. coli expressing SMO found that resting 
cells have higher specific activity (U/g cdw) and product yield on glucose (mol 
product/mol glucose) than growing cells in a similar setup, however, resting cells are 
prone to product inhibition/toxicity and enzyme loss.[224]   
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iii) Another type of whole-cell catalyst is dead cells, which are usually obtained 
by freeze and thaw or lyophilization. Frozen or lyophilized cells prepared previously 
could be easily stored and transported to other places, avoiding the trouble to prepare 
the biocatalysts each time before performing reactions. This feature is especially 
welcome by organic laboratories without biological settings. Since they are 
metabolically inactive, additional enzymes should be co-produced for cofactor 
regeneration. An excellent example was reported by Prof. Xu’s group: lyophilized 
E.coli coexpressing a reductase and glucose dehydrogenase was used for asymmetric 
reduction of ethyl 2-oxo-4-phenylbutyrate at an unprecedented high concentration of 
620 g/L.[225] The enzymes used in lyophilized cells must be stable and robust to work 
independent of cell physiological status. 
2.4.3 Limitations of Whole-Cell Biocatalysis  
 Whole-cell biocatalysis suffers from two common problems: side reactions 
catalyzed by other enzymes in cells and limited mass transfer over cell 
membranes/walls.  
Microbial cells contain hundreds of enzymes which might transform the 
substrates or products to other undesired byproducts. The likelihood of side reactions 
depends on substrates, intermediate, and products. For instance, aldehydes are 
vulnerable to be reduced to alcohols or oxidized to acids by many dehydrogenases 
inside cells. Over expression of desired enzymes will increase the formation of targeted 
products, and knock-down or knock-out of problem-causing native enzymes would 
reduce the byproduct formation.  
Cell membranes and walls often act as possible barriers for the entry of 
substrates into cells and the exit of products from cells, which might compromise the 
productivity of whole-cell biocatalysis.[226]  Although small hydrophobic compounds 
could easily diffuse through cytoplasmic membranes (phospholipid bilayers), outer 
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membrane/cell wall (lipopolysaccharides) is the possible barrier. Many methodologies 
have been developed to reduce the mass transfer limitation. Cell permeabilization by 
chemical treatment is a simple technique,[227, 228] but the method is often destructive to 
cell metabolism and leads to cofactor leakage and enzyme destabilization. Another 
interesting method is genetic engineering of E. coli host to produce less 
lipopolysaccharide, and thus increase the general permeability of cell walls.[229] More 
specific but powerful approach is engineering of transporter proteins. Recently, 
expression of outer membrane protein AlkL in E. coli was found to boost the 
oxyfunctionalization of fatty acid esters and the hydroxylation of limonene.[230, 231] This 
type of membrane transporters will provide an elegant solution to mass transfer issues 
of whole-cell biocatalysis. 
2.5 Cascade Biocatalysis  
Figure 2.12. Comparison of traditional multi-step synthesis and cascade/tandem catalysis in 
one pot: a) traditional multi-step synthesis requires a recovery step after each conversion step; 
b) cascade/tandem catalysis avoids intermediate recovery steps. 
Performing multiple catalyzed reactions in one pot is an important technology 
for chemical production, since it circumvents the tedious isolation and purification of 
intermediates which are usually time-consuming, labor-demanding, yield-decreasing, 
and waste-producing in traditional multi-step synthesis (Figure 2.12).[232-234] 
Furthermore, cascade/tandem catalysis also offers additional advantages, such as 
overcoming thermodynamic hurdles to drive the reversible reactions to complete and 
reducing accumulation of unstable or toxic intermediates. Enzymes, as they catalyze a 
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variety of reactions in living organisms naturally, are intrinsically compatible catalysts 
to perform the cascade/tandem catalysis in mild conditions.[34-40] Here, we would like 
to refer cascade biocatalysis as performing two or more enzyme-catalyzed chemical 
transformations in the same reaction vessel in a sequential or simultaneous manner. 
During the past decades, a variety of biocatalytic cascades have been developed, 
ranging from simple redox independent cascades to complex cascades with multiple 
interconnected redox reactions. The following review of biocatalytic cascades is 
subdivided into four sections according to the types of chemical transformation 
involved: i) cascades without oxidoreduction, ii) cascades with oxidation, iii) cascades 
with reduction, and iv) cascades with both oxidation and reduction. The multiple 
enzymatic reactions in cell metabolism are under the scope of metabolic engineering[55-
58] and will not be discussed here. And multiple enzymatic reactions only linked by 
cofactors have been developed as a matured technique (cofactor 
recycling/regeneration)[211-213] and will not be discussed neither. 
2.5.1 Cascades without Oxidoreduction 
 Biocatalytic non-oxidoreductions are usually facile, robust and efficient 
transformations without involving redox agents such as NAD(P)+/NAD(P)H. The 
enzymes are often more stable and active than redox enzymes. Therefore, many non-
redox cascades were first developed as early examples in cascade biocatalysis, and 
some of these processes have been implemented in industry.  
Scheme 2.11. Hydantoinase process for α-amino acids production. 
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An outstanding example is the racemase-hydantoinase-carbamoylase system 
(hydantoinase process) for production of optically pure α-amino acids (Scheme 
2.11).[235-237] The hydantoin  were first selectively hydrolyzed to D- or L-N-carbamoyl  
amino  acids by hydantoinases, and then the following hydrolysis by N-carbamoylases 
gives rise to free D-  or L-amino  acids. Sometimes, hydantoin racemases are involved 
as a third enzyme for kinetic dynamic resolution. The cascade was firstly discovered 
from some hydantoin-utilized microorganisms, thus it is a natural cascade similar to 
the degradation pathway of hydantoin. This method is particularly important to produce 
many useful D-amino acids, such as D-phenylglycine and D-hydroxy-phenylglycine 
for the side chains of β-lactam antibiotics.[238] Recently, an efficient in vivo cascade 
biocatalytic system was developed with recombinant E. coli cells coexpressing the 
three enzymes by engineering of the corresponding genes in a polycistronic 
structure.[239]    
Scheme 2.12. Non-redox bienzymatic cascade to produce for α-hydroxy acids/amides: a) a 
general scheme; b) a representative example of producing (S)-mandelic acid.[240]  
In addition to natural cascades, enzymes from different sources can be 
combined to form artificial cascades, a series of chemical transformations without any 
known natural counterparts (pathways). An interesting example of non-redox artificial 
cascade is transformation of aldehydes and ketones to α-hydroxyl amides/acids by 
several nitrile-related enzymes (Scheme 2.12a). Prof. Sheldon’s group first reported 
the bienzymatic cascade to convert cheap benzaldehyde to enantiopure (S)-mandelic 
acid by using cross-linked aggregate of plant-originated S-selective hydroxynitrile 
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lyase (oxynitrilase) and bacterial non-selective nitrilase (Scheme 2.12b).[240] 
Subsequently, similar bienzymatic cascade comprised of hydroxynitrile lyase and 
nitrile hydratase was developed to convert aldehydes to (S)-α-hydroxycarboxylic 
amides.[241] Recently, the in vivo version of this bienzymatic cascade was successfully 
demonstrated with recombinant E. coli coexpressing the enzymes,[242] and further 
development using ionic liquids improved the process efficiency to give synthetically 
relevant amounts of products.[243] A common problem of this cascade is the 
involvement of highly toxic HCN in the synthesis.  
2.5.2 Cascades with Oxidation 
 Biocatalytic oxidoreductions are generally more challenging than non-
oxidoreductions because of involvement of redox reagents. But oxidations are very 
important transformations since the major feedstock for organic synthesis are highly 
reduced hydrocarbons while functional organic chemicals are usually at higher 
oxidized states. Thus, many biocatalytic cascades involving at least one oxidation step 
were reported recently.  
 Scheme 2.13. Epoxidation-hydrolysis cascade to convert alkenes to vicinal trans-diols: a) a 
general scheme; b) a representative example of converting styrene;[247] c) a representative 
example of converting cyclic olefins.[248]  
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 One useful oxidative cascade is epoxidation-hydrolysis to convert C=C double 
bond to two vicinal alcohol groups by a monooxygenase and an epoxide hydrolase 
(Scheme 2.13a). The overall transformation is a formal trans-dihydroxylation. The 
cascade is not involved in the major pathways of microbial alkene degradation, but it 
was discovered in fungal transformation of some terpenes (e.g. limonene).[244-246] 
Previously, our lab discovered that the alkane-degrading bacterium Sphingomonas sp. 
HXN-200 could convert N-substituted tetrahydropyridines and pyrrolines to the 
corresponding trans-diols in high enantioselectivity via the epoxidation-hydrolysis 
cascade.[126] However, these wild type strains containing appropriate monooxygenases 
and epoxide hydrolases are rare and with very limited potential. As a solution, enzymes 
from different origins can be purposely combined in one pot to convert cheap alkenes 
to more useful trans-diols. To demonstrate the concept, we combined recombinant E. 
coli cells expressing SMO and cells of Sphingomonas sp. HXN-200 containing EH to 
convert styrene and chlorostyrenes to the corresponding (S)-phenyl-1,2-ethanediols in 
high ee (Scheme 2.13b).[247] This is a significant progress in epoxidation-hydrolysis 
cascade. However, two different strains need to be cultured separately, and impractical 
high loading of Sphingomonas sp. HXN-200 (up to 65 g/L) was used because of the 
low EH activity in the wild type strain. Furthermore, the substrate scope of the cascade 
was rather unexplored, considering the broad scope of SMO. Last, only S-enantiomers 
of diols were produced in the study, with R-enantiomers inaccessible. Recently, the 
cascade was applied to convert several cyclic olefins with lipase-mediated epoxidation 
and hydrolysis by Sphingomonas sp. HXN-200.[248] However, the lipase-mediated 
epoxidation used reactive H2O2 as oxidant which was incompatible with EH-catalyzed 
hydrolysis. The relatively incompatible conditions led to a sequential cascade in a 
highly diluted solution. Obviously, an efficient and facile system for epoxidation-
hydrolysis cascade is yet to be demonstrated. 
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Scheme 2.14. Hydroxylation-oxidation cascade to convert methylene groups to ketone 
groups: a) a general scheme; b) a representative example of converting non-activated 
methylene groups;[251] c) a representative example with internal cofactor recycling.[252]  
The hydroxylation-oxidation cascade converting the methylene group (-CH2-) 
to carbonyl group (C=O) is a useful but challenging reaction (Scheme 2.14a), because 
it involves activation of C-H bonds which is difficult to achieve by chemocatalysis 
under mild conditions. Naturally, some bacteria use monooxygenases and 
dehydrogenases for the two steps (hydroxylation and oxidation) in alkane 
degradation.[249, 250] To produce more synthetic relevant products, the cascade could 
combine monooxygenases and ADHs from different sources for the two individual 
reactions, respectively. Previously, our lab developed a system comprised of a 
monooxygenase-containing microorganism (in vivo) and a commercially purified ADH 
(in vitro) to convert benzylic or non-activated methylene groups to ketone groups with 
excellent regioselectivity (Scheme 2.14b).[251] However, the required cofactors were 
individually regenerated in the system: NADH for the P450 monooxygenase was 
regenerated via cell metabolism of glucose, and NAD(P)+ for the ADH was regenerated 
by adding co-substrate acetone to ADH. Recently, Prof. Gröger’s group demonstrated 
the cascade on cyclohexene and n-heptane using P450BM3 monooxygenase and ADH 
in vitro with internal recycling of cofactors (Scheme 2.14c).[252, 253] And the same 
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system was further demonstrated and optimized in recombinant E. coli to improve the 
efficiency and product concentration.[254]     
2.5.3 Cascades with Reduction 
Scheme 2.15. Reduction-dehalogenation cascade to convert α-halo ketones to various non-
halogenated compounds: a) a general scheme; b) a representative example of production of an 
atorvastatin precursor.[260] 
Asymmetric reductions by alcohol dehydrogenases (ADHs), ketone reductases 
(KERDs), enoate reductases (ERs), and ω-transaminases (ω-TAs) can be combined 
with other non-redox reactions to form useful reductive cascades. Two types of 
reductive cascades are reviewed here.  
 The reduction-dehalogenation cascade converts achiral α-halo ketones to 
various chiral non-halogenated compounds by ADHs/KERDs and halohydrin 
dehalogenases (HHDHs) (Scheme 2.15a). Prof. Kroutil’s group firstly developed the 
one-pot process to produce both enantiomers of epoxides from α-chloro ketones by 
combining a Prelog- or anti-Prelog ADH with a non-selective HHDH.[255] Because 
HHDH also exhibits catalytic promiscuity for ring opening of epoxides by various 
nucleophiles (e.g. N3-, CN-),[256, 257] they further extended the cascade to produce 
enantiopure β-azidoalcohols and β-hydroxynitriles.[258] Recently, a in vivo version of 
this cascade was developed to have higher efficiency.[259] To efficiently produce useful 
pharmaceutical intermediates, Codexis applied protein engineering of KERD and 
HHDH to achieved a practical two-step synthesis of chiral hydroxynitrile precursor for 
the blockbuster drug Lipitor® (Atorvastatin, Scheme 2.15b).[260] 
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Scheme 2.16. Carboligation-reduction cascade to convert aldehyde and α-keto acid to diol and 
amino alcohol: a) a general scheme; b) a representative example of production of 
nor(pseudo)ephedrine.[266] 
Another interesting reductive cascade combines carboligation by 
decarboxylases or other C-C bond forming enzymes[261, 262] and ketone 
reduction/amination by ADHs (KERDs)/ω-TAs (Scheme 2.16a). The cascade was first 
reported in an early study of two-step enzymatic synthesis of all stereoisomers of 1-
phenylpropane-1,2-diol starting from benzaldehyde and acetaldehyde using 
lyase/decarboxylase and ADHs.[263] Prof. Rother’s group successfully further 
developed the two-step biocatalytic cascade to produce (1R, 2R)-phenylpropane-1,2-
diol in high concentration with combination of resting or lyophilized whole cells.[264, 
265] In comparison with chiral diols, chiral amino alcohols are more useful and could be 
achieved with similar cascade by ω-TAs instead of ADHs. The same group recently 
reported a significant progress to produce very useful alkaloids (1R, 2S)-norephedrine 
and (1R, 2R)-nor(pseudo)ephedrine from benzaldehyde and pyruvate using 
acetohydroxyacid synthase I and S-ω-TA or R-ω-TA (Scheme 2.19b).[266] The process 
was further optimized and other two stereoisomers of nor(pseudo)ephedrine were also 
produced in a following study.[267]     
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2.5.4 Cascades with Both Oxidation and Reduction 
 Because of the divergent reaction conditions of oxidation and reduction, these 
two types of reaction are generally challenging in chemistry to be performed 
simultaneously in one reaction vessel. However, enzymes are suitable to perform 
multiple independent redox reactions due to their high substrate and cofactor specificity, 
and cellular and subcellular compartment. Recent development of cascades containing 
both oxidation and reduction is reviewed here.  
Scheme 2.17. Three redox cascades containing oxidation and reduction: a) an elegant design 
for deracemization of secondary alcohols;[269] b) a cascade to convert alcohol group to amine 
group;[271-273] c) a cascade for direct terminal amino-functionalization.[274] 
 One of the best early examples of redox cascade is deracemization of 
secondary alcohols to enantiopure form reported by Prof. Kroutil’s group in 2008 
(Scheme 2.17a). The concept was first proved by using in vivo R-selective oxidation 
with wild type strains, in vitro S-selective reduction with ADHs, and cofactor 
recycling.[268] In the following study, the authors designed an elegant in vitro system 
comprised of selective oxidation with NADPH specific ADH, selective reduction with 
NADH specific ADH, and recycling of both cofactor NADP+ and NADH (Scheme 
2.17a).[269] The same cascade was also employed for deracemization of α-hydroxy 
acids.[270] In addition, the second step in the cascade could be replaced with ω-TA-
catalyzed reductive amination to achieve conversion of hydroxy group to amine group 
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(Scheme 2.17b). This concept was first proved for amination of aliphatic and aromatic 
primary alcohols[271, 272] and then demonstrated for enantioselective amination of 
secondary alcohols.[273] Adding one hydroxylation step to the cascade could achieve 
formal amino-functionalization of C-H bond (Scheme 2.17c), which was recently 
achieved using one recombinant whole-cell catalyst coexpressing the necessary 
enzymes.[274]  
Scheme 2.18. Three redox cascades containing Baeyer-Villiger oxidation and/or C-C double 
bond reduction: a) a cascade to convert unsaturated ketone to lactone;[275] b) a cascade to convert 
allyl alcohol to lactone;[277] c) a cascade to convert alkene to ketone.[278] 
Other interesting redox cascades contain C=C double bond reduction and/or 
Baeyer-Villiger oxidation. Recently, our group developed a cascade to convert 
cyclopentanones (unsaturated ketones) to (R)‑δ-lactones using a wild type strain 
containing C=C double bond reaction enzyme and a recombinant E. coli strain 
expressing cyclohexanone monooxygenase (Scheme 2.18a).[275] An enoyl-ACP 
reductase was later identified from the wild type strain for the reation, and further 
selective Baeyer-Villiger oxidation polished the ee of (R)‑2-alkylcyclopentanones up 
to 99%.[276] Prof. Bornscheuer’s group added one more ADH-catalyzed oxidation step 
to the cascade to convert allyl alcohols to chiral lactones (Scheme 2.18b).[277] And prof. 
Reetz’s group utilized P450BM3 for hydroxylation and oxidation of 1-cyclohexene 
carboxylic acid methyl ester and a reductase for the following C=C double bond 
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reduction (Scheme 2.18c).[278] Other useful cascades involving Baeyer-Villiger 
monooxygenase were reported to break unsaturated long-chain fatty acids or 
cyclohexanol into medium-chain α,ω-dicarboxylic acids, ω-hydroxycarboxylic acids, 
and ω-aminocarboxylic acids. [279-281]                        
2.5.5 Challenges in Cascade Biocatalysis 
As mentioned above, various types of biocatalytic cascades have been 
demonstrated in academic research, but many of them are still suffering from 
limitations, and development of novel and useful cascade biocatalysis is facing several 
challenges. The following part discusses five issues in cascade biocatalysis, and the 
opportunities to overcome these problems as well.  
Figure 2.13. Illustration of five challenges in cascade biocatalysis. 
i) Multiple-step conversion without significant side reactions. When multiple 
chemicals are exposed to multiple catalysts in one reaction vessel, the system will be 
vulnerable to catalytic crosstalk, namely, undesired reactions from unintended 
precursors catalyzed by enzymes in the cascade. This is not uncommon phenomenon 
when using enzymes with catalytic promiscuity or broad substrate scope. As a solution, 
the cascade can be performed sequentially instead of simultaneously. Another possible 
solution is to use more specific enzymes by discovery or protein engineering.           
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ii) Synthetically useful cascades. From synthetic point of view, the unit price 
of initial substrates should be lower than those of final products and intermediates. 
However, in some of recent reported cascades, substrates seem more expensive and 
difficult to synthesize than intermediates and final products. In general, value-adding 
transformations increase molecular complexity, such as extension of carbon chain 
(carboligation), addition of functional groups (oxy- amino- functionalization), and 
generation of chiral center (asymmetric reaction). Through multiple value-adding 
reactions, cascade biocatalysis would possibly directly convert very cheap substrates, 
e.g. alkanes/alkenes, to generate useful and chiral products. Yet, this type of cascades 
are rare, especially for enantioselective functionalization of hydrocarbons.                  
iii) Broad scope cascades. Cascades accepting various substrates to produce 
various products could be particularly useful for synthesis of fine chemicals. Since 
many fine chemicals are with very limited market individually, a one-for-many 
approach is always welcome. In general, enzymes have relatively narrow scope 
compared to chemical catalysts, though some enzymes could accept substrates with 
similar structure. Thus, cascades with relatively broad scope are seldom reported, 
because they require multiple enzymes with broad substrate scopes, which are not easy 
to be satisfied simultaneously.   
iv) Efficiency of cascade biocatalysis. Efficiency of biocatalytic process (e.g. 
activity, productivity, product concentration) is often the key performance index for 
industrial application. As for cascade biocatalysis, it is more challenging because it 
requires high efficiency of each step of the reactions involved. As far as we know, most 
of the reported redox cascade biocatalysis produced products in low concentration of 
0.1-100 mM (about 0.01-10 g/L). To achieve highly efficient cascade biocatalysis, 
efficient enzymes for each step should be discovered or engineered, and the catalytic 
systems and conditions need to be optimized (e.g. balance the amount of each enzyme, 
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and search for the best compromised reaction conditions). Therefore, only a small 
number of cascade biocatalysis were applied in industry hitherto.  
v) Design, construct, and optimize cascade with >3 steps. The majority of 
cascades developed contain only 2 or 3 steps, but further extending them to multiple >3 
steps could face several significant challenges in design, construction, and optimization. 
For the design of long cascades, the retrosynthetic analysis in organic chemistry could 
assist design of meaningful cascades.[365] For construction and optimization of cascade, 
modularization of a serial of transformation into several modular transformations is a 
potential strategy to ease the construction and to reduce the number of variables in 
optimization. Such a modular approach has been successfully applied in synthetic 
biology[366-368] and metabolic engineering,[369-371] but it is still seldom used in cascade 
biocatalysis.     
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3 ENANTIOSELECTIVE HYDROLYSIS OF EPOXIDES 
WITH RECOMBINANT WHOLE CELLS EXPRESSING A 
NOVEL EPOXIDE HYDROALSE  
Figure 3.1. Enantioselective hydrolysis racemic and meso-epoxides with recombinant E. coli 
(SpEH) to prepare epoxides and diols in high enantiopurity.  
 
3.1 Introduction 
Enantiopure epoxides are versatile chiral building blocks in organic chemistry 
(refer to Scheme 2.2), and they are mainly produced via hydrolytic kinetic resolutions 
with Co(salen) catalysts developed by Prof. Jacobsen’s group in late 1990s to early 
2000s.[282, 283] However, chiral salen ligands are still expensive and cobalt is toxic to 
environment. On the other hand, nature provides epoxide hydrolase (EH) for the same 
epoxide hydrolysis reaction, representing a simple and green alternative method for the 
syntheses of enantiopure epoxides and vicinal diols.[97-104] Although many EHs have 
been discovered, cloned, and engineered recently, it is still challenging to develop 
easily available, highly active, and enantioselective EH for efficient production of 
desired epoxides and vicinal diols in a practical way, e.g. giving high product 
concentration and enantiopurity, with low catalyst loading, and in a short reaction time. 
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 We are interested in developing a novel EH and engineering a powerful 
biocatalyst for the efficient production of valuable chiral epoxides (S)-1−7, (−)-8, and 
vicinal diols (R, R)-12−14. The following Table 3.1 gives a brief summary of these 
desired products and their potential synthetic applications (final products can be 
synthesized from them).  
Table 3.1. Desired chiral epoxides and diols and their synthetic application.  
Structure Name Synthetic Applications 
 
(S)-Styrene oxide (S)-1 Levamisole (nematocide, 
anticancer),[284, 285] (−)-hyperolactone 
C (anti-HIV)[286] 
 
(S)-2-, 3-, and 4-
Chlorostyrene oxides 
(S)-2–4 
EMI39.3, EMI40.1, and EMI37.1 
















Single enantiomer of Ifoxetine sulfate 
(antidepressant),[291] Cisapride hydrate 
(prokinetic agent)[292]  
 
(1R, 2R)-Cyclopentane 
diol (1R, 2R)-12 
Hepatitis C virus protease 
inhibitors,[293] chiral ligands[294] 
 
(1R, 2R)-Cyclohexane 
diol (1R, 2R)-13 
Potential anticancer compounds,[295, 





Sialyl Lewis X mimetics,[298] aza-
sugars,[299] antibiotics[300] 
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 Several EHs have been reported to produce some of these target compounds. 
AnEH from fungus Aspergillus niger showed a low to moderate enantioselectivity 
factor (E) of 2-16 for the hydrolysis of racemic epoxides to produce (S)-1−3, 6, and 7, 
and an exceptional high E of 80 for hydrolysis to give (S)-4;[108-110, 116] ArEH from 
bacterium Agrobacterium radiobacter exhibited an moderate E of 10-16 for the 
hydrolysis to give (S)-1−4;[119] and RgEH from yeast Rhodotorula glutinis provided an 
E of 15 for the hydrolysis of racemic 1 to give (S)-1.[301] The majority of 
enantioselectivities of these EHs are not satisfactory. We recently discovered that an 
alkane-degrading strain Sphingomonas sp. HXN-200 showed a relatively high E of 29, 
12, 41, and 11 for the hydrolysis of racemic epoxide 1−4 to produce (S)-1−4, 
respectively.[127, 128] The enantioselectivity is higher than those of other known EHs for 
producing (S)-1 and (S)-3. It is also the only known biocatalyst for the hydrolysis of 
racemic 8 to afford (−)-8.[126] On the other hand, for the enantioselective hydrolysis of 
meso-epoxides 9–11, RgEH gave vicinal diols (1R, 2R)-12 in 98% ee and (1R, 2R)-13 
in 90% ee, respectively;[302] ArEH afforded (1R, 2R)-13 in 99% ee;[120] and engineered 
EHs BD10721, BD9883, and BD9884 produced (1R, 2R)-12 in 90% ee, (1R, 2R)-13 in 
96% ee, and (3R, 4R)-14 in 93% ee, respectively.[303] The Sphingomonas sp. HXN-200 
was also found to catalyze the enantioselective hydrolysis of meso-epoxides, giving 
(1R, 2R)-13 in 86% ee and (3R, 4R)-14 in 95% ee.[125, 126] However, the EH from 
Sphingomonas sp. HXN-200 has not been identified and cloned yet.  
 Besides the issue with selectivity, many reported EH processes were only 
demonstrated to produce chiral epoxides and diols in low concentration (e.g. <30 g/L). 
There are only a few examples with high product concentration: immobilized AnEH 
(20 g/L) was used to prepare 500 mM (S)-1 in 99% ee and 50% yield,[304] and crude 
extract of AnEH (256 g/L) was applied to produce 940 mM (S)-4 in 99% ee and 47% 
yield.[110] From a practical point of view, the use of easily available and low-cost whole 
cell biocatalysts is a much more economical alternative. In one example, 92 g cdw/L 
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recombinant yeast cells expressing RgEH were applied for the hydrolysis of racemic 1 
for 24 h to give 719 mM (S)-1 in 98% ee and 41% yield.[305] Obviously, the activity of 
the cells is too low, and the required cell density is too high for practical application. 
Moreover, the presence of surfactant (40% Tween 20) seriously hinders downstream 
processing. For Sphingomonas sp. HXN-200, the whole-cell activity for hydrolysis was 
also too low.[125-128] Furthermore, the growth of Sphingomonas sp. HXN-200 on n-
octane is troublesome and problematic.  
Herein, we report our progress in:  
i) Identification, cloning, and characterization of a novel SpEH from 
Sphingomonas sp. HXN-200;  
ii) Engineering of recombinant E. coli cells expressing the SpEH as easily 
available and highly active catalysts for the enantioselective hydrolysis of racemic and 
meso-epoxides (Scheme 3.1);  
iii) Development of an efficient biotransformation process to produce epoxides 
(S)-1−7, (−)-8 and vicinal trans-diols (R, R)-12−14 in high ee and high concentration 
at low catalyst loading within a short reaction time.  
Scheme 3.1. Enantioselective hydrolysis of racemic and meso-epoxides with recombinant E. 
coli expressing EH from Sphingomonas sp. HXN-200.     
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3.2 Experimental Section 
3.2.1 Chemicals, Strains, and Materials 
Most of chemicals and solvents were directly purchased from the following 
suppliers and used without further purification. Styrene oxide 1 (97%), (S)-1 (98%), 
(R)-1 (98%), 2-(4-chlorophenyl)oxirane 4 (96%), 2-(4-fluoro-phenyl)oxirane 6 (95%), 
cyclopentene oxide 9 (98%), cyclohexene oxide 10 (98%), (1R, 2R)-1,2-
cyclopentanediol 12 (98%), (±)-trans-1,2-cyclopentanediol 12 (97%), (1R, 2R)-1,2-
cyclo-hexanediol 13 (99%), (1S, 2S)-1,2-cyclohexane-diol 13 (99%), THF (99.9%), 
phenyl chloroformate (99%), benzyl chloroformate (99%), 1,2,5,6-tetrahydropyridine 
(97%), benzyl 3-pyrroline-1-carboxylate (90%), and m-CPBA (77%) were from 
Sigma-Aldrich. 2-(2-chlorophenyl)oxirane 2 (97%) and 2-(3-chlorophenyl)oxirane 3 
(97%) were from Amatek Chemical. 3-fluorostyrene (97%) and 3-bromostyrene (97%) 
were from Alfa Aesar. Dichloromethane (HPLC), ethyl acetate (HPLC), chloroform 
(HPLC), and isopropanol (HPLC) were from Fisher. Acetonitrile (HPLC) and n-hexane 
(HPLC) were from TEDIA. Silica gel 60 (0.040–0.063 mm) was from Merck. 2-(3-
Fluorophenyl)oxirane 5 and 2-(3-Bromophenyl)oxirane 7, were synthesized according 
to a published method.[108] N-phenoxycarbonyl-3,4-epoxy-piperidine 8 and N-
benzyloxycarbonyl-3,4-epoxy-pyrrolidine 11 were synthesized according to published 
procedures.[126] All the synthesized chemicals were puriﬁed by ﬂash chromatography 
on silica gel columns, and confirmed by 1H NMR analysis. 
T7 Express Competent Escherichia coli, restriction enzymes, and Quick DNA 
Ligase were from New England Biolabs. DNA oligos, Tris buffer (1 M) and IPTG 
(>99%) were purchased from first BASE. Phusion DNA polymerase was purchased 
from Thermo Scientific. Medium components (LB, tryptone, and yeast extract) were 
from Biomed Diagnostics. Antibiotics kanamycin (>99%) and NaCl (>99%) were 
bought from Sigma-Aldrich.  
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3.2.2 Analytical Methods 
The concentrations of epoxides 1–7 and their corresponding diols were 
determined using a Shimadzu prominence HPLC system (reverse phase) with UV 
detection at 210 nm (Column: Agilent Poroshell 120 EC-C18 150 × 4.6 mm, 2.7 µm). 
Condition: 40% water: 60% acetonitrile. Flow rate: 0.5 mL min−1. Retention times 
(min): 1 (6.4) and its diol (3.6); 2 (8.8) and its diol (3.9); 3 (8.3) and its diol (3.9); 4 
(8.2) and its diol (3.9); 5 (6.9) and its diol (3.9); 6 (6.6) and its diol (3.6); 7 (9.3) and 
its diol (4.2).  
The ee values and concentrations of 1–8 and 14 were measured using a 
Shimadzu prominence HPLC system (normal phase) and UV detection at 210 nm with 
a Daicel AS-H or OB-H chiral column (250 × 4.6 mm, 5µm) (Table 3.2).  
Table 3.2. Chiral HPLC methods for separate different enantiomers of 1–8 and 14. 
Sub. Column Conditions Retention time (min) 
1 AS-H 10% IPA: 90% n-Hex, 0.5 mL min−1 10.9 (R) 11.9 (S) 
2 AS-H 0% IPA: 100% n-Hex, 0.5 mL min−1 22.5 (R) 23.2 (S) 
3 AS-H 10% IPA: 90% n-Hex, 0.5 mL min−1 11.1 (R) 11.9 (S) 
4 AS-H 10% IPA: 90% n-Hex, 0.5 mL min−1 11.9 (R) 14.0 (S) 
5 AS-H 10% IPA: 90% n-Hex, 0.5 mL min−1 10.2 (R) 11.0 (S) 
6 AS-H 10% IPA: 90% n-Hex, 0.5 mL min−1 13.5 (R) 14.0 (S) 
7 AS-H 10% IPA: 90% n-Hex, 0.5 mL min−1 11.4 (R) 12.0 (S) 
8 OB-H 40% IPA: 60% n-Hex, 0.5 mL min−1 56.2 (+) 64.7 (−) 





The concentrations of 9–11 were determined by using an Agilent 7890A GC 
system with an HP-5 column (30 m × 0.32 mm × 0.25 mm). Temperature program for 
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9 and 10: 45 oC for 1 min, increase to 140 oC at 15 ◦C min−1 and to 280 oC at 49 oC 
min−1. Retention times (min): 9 (5.6) and 10 (6.7). Temperature program for 11: 100 
oC for 1 min, increase to 280 oC at 10 oC min−1. Retention time (min): 11 (14.6).  
The ee values of diols 12 and 13 were determined using an Agilent 7890A GC 
system with Macherey-Nagel Lipodex-E chiral column (25 m × 0.25 mm) at 100 oC 
constant. Retention times (min): (1S, 2S)-12 (31.3), (1R, 2R)-12 (34.1), (1R, 2R)-13 
(32.7), and (1S, 2S)-13 (33.9). 
The configurations of 1, 12 and 13 were assigned by using authentic samples 
of (S)-1 and (1R, 2R)-12 and (1R, 2R)-13. And the configurations of 2, 3, 4, 8, and 14 
were established by comparison with our previous published HPLC data of (S)-2, (S)-
3, (S)-4, (−)-8 and (3R, 4R)-14.[126, 128, 248] The other bioproducts 5, 6, and 7 were 
assigned by comparison with the epoxidation products by a well-known S selective 
styrene monooxygenase.[138-152] 
3.2.3 Identification of SpEH and Genetic Engineering of E. coli (SpEH)  
The strain Sphingomonas sp. HXN-200 was grown in E2 medium with n-
octane vapor as reported previously.[127] The genomic DNA of Sphingomonas sp. 
HXN-200 was extracted by using Blood and Tissue Kit (Qiagen), and then sent to 
Beijing Genome Institute for de novo bacterial genome sequencing with Illumina 
Highseq2000. The whole genome of Sphingomonas sp. HXN-200 was about 4.75 Mb 
with 4,544 open reading frames (genes) predicted by Glimmer 3.0 software and 
functional annotated by searching against the KEGG, COG, SwissProt, TrEMBL, NR 
databases. There are four possible EHs in the genome: Sp154 (SpEH), Sp990, Sp3688, 
and Sp4354. All of these putative EHs were amplified by PCR using the genome as 
template with appropriate primers (Table 3.3). PCR procedures were according to the 
instruction of Phusion DNA polymerase. The PCR product was subjected to double 
digestion with appropriate restriction enzymes (NdeI/XhoI) and ligated to pRSFduet 
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plasmid (Novagen). The ligation products were transformed into T7 Express competent 
E. coli cells to give E. coli strains for recombinant protein expression and activity test. 
Table 3.3. Primers (DNA oligos) used in the study of SpEH. 
Name Sequence 
Sp154-NdeI-F  ATCGCATATGATGAACGTCGAACATATCCGCCC 











3.2.4 Cell Growth and Specific Activity of E. coli (SpEH) 
The E. coli (SpEH) was grown in 2 mL LB medium containing kanamycin (50 
mg/L) at 37°C for 7−10 h and then inoculated into 50 mL TB (terrific broth) medium 
containing kanamycin (50 mg/L). When OD600 reached 0.6 (about 2 h), IPTG 
(Isopropyl β-D-1-Thiogalactopyranoside, 0.5 mM) was added to induce the expression 
of protein. The cells continued to grow for 10−12 h at 25°C 250rpm, and the cell density 
reached > 4 g cdw/L. Then the cells were harvested by centrifugation (5000 g, 5 min) 
and resuspended in Tris buffer (50 mM, pH 7.5) for activity testing and asymmetric 
hydrolysis. Activity test: freshly prepared E. coli (SpEH) cells were diluted by Tris 
buffer (50 mM, pH 7.5) to 2 mL with 0.5 g cdw/L cell density. And then 2 mL of n-
hexane containing styrene oxide 1 (200 mM) was added to the reaction system in the 
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flask. The reaction mixture was shaken (250 rpm) in an incubator at 30°C for the 30 
min. 300μL aliquots were taken out at 0, 10, 20, and 30 min for HPLC analysis.  
3.2.5 His-tagged SpEH Cloning and Purification for Kinetic Data Determination  
For engineering of His-tagged SpEH, the similar cloning protocol applied with 
slightly different primers (Sp154-BspHI-F, Sp154-His-KpnI-R) and different 
restriction sites (NcoI/KpnI) on pRSFduet. The E. coli (His-tagged SpEH) was grown 
and expressed the His-tagged SpEH in the same condition of E. coli (SpEH). Then the 
cells were broken by cell homogeniser (Stansted fluid power LTD), and then subjected 
to centrifugation (15000 rpm, 20 min, 4 oC). The His-tagged SpEH was purified from 
the supernatant (cell free extract) by using Ni-NTA agarose (Qiagen) according to the 
standard protocol. A SDS-PAGE (12% resolving gel and 4% stacking gel) was applied 
to check the purity of the protein.  
To determine the kinetics data, 1 µg of the purified SpEH was incubated with 
(S)-1 (0.5–8 mM) or (R)-1 (0.2–4 mM) in 1 mL of Tris buffer (50 mM, pH 7.5). The 
mixtures were shaken at 30 oC. 300 µL aliquots were taken out at different time points 
(0, 2, 4 and 8 min) and immediately mixed with 300 µL cold acetonitrile to quench the 
reaction. The samples were analyzed by HPLC to quantify the diol formation 
immediately. The initial velocities were calculated and used to give a Lineweaker-Burk 
plot (1/v vs. 1/[S]) to determine Km, Vmax and kcat. 
3.2.6 General Procedure for Enantioselective Hydrolysis of Racemic Epoxides 
with Resting Cells of E. coli (SpEH) 
 Freshly prepared E. coli (SpEH) cells were diluted by Tris buffer (50 mM, pH 
7.5) to a 5 mL system with required cell density (Table 3.4) in a 100 mL flask. And 
then 5 mL of n-hexane containing appropriate amount of epoxides (Table 3.4) was 
added to the reaction system in the flask. The reaction mixture was shaken (250 rpm) 
in an incubator (New Brunswick Scientific) at 30°C for the appropriate time. 200 μL 
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aliquots were taken out at different time points for HPLC analysis. Analytic samples 
were prepared by centrifugation, and then organic phases (50μL) were separated and 
diluted with n-hexane (containing 2 mM ethyl benzene as internal standard) before 
HPLC analysis for quantification of ee and concentration of the epoxides. 
3.2.7 General Procedure for Enantioselective Hydrolysis of Meso-epoxides with 
Resting Cells of E. coli (SpEH) 
Freshly prepared E. coli (SpEH) cells were diluted by Tris buffer (50 mM, pH 
7.5) to multiple 1 mL systems with required cell density (Table 3.5) in 50 mL flasks. 
Next, an appropriate amount of epoxides (Table 3.5) was directly added to the reaction 
systems in the flasks. The reaction mixture was shaken (250 rpm) in an incubator at 
30°C for the appropriate time. One flask was taken out at different time points and 
totally extracted by adding 2 mL ethyl acetate. Analytic samples were prepared by 
centrifugation, and then 300μL of organic phases were separated, diluted with ethyl 
acetate (containing 2 mM n-dodecane as internal standard), and dried over Na2SO4 
before GC quantification of ee and concentration of the epoxides.  
3.2.8 Procedure for Preparation of (S)-1, (S)-3, and (S)-6 by Enantioselective 
Hydrolysis of the Corresponding Racemic Epoxides with Resting Cells of E. coli 
(SpEH) 
Freshly prepared E. coli (SpEH) cells were diluted by Tris buffer (50 mM, pH 
7.5) to a 20−110 mL system with required cell density (Table 3.6) in a 250−1000 mL 
flask. And then 20−100 mL n-hexane containing appropriate amount of epoxides 
(Table 3.6) was added to the reaction system in the flask. The reaction mixture was 
shaken (250 rpm) in an incubator at 30 °C for the appropriate time. The reaction was 
monitored by HPLC, and terminated by cooling down on ice once the ee value of 
residual epoxide reached 99%. The reaction system was then immediately extracted 
three more times by 3×20−100 mL n-hexane, and all the organic phases were combined. 
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After drying over Na2SO4, the solvents were removed by evaporation. The crude 
product was then purified by flash chromatography on a silica gel column with n-
hexane: ethyl acetate = 50: 1 (Rf  = 0.3 for all the three products). 
3.2.9 Procedure for Preparation of (1R, 2R)-12, (1R, 2R)-13, and (3R, 4R)-14 by 
Enantioselective Hydrolysis of the Corresponding Meso-epoxides with Resting 
Cells of E. coli (SpEH) 
Freshly prepared E. coli (SpEH) cells were diluted by Tris buffer (50 mM, pH 
7.5) to a 5−200 mL system with required cell density (Table 3.7) in a 100−1000 mL 
flask. And appropriate amount of epoxides (Table 3.7) was added to the reaction system 
in the flask. The reaction mixture was shaken (250 rpm) in an incubator at 30 °C for 
the appropriate time. The reaction was monitored by GC, and terminated by cooling 
down on ice once the conversion of meso-epoxides reached 99%. The reaction system 
was immediately saturated with NaCl and extracted four times by 4×5−200 mL ethyl 
acetate, and then all the organic phases were combined. After drying over Na2SO4, the 
solvents were removed by evaporation. The crude product of (3R, 4R)-14 was then 
purified by flash chromatography on a silica gel column with ethyl acetate (Rf = 0.3). 
The crude product of (1R, 2R)-13 was purified by crystallization in ethyl acetate (first 
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3.3 Results and Discussion    
3.3.1 Identification of SpEH, Genetic Engineering of Recombinant E. coli 
Expressing SpEH 
 Genome information is a valuable source to identify powerful enzymes from 
microbes.[65, 66] To identify and clone the EH, the whole genome of Sphingomonas sp. 
HXN-200 was sequenced. Bioinformatic analysis suggested four putative EH genes 
from a total of 4544 possible open reading frames (genes) in the genome. All four 
putative EHs were successfully cloned and heterologously expressed in E. coli. 
However, only one EH (SpEH) was found to show significant activity for the 
hydrolysis of racemic styrene oxide 1 to give the corresponding diol.  
 The gene of SpEH consists of 1146 bp encoding a 381 amino acids polypeptide 
with a calculated molecular weight of 43.04 kDa (Sequence see Appendix I). A 
BLASTP search against the NCBI protein database reveals that the most related protein 
is a putative EH from marine gamma proteobacterium HTCC2148, which shares 54% 
amino acid identity. The low identity suggests that SpEH is unique. Multiple 
alignments of SpEH and other well-studied EHs (Figure 3.2) showed that SpEH shares 
the conserve motifs (H-G-X-P and G-X-Sm-X-S/T), the catalytic trial (D-H-D/E), and 
two conserve Y229 and Y294 with other known EHs, such as AnEH[114] and ArEH.[118] 
This indicates a similar reaction mechanism of SpEH to these EHs: i) epoxide substrate 
is stabilized at the catalytic center by forming two hydrogen bonds between epoxide 
oxygen with two Tyr residues (Y229, Y294); ii) the epoxide carbon is under 
nucleophilic attack by Asp residue (D171) to form a ester intermediate; iii) the ester 
intermediate is hydrolyzed by an activated water to give diol product.      
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Figure 3.2. Sequence alignment of SpEH with several known EHs (by ClustalW2). SpEH, EH 
from Sphingomonas sp. HXN-200 (this study); MgEH, putative EH from marine gamma 
proteobacterium HTCC2148 (EEB77043.1); AnEH, EH from Aspergillus niger (Q9UR30); 
ArEH, EH from Agrobacterium radiobacter AD1 (O31243); StEH, EH from Solanum 
tuberosum (Q41415); HsEH, EH from Homo sapiens (P34913).  Yellow: conserve motifs, H-
G-X-P and G-X-Sm-X-S/T; Green: catalytic trial, D-H-D/E; Cyan: two conserve tyrosine 
residues, Y. “*”: the identical residues; “.”: similar residues; “:”: highly similar residues.     
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 The recombinant E. coli (SpEH) grown easily in TB medium, and the 
expression of SpEH was induced by adding IPTG. As shown in Figure 3.3, a cell 
density of 4.0−4.5 g cdw/L was achieved at 12−15 h. Cells taken at different time points 
showed different whole-cell activity toward the hydrolysis of racemic styrene oxide 1. 
The highest cell-based specific activity was observed for the cells grown at 11−14 h at 
the late exponential growing phase. The expressing of SpEH was clearly shown in the 
SDS-PAGE of the cell-free extracts (CFE) of the E. coli cells taken at 14 h (Figure 3.4, 
Lane 3). The specific activity of the E. coli cells reached 1.6 U/mg cdw (cell dry weight) 
which is 172 times higher than that of the cells of the wild-type strain Sphingomonas 
sp. HXN-200 (9.3U/g cdw).[127] These results demonstrated clearly that E. coli (SpEH) 
cells are highly active and easily available biocatalyst for epoxide hydrolysis. The use 
of the E. coli cells as catalyst is of economic advantage over the use of CFE or purified 
enzyme. In addition to the higher specific activity, recombinant E. coli cells gave also 
cleaner reaction than the wild-type cells which contain the EH at low level and also 
other enzymes for side reactions. 
 
Figure 3.3. Cell growth and cell-based specific activity for the hydrolysis of styrene oxide of E. 
coli (SpEH). Initially, cells were grown at 37 oC, induced at 2 h by IPTG (0.5 mM), and then 
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Figure 3.4. SDS-PAGE of SpEH in different forms. Lane 1: protein marker; Lane 2: cell debris 
of E. coli (SpEH); Lane 3: cell free extract of E. coli (SpEH); Lane 4: purified His-tagged SpEH.  
 
3.3.2 Kinetic Characterization of Purified SpEH 
 An E. coli strain expressing SpEH with His-tagged at the C-terminal was 
genetically engineered to facilitate the purification of SpEH. Cells were grown and 
homogenized, and the CFE was subjected to affinity chromatography with a Ni-NTA 
column. His-tagged SpEH was purified to apparent homogeneity as indicated in SDS-
PAGE (Figure 3.4, Lane 4), with the molecular weight of 46 kDa. This value is very 
close to the calculated one of 43.9 kDa. The specific activity for the hydrolysis of 
styrene oxide 1 was determined to be 16 U/mg protein for His-tagged SpEH. A set of 
hydrolysis reactions were performed with SpEH (1μg/mL) at various concentrations 
(0.2−8 mM) of (S)-1 and (R)-1, respectively, to determine the kinetic data. The initial 
velocities at different substrate concentrations were used for a Lineweaker−Burk plot 
(Figure 3.5). The kinetic data were obtained from the plot (Table 3.4). The 






m) as 16 for the 
hydrolysis of racemic styrene oxide 1. This value is slightly lower than the E value of 
21−23 established previously by the kinetic resolution of 1 with resting cells of 
Sphingomonas sp. HXN-200 in the same single aqueous phase system.[127]  
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Table 3.4. Kinetic data of hydrolysis of (S)-1 and (R)-1 with SpEH. 
Substrate Km (mM) Vmax (μmol min−1 mg−1) kcat (s−1) kcat/Km (mM−1 s−1) 
(S)-1 1.24 10.3 7.4 6.0 
(R)-1 0.15 19.8 14.2 97.3 
 
Figure 3.5. Lineweaver-Burk Plot of SpEH for (R)-1 and (S)-1. 
3.3.3 Enantioselective Hydrolysis of Racemic Epoxides with Resting Cells of E. 
coli (SpEH)  
 Resting cells of E. coli (SpEH) were explored for the enantioselective 
hydrolysis of racemic epoxides 1−8 in a two-phase system consisting of n-
hexane/aqueous buffer (1:1). In such a system, n-hexane acts as a reservoir of the 
substrate, which reduces the nonenzymatic hydrolysis as well as the toxic effect of the 
epoxide on cells; the maintaining of diol products in aqueous phase allows for easy 
separation of epoxides and diols.[306] Substrate concentration of 200−100 mM and cell 
density of 0.5−1.0 g cdw/L were used (Table 3.5). (S)-1 was produced in 99.1% ee and 
41.6% yield after 2.5 h reaction, with a specific activity of 1.4 U/mg cdw. The 
enantioselectivity factor E reached 30, similar to that obtained with the cells of the 
wild-type stain Sphingomonas sp. HXN-200 in the same two-liquid phase system.[127] 
y = 7.3709x + 0.0505
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 Furthermore, hydrolysis of epoxide 3, 5−7 gave (S)-3, (S)-5−7 in 98.0−99.4% 
ee and 42.3−46.5% yield within 1.5−5.5 h. The E values of 36, 35, 28, and 57 represent 
the highest enantioselectivities among all the known EHs for the preparation of (S)-
3,[109, 307] (S)-5, (S)-6,[108, 109] and (S)-7,[109] respectively. The specific activities of 
2.9−0.88 U/mg cdw of the E. coli cells were also very high. Compared to the epoxides 
with a substitution at the para or ortho position (2, 4, 6), the epoxides with a 
substitution at the meta position (3, 5, 7) were hydrolyzed faster (higher specific 
activity) and more selectively (higher E). This preference is significantly different from 
other well-known EHs (such as AnEH),[108, 109] indicating the unique substrate 
specificity and special synthetic application of SpEH. 
Table 3.5. Enantioselective hydrolysis of racemic epoxides 1–8 with E. coli (SpEH)a 
aThe reaction was performed in a two-phase system consisting of Tris–HCl buffer (50 mM, pH 
7.5) and n-hexane (1:1). bConcentration was based on the volume of organic phase. bCell density 
was based on the volume of aqueous phase. dSpecific activity was determined at 30 min. eee 
value and yield were determined by chiral HPLC analysis (chromatograms see Appendix I). fE 















1 200 0.5 150 1.4 (S)-1 99.1 41.6 30 
2 200 1.0 420 0.28 (S)-2 99.3 19.9 7 
3 200 0.5 330 2.2 (S)-3 98.0 44.3 36 
4 200 0.5 480 0.92 (S)-4 98.1 35.1 14 
5 200 0.5 90 2.5 (S)-5 99.4 42.3 35 
6 200 0.5 280 0.88 (S)-6 98.3 42.3 28 
7 150 0.5 180 2.9 (S)-7 98.0 46.5 57 
8 100 1.0 25 4.3 (–)-8 99.5 37.6 22 
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 In addition, E. coli (SpEH) cells showed an E value of 22 for the hydrolysis of 
100 mM N-phenoxycarbonyl epoxypiperidine 8 to give (−)-8 in 99.5% ee and 37.6% 
yield. The specific activity reached 4.3 U/g cdw, and the resolution was completed 
within only 25 min. 
 In the view of even more practical applications, the enantioselectivity of SpEH 
could be further improved. Currently, we are working on elucidation of the 3D structure 
of SpEH and directed evolution of this EH to enhance its enantioselectivity toward the 
hydrolysis of racemic epoxides 1−8.  
 
3.3.4 Enantioselective Hydrolysis of meso-Epoxides with Resting Cells of E. coli 
(SpEH)  
 Biotransformation of meso-epoxides 9−11 at 100 mM was carried out with 
resting cells of E. coli (SpEH) at a cell density of 1.0 g cdw/L. Aqueous buffer was 
used as a single phase for the reaction, since the nonenzymatic hydrolysis rates were 
low for these cyclic epoxides. As shown in Table 3.6, the corresponding (R, R)-vicinal 
trans-diols 12−14 were produced in 86−93% ee and 90−99% yield, respectively. 
Although the ee of (1R, 2R)-12 is lower than that obtained with RgEH, the specific 
activity of 0.34 U/mg cdw is much higher than that of the R. glutinis cells.[302] The ee 
of (1R, 2R)-13 is also lower than that obtained with ArEH;[120] however, a simple 
crystallization in ethyl acetate improved the ee to 99%. The high specific activity of 
0.81 U/mg cdw makes the application of the E. coli (SpEH) cells for the preparation of 
(1R, 2R)-13 practical. The E. coli (SpEH) cells showed also very high activity (2.3 
U/mg cdw) for the hydrolysis of meso-epoxide 11 to (3R, 4R)-14, allowing for the 
completion of the reaction within 1 h. The enantioselectivity for this substrate is the 
best among known examples.[303] 
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Table 3.6. Enantioselective hydrolysis of meso-epoxides 9–11 with E. coli (SpEH)a 
aThe reaction was performed in Tris–HCl buffer (50 mM, pH 7.5). bSpecific activity was 
determined at 30 min. cee value was determined by chiral GC or HPLC analysis (chromatograms 
see Appendix I). dYield was determined by GC analysis. eE value was calculated by E = (1+eep)/ 
(1-eep). 
 
3.3.5 Synthesis of (S)-Styrene Oxide in High Concentration with Resting Cells of 
E. coli (SpEH)  
 The easily available and highly active E. coli (SpEH) cells were examined for 
the hydrolysis at even higher substrate concentration. For demonstration, styrene oxide 
1 was chosen as a model substrate. 1 M (120 g/Lorg) racemic 1 was hydrolyzed in a 
simple two-phase system consisting of n-hexane: aqueous buffer (1:1) at a density of 
E. coli (SpEH) cells of 5.0 g cdw/Laq. As shown in the time course of the 
biotransformation (Figure 3.6), the decrease of (R)-1 is linear during the first 40 min, 
and the reaction finished within 1 h to give (S)-1 >99% ee and 43% yield. The E value 
at this high substrate concentration was 39, which is the highest among all EHs in the 
form of free enzyme, cell extracts, or whole cells.[116, 119, 127, 305, 308, 309] The product 
concentration reached 430 mM in organic phase (51 g/Lorg), and the overall space-time-
yield amounted to 26 g/L/h. The cell-based specific productivity reached 10.3 g/h/g 
cdw. This value is 542 times higher than that (0.019 g/h/g dry weight of cell-free 















9 100 1.0 360 0.34 (1R, 2R)-12 88 99 16 
10 100 1.0 120 0.81 (1R, 2R)-13 86 99 13 
11 100 1.0 60 2.3 (3R, 4R)-14 93 90 28 
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(0.039 g/h/g cdw) achieved in recombinant RgEH-catalyzed kinetic resolution of 1.8 
M 1 at a cell density of 92 g cdw/L for 24 h.[305] Obviously, E. coli (SpEH) cells are 
highly productive catalysts for the resolution of styrene oxide 1 to prepare (S)-1.  
Figure 3.6. Time course of the enantioselective hydrolysis of 1 M racemic styrene oxide 1 with 
resting cells of E. coli (SpEH) (5 g cdw/L) in a two-phase system consisting of Tris–HCl buﬀer 
(50 mM, pH 7.5) and n-hexane (1:1). The error bar represents standard deviation of three 
independent experiments. 
 
3.3.6 Synthesis of (1R, 2R)-Cyclohexane 1,2-Diol in High Concentration with 
Resting Cells of E. coli (SpEH) 
 There is no report on EH-catalyzed enantioselective hydrolysis of meso 
epoxides in high concentration (e.g. > 30 g/L). The E. coli (SpEH) cells were thus 
examined for the hydrolysis of cyclohexene oxide 10, as a mode meso-epoxide, in high 
concentration. The reaction was carried out in aqueous buffer. Because of the limited 
solubility of 10, a second phase was formed initially at high substrate concentration, 
and it was emulsified into aqueous buffer during the course of biotransformation. 
Various substrate concentrations and cell densities were tested, while their ratio was 
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the lower the conversion. While 200 mM and 400 mM 10 were fully converted to (1R, 
2R)-diol 13 in 86% ee in 2 and 3 h, respectively, 600 mM, 800 mM, and 1 M substrate 
were transformed to (1R, 2R)-13 in only 70%, 45%, and 17%, respectively, after 3 h 
reactions. Obviously, substrate at these concentrations can become toxic to the cells 
and inhibit the catalytic activity. To achieve high conversion at higher substrate 
concentration, higher cell density was applied. For instance, at the cell density of 10 g 
cdw/L, 500 mM 10 was transformed to diol 13 in >99% yield (58 g/L) in 1 h. To our 
knowledge, this is the first example of EH-catalyzed enantioselective hydrolysis of 
meso-epoxide to give high product concentration (>30 g/L). 
Figure 3.7. Time course of enantioselective hydrolysis of cyclohexene oxide 10 with resting 
cells of E. coli (SpEH) in Tris–HCl buﬀer (50 mM, pH 7.5) with various substrate 
concentrations (mM): cell densities (g cdw/L). 
 
3.3.7 Preparation of (S)-Epoxides with Resting Cells of E. coli (SpEH) 
 Enantioselective hydrolysis of styrene oxide 1 was performed on a 10-g scale. 
Biotransformation was carried out in 200 mL mixture of Tris−HCl buffer and n-hexane 
(1:1) containing 1 M (120 g/Lorg) styrene oxide 1 in the organic phase and 5.0 g cdw/Laq 
of E. coli (SpEH) cells. Additional ten milliliters of cell suspension (5 g cdw/L) was 

















200 mM:   2 g cdw/L 400 mM:   4 g cdw/L
500 mM:   5 g cdw/L 600 mM:   6 g cdw/L
1000 mM: 10 g cdw/L 500 mM: 10 g cdw/L
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ee. The space-time yield reached 18 g/L/h, which is higher than those of known 
bioprocesses for the preparation of (S)-1, including the asymmetric epoxidation of 
styrene.[152] Workup and flash chromatography gave 4.338 g of enantiopure (S)-1 in 
36.4% isolated yield (Table 3.7). Gram scale resolution of 3 (200 mM, 30 g/Lorg) and 
6 (500 mM, 69 g/Lorg) was also achieved with the resting cells of E. coli (SpEH) under 
non-optimized conditions within 80−90 min. Enantiopure epoxides (S)-3 and (S)-6 
were obtained in 37.9% and 31.3% isolated yields, respectively (Table 3.7). In addition 
to the high product concentrations, the product/cells ratios (7.9−11.7 g/g cdw) as well 
as cell-based specific productivities (5.7−8.8 g/h/g cdw) of these three preparative 
biotransformations are also high. These results suggested that E. coli (SpEH) is a 
powerful catalyst for the practical preparation of these useful and valuable (S)-epoxides. 
When E. coli (SpEH) was compared with the industrial standard, Jacobsen’s Co(salen) 
catalyst, for the preparation of (S)-styrene oxide 1,[283] the product/catalyst ratio is 
similar; but E. coli (SpEH) showed higher catalyst-based specific productivity (6.8 g 
product/h/g cells) than Co(salen) catalyst (0.2 g product/h/g cat); moreover, E. coli 
(SpEH) cells are greener and cheaper than Co(salen) catalyst.  
Table 3.7. Preparation of (S)-1, (S)-3, and (S)-6 with resting cells of E. coli (SpEH).  
aThe reaction was performed in a two-phase system consisting of Tris–HCl buffer (50 mM, pH 
7.5) and n-hexane (1:1), and the scale was referred to the total volume. bConcentration was 
based on the volume of the organic phase. cCell density was based on the volume of the aqueous 
phase. dProduct concentration was determined by chiral HPLC analysis and based on the volume 
of the organic phase. eee was determined by chiral HPLC analysis. 
 
















ee    
(%)e 
Isolated 
yield        









1 210 1000 5.0 70 (S)-1 50.4 >99 4.338   36.4   7.9 6.8 
3  80   200 1.0 80 (S)-3 12.7 >99 0.468   37.9 11.7 8.8 
6  40  500 2.5 90 (S)-6 26.1 >99 0.432   31.3   8.6 5.7 
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 Practical syntheses of vicinal trans-diols from meso-epoxides were also 
demonstrated. Preparation of (1R, 2R)-1, 2-cyclohexanediol 13 was performed in 200 
mL of aqueous buffer containing 500 mM (49.1 g/L) cyclohexene oxide 10 and 10 g 
cdw/L of resting cells of E. coli (SpEH). A conversion of >99% was achieved at 2 h. 
The space time yield reached 26 g/L/h, which is attractive for industrial application and 
also the highest one reported for the biocatalytic synthesis of (1R, 2R)-13. Simple 
workup afforded 10.284 g (89% isolated yield) (1R, 2R)-13 in 86% ee (Table 3.8). Very 
importantly, the ee value was improved to 99% by simple crystallization in ethyl 
acetate, with an overall isolated yield of 68.5% starting from substrate 10. Other two 
useful vicinal trans-diols (1R, 2R)-12 and (3R, 4R)-14 were also synthesized by the 
enantioselective hydrolysis of meso-epoxides 9 (200 mM, 17 g/L) and 11 (200 mM, 44 
g/L) with resting cells of E. coli (SpEH) (4.0 g cdw/L), respectively (Table 3.8). 
After >99% conversion was reached at 3 and 2 h, respectively, simple workup afforded 
(1R, 2R)-12 in 87% ee and 70.4% isolated yield and (3R, 4R)-14 in 93% ee and 94.1% 
isolated yield, respectively. Moreover, the product/cells ratios (3.6−11.1 g/g cdw) and 
the cell-based specific productivities (1.2−5.6 g/h/g cdw) of these three preparations 
are also attractive for practical syntheses. The facile preparation of these useful vicinal 
trans-diols in high ee, high concentration, and high yield demonstrated the great 
application potential of the E. coli (SpEH). 
Table 3.8. Preparation of (R, R) vicinal trans-diols 12, 13, and 14 with E. coli (SpEH).  
aThe reaction was performed in Tris–HCl buffer (50 mM, pH 7.5). bProduct concentration was 
determined by GC analysis. cProduct ee value was determined by chiral GC analysis. dProduct 






















yield         









9 100 200 4.0 180 (1R,2R)-12 20.4 87 1.436  70.4 3.6 1.2 
10 200 500 10.0 120 (1R,2R)-13 58.1 86   
99d 
10.28  88.6               
          68.5d 
5.1 2.6 
11 5 200 4.0 120 (3R,4R)-14 47.4 93 0.223  94.1 11.1 5.6 
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Table 3.9. Physical properties, 1H NMR analysis, and optical rotations of chiral epoxides and 
diols prepared by using E. coli (SpEH).  
Prod. Appearance 1H NMR chemical shift a [α]D28 b Lit. [α]D 
(S)-1 colourless 
liquid 
7.26–7.38 (m, 5H, ArH), 3.85–3.88 (dd, J 
= 4.0, 2.8 Hz, 1H), 3.14–3.16 (dd, J = 5.2, 





[α]D21 =  
+24o (c 1.00, 
CHCl3)[310] 
(S)-3 light yellow 
liquid 
7.26–7.28 (m, 3H, ArH), 7.16–7.18 (m, 
1H, ArH), 3.82–3.84 (dd, J = 4.0, 2.4 Hz, 
1H), 3.13–3.16 (dd, J = 5.6, 4.0 Hz, 1H), 










7.22–7.27 (m, 2H, ArH), 7.00–7.06 (m, 
2H, ArH), 3.83–3.85 (dd, J = 4.0, 2.4 Hz, 
1H), 3.12–3.15 (dd, J = 5.6, 4.0 Hz, 1H), 












3.93–3.98 (m, 2H), 3.18 (s, 2H, OH), 
1.94–2.04 (m, 2H), 1.67–1.74 (m, 2H), 









white crystal 3.32–3.34 (m, 2H), 3.08 (br s, 2H, OH), 
1.95–1.96 (m, 2H), 1.68–1.69 (m, 2H), 











7.24–7.36 (m, 5H, ArH), 5.07 (s, 2H), 
4.08–4.09 (m, 2H), 3.62–3.66 (m, 2H), 




[α]D25 = +7.56 
(c 1.80, 
CHCl3)[126] 
a1H NMR was determined in CDCl3 with TMS as internal standard using a 400 MHz Bruker 
NMR system (spectral see Appendix I). bOptical rotation was determined using a Jasco 










A unique epoxide hydrolase (SpEH) from Sphingomonas sp. HXN-200 was 
successfully identified and cloned based on genome sequencing and bioinformatics 
analysis. The engineered E. coli (SpEH) highly expressed SpEH and gave 172 times 
higher cell-based activity for the hydrolysis of styrene oxide 1 than that of 
Sphingomonas sp. HXN-200. Hydrolysis of racemic styrene oxide 1, substituted 
styrene oxides 3, 5–7, and N-phenoxycarbonyl-3,4-epoxypiperidine 8  (200–100 mM) 
with resting cells of E. coli (SpEH) provided (S)-epoxides 1, 3, 5–7 and (–)-8 in 98.0–
99.5% ee and 37.6–46.5% yield. Hydrolysis of meso- cyclopentene oxide 9, 
cyclohexene oxide 10, and N-benzyloxycarbonyl-3,4-epoxypyrrolidine 11 (100 mM) 
afforded the corresponding (R, R)-vicinal trans-diols 12–14 in 86–93% ee and 90–99% 
yield. The ee of (1R, 2R)-cyclohexane-1,2-diol 13 was improved to 99% by simple 
crystallization. These biotransformations showed high cell-based specific activities 
(0.28–4.3 U/mg cdw), product concentration, product/cells ratio, and cell-based 
productivity. Hydrolysis at even higher substrate concentrations was also achieved: (S)-
1 was produced in 430 mM (51 g/Lorg) and 43% yield; (1R, 2R)-13 was produced in 
500 mM (60 g/L) and >99% yield. Gram-scale preparation of epoxides (S)-1, (S)-3, 
(S)-6 and diols (1R, 2R)-12, (1R, 2R)-13, (3R, 4R)-14 were also demonstrated. E. coli 
(SpEH) cells showed the highest selectivity to produce (S)-1 (E of 39) among all known 
EHs in the form of whole cells or free enzymes and the highest enantioselectivities to 
produce (S)-3, 5, 6, 7 and (–)-8 (E of 36, 35, 28, 57 and 22, respectively) and (R, R)-14 
among all known EHs. The easily available and highly active E. coli (SpEH) cells are 
the best biocatalysts known thus far for the practical preparation of these useful and 
valuable enantiopure epoxides and vicinal diols via hydrolysis. In addition, the SpEH 
could be applied in other applications, such as in multistep cascade biocatalysis to 
produce chiral diols or other α-hydroxy compounds.  
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4 ENANTIOSELECTIVE CASCADE BIOCATALYSIS: 
AYMMETRIC TRANS-DIHYDROXYLATION OF ARYL 
OLEFINS WITH RECOMBINANT BIOCATALYSTS 
Figure 4.1. Asymmetric trans-dihydroxylation of aryl olefins with recombinant E. coli 
coexpressing styrene monooxygenase and different epoxide hydrolases.     
 
4.1 Introduction 
In comparison with hydrolysis and reduction, enantioselective oxidation is 
more challenging in chemistry because it is difficult to fully control selectivity in a 
system with highly reactive oxidants. Nevertheless, several types of asymmetric 
oxidations have been developed. One of the most elegant asymmetric oxidations is 
Sharpless dihydroxylation, which together with Sharpless epoxidation and Sharpless 
aminohydroxylation was recognized by winning Nobel Prize in 2001.[314] In Sharpless 
asymmetric dihydroxylation, C=C double bond is stereoselectively oxidized to two cis- 
hydroxyl groups with osmium tetroxide and chiral cinchona alkaloid ligands (Figure 
4.2).[315] Although it is a powerful reaction with broad substrate scope and high site 
selectivity, it suffers from several drawbacks: the osmium is highly toxic; cinchona 
ligands are expensive; and ferricyanide oxidants are inefficient. On the other hand, 
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nature provides dioxygenases for dihydroxylation with oxygen, however, they are 
usually limited to low regioselectivity and moderate enantioselectivity.[316, 317]     
Figure 4.2. Sharpless asymmetric dihydroxylation of olefins to chiral vicinal cis-diols with 
osmium tetroxide catalyst, chiral cinchona alkaloid ligands, and ferricyanide oxidants.  
To provide a highly selective and green alternative method for asymmetric 
dihydroxylation of olefins, we recently developed a novel type of cascade biocatalysis, 
one-pot cascade epoxidation-hydrolysis, to achieve formal trans-dihydroxylation. 
Cells of Sphingomonas sp. HXN-200 containing a P450 monooxygenase and epoxide 
hydrolase (EH) were used to catalyze the enantioselective trans-dihydroxylation of 
several cyclic olefins.[126] A tandem biocatalysts system consisting of the Escherichia 
coli cells expressing styrene monooxygenase (SMO)[138-152] and the cell-free extract of 
Sphingomonas sp. HXN-200 containing the EH (SpEH)[125-128] was engineered for one-
pot (S)-enantioselective dihydroxylation of aryl olefins;[247] lipase-mediated 
epoxidation and EH-catalysed epoxide hydrolysis were combined for the 
enantioselective trans-dihydroxylation of cyclic olefins via one-pot sequential 
epoxidation and hydrolysis.[248] While asymmetric cis-dihydroxylation of olefins can 
be achieved in one step by Sharpless dihydroxylation,[315] chemical trans-
dihydroxylation of olefins requires two reaction steps: epoxidation of olefins[318] and 
subsequent hydrolysis of epoxides,[282] which needs the separation of toxic and unstable 
epoxide intermediates and also utilizes toxic metals (e.g. Osmium, Cobalt). Thus, one-
pot cascade biocatalysis for trans-dihydroxylation of alkenes provide a greener and 
more efficient synthetic method for the preparation of enantiopure vicinal diols than 
the corresponding two-step chemical catalysis. It is a complementary tool to Sharpless 
dihydroxylation. 
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We are interested in further developing this type of cascade biocatalysis as a 
practical method for the preparation of enantiopure vicinal diols that are useful and 
valuable synthetic intermediates for many pharmaceuticals, bioactive compounds, and 
chiral reagents.[319-328] A group of enantiopure vicinal diols are selected as target 
compounds (Scheme 4.1). For example, (S)-1-phenyl-1,2-ethanediol 1c is a crucial 
synthetic precursor for pharmaceutical (R)-fluoxetine,[320] chiral phosphoramidite 
ligand,[321] and auxiliary for stereoselective glycosylation;[322] (R)-1-(4-fluorophenyl)-
1,2-ethanediol 2c is an intermediate for preparing cholesterol-lowering medicine 
Ezetimibe;[323] (R)-1-(3-chlorophenyl)-1,2-ethanediol 9c is a key chiral synthon for β3-
adrenergic agonists;[324] (S)-1-(3-methoxyphenyl)-1,2-ethanediol 12c is a chiral ligand 
for chromium complexes catalysts;[325] (1R,2S)-phenylpropanediol 16c  and (1S,2S)-
16c are useful for the synthesis of muscle relaxant phenylcarbanate[326] and 
selegiline,[327] respectively; (1R, 2R)-indanediol 18c can be easily converted to (1S)-
amino-(2R)-indanol for the synthesis of anti-HIV drug Indinavir.[328] Thus far, the 
reported cascade biocatalysis system for the dihydroxylation of olefins is relatively 
complicated, its efficiency needs to be further improved for practical application, the 
substrate scope is not fully explored, and the dihydroxylation is only S-selective.  
 
Scheme 4.1. Some important applications of chiral aryl vicinal diols.  
Here, we report our progress in:  
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i) Development of E. coli (SSP1) cells coexpressing SMO and SpEH as a 
simpler and more efficient biocatalyst for S-enantioselective dihydroxylation of 15 
terminal aryl olefins 1a–15a to produce the corresponding (S)-vicinal diols 1c–15c in 
high ee and good yield (Scheme 4.2).  
ii) Engineering of E. coli (SST1) cells coexpressing SMO and another EH 
(StEH, with the complementary regioselectivity of SpEH) as a simple and efficient 
biocatalyst for R-enantioselective dihydroxylation of 15 terminal aryl olefins 1a–15a 
to produce the corresponding (R)-vicinal diols 1c–15c in high ee and good yield 
(Scheme 4.2).  
iii) Further exploration of E. coli (SSP1) and E. coli (SST1) cells for the highly 
enantioselective trans-dihydroxylation of non-terminal aryl olefins 16a–17a to 
synthesize all four enantiomers of 1-phenyl-1,2-propanediol 16c and conversion of aryl 
cyclic olefins 18a–19a to prepare (1R, 2R)-trans-diols 18c–19c.  
iv) Scaling up the cascade biocatalysis process in a bioreactor and preparation 
of 10 useful chiral vicinal diols.  
Scheme 4.2. Enantioselective dihydroxylation of aryl olefins 1a–15a with E. coli (SSP1) to 
produce (S)-vicinal diols (S)-1c–15c, and with E. coli (SST1) to produce (R)-vicinal diols (R)-
1c–15c, respectively. 
 Chapter 4. Cascade Biocatalysis for Asymmetric Dihydroxylation  
79 
 
4.2 Experimental Section 
4.2.1 Chemicals, Strains, and Materials 
The chemicals, strains, and materials which have been used in Chapter 3 were 
not listed here. Please refer to section 3.2.1 for detail.  
Many chemicals and solvents were directly purchased from the commercial 
suppliers and used without further purification. Chemicals from Sigma-Aldrich: 
styrene 1a (≥99%), 4-fluorostyrene 2a (99%), 4-chlorostyrene 3a (97%), 4-
bromostyrene 4a (97%), 4-methylstyrene 5a (≥99%), 3-chlorostyrene 9a (98%), 3-
bromostyrene 10a (97%), 3-methylstyrene 11a (99%), 3-methoxystyrene 12a (97%), 
2-fluorostyrene 13a (98%), 2-methylstyrene 15a (≥95%), trans-β-methylstyrene 16a 
(99%), 2-methyl-1-phenyl-1-propene 20a (99%), α-methylstyrene 21a (99%), 3-
trifluoromethylstyrene 22a (99%), 1-phenyl-1,2-ethanediol 1c (97%),  2-phenyl-1,2-
propanediol 21c (97%), (R)-1-phenyl-1,2-ethanediol (R)-1c (99%), (S)-1-phenyl-1,2-
ethanediol (S)-1c (99%), (S)-1-(2-chlorophenyl)-1,2-ethanediol (S)-14c (96%), (1R, 
2R)-trans-1,2,3,4-tetrahydro-1,2-naphthalenediol (1R, 2R)-19c (≥96%), (1S, 2S)-trans-
1,2,3,4-tetrahydro-1,2-naphthalenediol (1S, 2S)-19c (≥96%), H2SO4 (98%), NaOH 
(pellets), AD-mix-α, AD-mix-β, Hexadecane (99%), Na2SO4 (anhydrous, ≥99%), 
Na2CO3•H2O (puriss), NaHCO3 (ACS reagent), tert-Butyl alcohol (≥99%). Chemicals 
from Alfa Aesar: 4-methoxystyrene 6a (98%), 4-trifluoromethylstyrene 7a (98%), 3-
fluorostyrene 8a (97%), 2-chlorostyrene 14a (98%), 1,2-dihydronaphthalene 19a 
(96%). Chemical from Merck: Indene 18a (≥95%). Chemicals from TCI: cis-β-
methylstyrene 17a (≥98%), 1,2-dihydroxyindan 18c (≥98%, mixture of cis and trans). 
Chemicals from Enamine: 2-(4-trifluoromethylphenyl)oxirane 7b (95%), 2-(3-
trifluoromethylphenyl)oxirane 22b (95%). Chemicals from Spectra Group: 1-(4-
methylphenyl)-1,2-ethandediol 5c, 1-(3-chlorophenyl)-1,2-ethandediol 9c. Chemical 
from Maybridge: (1R, 2R)-indan-1,2-diol (1R, 2R)-18c (97%). Solvent from Fisher: 
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dichloromethane (HPLC). trans-1,2-Dihydroxyindan trans-18c (>95%) was from 
previous synthesis.[329]  
Many racemic diols were synthesized and purified as analytical standards with 
the following three methods:  
i) Chemical synthesis method A: direct acid hydrolysis of racemic epoxide. 
According to a previous publication:[108] 200 mg epoxides were dissolved in the mixture 
of 10 mL THF and 5 mL water. Then 100 µL concentrated H2SO4 (98%) was added 
into the system. The reaction was magnetically stirred at room temperature and TLC 
was performed to check the conversion of epoxide and formation of diol. When the 
majority of epoxide was hydrolyzed (usually take 12–36 h), the reaction system was 
neutralized by adding saturated NaHCO3 solution, saturated with solid NaCl, followed 
by extraction by ethyl acetate three times (3×10 mL). The combined organic phase was 
washed with saturated NaCl solution and dried over Na2SO4 overnight. The solvent 
was then removed by evaporation. The crude product was puriﬁed by ﬂash 
chromatography on a silica gel column (n-hexane: ethyl acetate = 2:1 to 1:1, Rf ≈ 0.3). 
The racemic diols produced by method A including: 1-(4-fluorophenyl)-1,2-ethanediol 
2c, 1-(4-chlorophenyl)-1,2-ethanediol 3c, 1-(4-bromophenyl)-1,2-ethanediol 4c, 1-(4-
trifluoromethyl)-1,2-ethanediol 7c, 1-(3-fluorophenyl)-1,2-ethanediol 8c, 1-(3-
bromophenyl)-1,2-ethanediol 10c, 1-(2-chlorophenyl)-1,2-ethanediol 14c, and 1-(3-
trifluoromethyl)-1,2-ethanediol 22c. All the racemic diols were obtained in 40–80% 
yield. Only 8c is colorless oil, and others are white to light yellow solids under 4 oC 
storage.  
ii) Chemical synthesis method B: m-CPBA epoxidation of olefins and followed 
by acid hydrolysis. According to a previous report:[126] m-CPBA (2 mmol) was stepwise 
added to a stirred solution of olefin (2 mmol) in a CH2Cl2: water system (20 mL, 1:1) 
on ice, and the mixture was stirred at room temperature for 3–12 h. If needed, a second 
equivalent of m-CPBA (2 mmol) was then added to the mixture and stirred for longer 
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time (additional 12 h) to complete the reaction. Na2CO3 (10%) was added to adjust pH 
to 8, and then the mixture was extracted with CH2Cl2 three times (3 × 20 mL). The 
organic phase was separated, washed with saturated NaCl solution, and dried using 
Na2SO4, and the solvent was removed by evaporation. The crude epoxide intermediate 
was directly used for acid hydrolysis without purification.  A mixture of 10 mL THF 
and 5 mL water was added to the system, followed by addition of 100 µL concentrated 
H2SO4 (98%) to start hydrolysis at room temperature. When the hydrolysis completed 
(12–36 h), the reaction system was neutralized by NaHCO3 solution, saturated with 
solid NaCl and then extracted by ethyl acetate three times (3×10 mL). The combined 
organic phase was washed with saturated NaCl solution and dried over Na2SO4 
overnight. The solvent was then removed by evaporation. The crude product was 
puriﬁed by ﬂash chromatography on a silica gel column (n-hexane: ethyl acetate = 2:1 
to 1:1, Rf ≈ 0.3). The racemic diols produced by method B including: 1-(4-
methoxyphenyl)-1,2-ethanediol 6c, 1-(3-methylphenyl)-1,2-ethanediol 11c, 1-(3-
methoxyphenyl)-1,2-ethanediol 12c, 1-(2-fluorophenyl)-1,2-ethanediol 13c, 1-(2-
methylphenyl)-1,2-ethanediol 15c, 1,2,3,4-tetrahydro-1,2-naphthalenediol (trans: cis ≈ 
5: 1) 19c. Except 6c was obtained in 10% yield, all the other racemic diols were 
obtained in 30–70% yield. While 11c is colorless oil, others are white to light yellow 
solid under 4 oC storage. 
iii) Chemical synthesis method C: m-CPBA epoxidation of olefins and base 
hydrolysis in one pot. According to a previous study[330]: m-CPBA (2 mmol) was 
stepwise added to a stirred solution of olefin (2 mmol) in CH2Cl2 (15 mL) on ice, and 
the mixture was stirred at room temperature for 3–12 h. If needed, a second equivalent 
of m-CPBA (2 mmol) was then added to the mixture and stirred for longer time 
(additional 12 h) to complete the reaction. Once the epoxidation finished, high 
concentrated NaOH (10 M, 100 µL) was added, and the mixture was reflex at 80 oC. 
The reaction was monitored by TLC, and once completed, extracted with CH2Cl2 three 
 Chapter 4. Cascade Biocatalysis for Asymmetric Dihydroxylation  
82 
 
times (3 × 20 mL). The organic phase was separated, washed with saturated NaCl 
solution, and dried using Na2SO4, and the solvent was removed by evaporation. The 
crude product was puriﬁed by ﬂash chromatography on a silica gel column (n-hexane: 
ethyl acetate = 2:1 to 1:1, Rf ≈ 0.3). The racemic diols produced by method C including: 
1-phenyl-1,2-propanediol 16c (as mixture of four enantiomers), 2-methyl-1-phenyl-
1,2-propanediol 20c, which were obtained in 40–60% yield, and become white solid 
under 4 oC storage.  
Many enantiopure/enriched diols were synthesized in 10 mg-scale as chiral 
standards using Sharpless dihydroxylation method. The asymmetric synthesis was 
performed as reported[331]: 0.1 mmol olefin was added to 1 mL mixture of tert-BuOH 
and water (1:1) with 0.15g AD-mix-α (or AD-mix-β for another enantiomer). The 
reaction was shaken on a mixing block at room temperature for 3 h, and then 50 mg 
Na2SO3 was added to quench the dihydroxylation. The tert-BuOH was removed by 
evaporation, and the remaining aqueous phase was saturated with NaCl and extracted 
with ethyl acetate (2 mL). The organic layer was dried by Na2SO4 for 5 h, and then the 
clear upper layer was separated and evaporated. The enantiopure/enriched diols were 
obtained and directly used in chiral HPLC analysis without further purification. The 
enantiopure/enriched diols prepared including: (S)-2c, (S)-3c, (S)-4c, (S)-5c, (S)-6c, 
(S)-7c, (S)-8c, (S)-9c, (S)-10c, (S)-11c, (S)-12c, (S)-13c, (S)-15c, (1S, 2S)-16c, (1S, 2R)-
16c, (S)-20c, (S)-21c, (S)-22c, (R)-2c, (R)-3c, (R)-4c, (R)-5c, (R)-6c, (R)-7c, (R)-8c, 
(R)-9c, (R)-10c, (R)-11c, (R)-12c, (R)-13c, (R)-15c, (1R, 2S)-16c, (1R, 2R)-16c, (R)-
20c, (R)-21c, (R)-22c. 
Glucose, and other salts in culture medium were from Sigma Aldrich or Merck. 
IPTG from Gold Biotechnology. Other biochemicals and strains are the same to 
Chapter 3.  
The following two culture media were used:  
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1 L M9 medium containing: 8.5 g Na2HPO4•2H2O, 3.0 g KH2PO4, 0.5 g NaCl, 
1.0 g NH4Cl, 2 mL MgSO4 solution (1M), 0.1 mL CaCl2 solution, 1 mL 1000X MT 
solution (8.3 g/L FeCl3•6H2O, 0.84 g/L ZnCl2, 0.13 g/L CuCl2•2H2O, 0.1 g/L 
CoCl2•2H2O, 0.1 g/L H3BO3, 0.016 g/L MnCl2•4H2O, 1 M HCl), 30 g/L glucose, and 
5 g/L yeast extract.  
1 L modified Riesenberg medium[332] containing: 13.3 g KH2PO4, 4.0 g 
(NH4)2HPO4, 1.7 g Citric acid, 1.2 g MgSO4•7H2O, 4.5 mg Thiamin HCl, 15 g Glucose, 
10 mL trace metal solution (6 g/L Fe(III) citrate, 1.5 g/L MnCl2•4H2O, 0.8 g/L 
Zn(CH3COO)2•2H2O, 0.3 g/L H3BO3, 0.25 g/L Na2MoO4•2H2O, 0.25 g/L CoCl2•6H2O, 
0.15 g/L CuCl2•2H2O, 0.84 g/L EDTA, 0.1 M HCl).  
 
4.2.2 Analytical Methods  
The concentrations of diol products (1c–22c) from biotransformations were 
determined using a Shimadzu prominence reverse phase HPLC system with an Agilent 
Poroshell 120 EC-C18 column (150 × 4.6 mm, 2.7 µm) and UV detection at 210 nm. 
Conditions: 40% water: 60% acetonitrile, flow rate: 0.4 mL min−1. The retention times 
for most of the diols (1c–22c) are from 4 to 5 min. The concentrations of alkene 
substrates (1a–22a) were quantified using a Shimadzu prominence normal phase HPLC 
system with an Agilent Zorbax Rx-SIL column (150 × 4.6 mm, 5 µm) and UV detection 
at 210 nm. Condition: 10% IPA: 90% n-hexane, flow rate: 1.0 mL min−1. The retention 
times for most of the alkenes (1a–22a) are from 1 to 2 min.  
The ee and de values of diol products (1c–22c) were determined by chiral 
HPLC using a Shimadzu prominence HPLC system (normal phase) and UV detection 
at 210 nm with a Daicel AS-H, OB-H, or IA-3 chiral column (250 × 4.6 mm, 5µm) 
(Table 4.1). 
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Table 4.1. Chiral HPLC methods and retention times for all diols (1c–22c). 
Prod. Column Conditions Retention time (min) 
1c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 10.9 (S) 11.6 (R) 
2c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 11.6 (S) 12.7 (R) 
3c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 10.9 (S) 12.4 (R) 
4c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 10.9 (S) 12.5 (R) 
5c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 9.9 (S) 11.1 (R) 
6c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 18.3 (S) 19.7 (R) 
7c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 7.3 (S) 8.7 (R) 
8c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 9.9 (S) 10.6 (R) 
9c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 10.3 (S) 10.7 (R) 
10c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 10.7 (S) 11.0 (R) 
11c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 9.3 (S) 9.8 (R) 
12c IA-3 10% IPA: 90% n-Hex, 1.0 mL min−1 12.8 (S) 13.8 (R) 
13c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 10.9 (S) 9.7 (R) 
14c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 11.5 (S) 9.5 (R) 
15c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 9.3 (S) 8.9 (R) 
16c IA-3 5% IPA: 95% n-Hex, 1.0 mL min−1 16.8 (1S, 2S); 
18.2 (1S, 2R) 
18.7 (1R, 2S); 
20.5 (1R, 2R) 
18c OB-H 10% IPA: 90% n-Hex, 1.0 mL min−1 11.9 (1S, 2S); 
16.0&17.2 (cis) 
13.4 (1R, 2R); 
16.0&17.2 (cis) 
19c OB-H 10% IPA: 90% n-Hex, 1.0 mL min−1 12.5 (1S, 2S); 
15.2&16.6 (cis) 
13.7 (1R, 2R); 
15.2&16.6 (cis) 
20c IA-3 10% IPA: 90% n-Hex, 1.0 mL min−1 8.6 (S) 10.6 (R) 
21c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 8.6 (S) 10.2 (R) 
22c AS-H 10% IPA: 90% n-Hex, 1.0 mL min−1 6.9 (S) 7.4 (R) 
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4.2.3 Genetic Engineering of Recombinant E. coli Strains Coexpressing SMO and 
SpEH or StEH 
Construction of plasmid SSP1: primers StyA-BspHI-F and StyA-EcoRI-R (see 
Table 4.2 for a full list of primers) were used to amplify the styA from pSPZ10,[149] and 
primers StyB-EcoRI-RBS-F and StyB-KpnI-R were used to amplify the styB from 
pSPZ10, and primers SpEH-KpnI-RBS-F and SpEH-XhoI-R were used to amplify the 
spEH from the genome of Sphingomonas sp. HXN-200. Phusion DNA polymerase was 
used for all the PCRs according to the instruction. The PCR products were subjected 
to double digestion with appropriate restriction enzymes (New England Biolabs), and 
the parental plasmid pRSFduet (Novagen) was also subjected to digestion. Then 
ligation of digested PCR product and plasmid was performed, and then the ligation 
products were used for chemical transformation of competent T7 Express Competent 
E. coli cell (New England Biolabs). The three genes (styA, styB, and spEH) were 
inserted to pRSFduet one by one (first styA, then styB, last spEH). The final successful 
construction is SSP1 which was transformed to E. coli to give E. coli (SSP1).  
Similarly, the construction of plasmid SSP2-1 used primers StyA-BspHI-F, 
StyA-EcoRI-R, StyB-EcoRI-RBS-F, StyB-HindIII-R, SpEH-NdeI-F, and SpEH-XhoI-
R. The genetic construction is on the same parental plasmid pRSFduet but using 
different cloning sites. The transformation of SSP2-1 gave E. coli (SSP2-1). 
Similarly, the construction of plasmid SSP2-2 used primers StyA-BspHI-F, 
StyA-EcoRI-R, StyB-NdeI-F, StyB-KpnI-R, SpEH-KpnI-RBS-F, and SpEH-XhoI-R. 
The genetic construction is on the same parental plasmid pRSFduet but using different 
cloning sites. The transformation of SSP2-2 gave E. coli (SSP2-2). 
Construction of plasmid SST1 is similar to SSP1, but stEH was amplified from 
the synthesized stEH gene (codon optimized for E. coli, See appendix II for the DNA 
sequence) from Genscript according to the sequence Genbank U02497 using primers 
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StEH-KpnI-RBS-F and StEH-XhoI-R. Other styA and styB construction is the same to 
SSP1 by using the intermediate genetic construct in the last step engineering of SSP1. 
The transformation of SST1 gave E. coli (SST1). 


















Construction of plasmid SST2-1 is similar to SSP2-1, but just the gene of last 
enzyme stEH was amplified using StEH-NdeI-F, and StEH-XhoI-R. And the 
construction intermediate in the last step of SSP2-1 was used for SST2-1. The 
transformation of SST2-1 gave E. coli (SST2-1). 
Construction of plasmid SST2-2 is similar to SSP2-2, but just the gene of last 
enzyme stEH was amplified using StEH-KpnI-RBS-F, and StEH-XhoI-R. And the 
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construction intermediate in the last step of SSP2-2 was used for SST2-2. The 
transformation of SST2-2 gave E. coli (SST2-2).  
4.2.4 Cell Growth and Dihydroxylation Activity of E. coli (SSP1) or E. coli (SST1) 
 E. coli strain, E. coli (SSP1) or E. coli (SST1), was cultured in 2mL LB 
medium containing kanamycin (50 mg/L) at 37 oC for 7–10 h, and then inoculated into 
50 mL M9 medium containing glucose (30 g/L), yeast extract (5 g/L), and kanamycin 
(50 mg/L). The cells were grown at 37 oC for 2 h to reach an OD600 of 0.6, and then 
IPTG (0.5 mM) was added to induce the expression of enzymes. The cells continued 
to grow for 10–12 h at 25 oC to reach a cell density of 5–6 g cdw/L. The cells were 
harvested by centrifugation (5000g, 5 min), and the cell pallets were used as catalysts 
for the activity test or biotransformation. 
Activity test: freshly prepared E. coli (SSP1) or E. coli (SST1) cells were 
suspended to a cell density of 1.0 g cdw/L in KP (potassium phosphate) buffer (200 
mM, pH 8.0) containing glucose (2%, w/v) and 40 µL styrene 1a stock solution (0.5 M 
in ethanol) to 2 mL system. The reaction mixture was shaken at 250 rpm and 30 oC for 
30 min. 1 mL aliquots were taken out and mixed with 1 mL acetonitrile to stop reaction. 
After centrifugation, the supernatant was used for HPLC analysis of the diol product. 
4.2.5 General Procedure for Enantioselective Dihydroxylation of Aryl Olefins 1a–
22a with Resting Cells of E. coli (SSP1) or E. coli (SST1) 
Freshly prepared E. coli (SSP1) or E. coli (SST1) cells were resuspended to a 
cell density of 10 g cdw/L in KP buffer (200 mM, pH 8.0) containing glucose (2%, w/v) 
to 2 mL system in a shaking flask (100 mL). 2 mL n-hexadecane containing 20 mM 
aryl olefins 1a–22a was added to the reaction system to form a second phase. The 
reaction mixture was shaken at 250 rpm and 30 oC for 8 h. 200 µL aliquots of each 
phase were taken out at 0 h, 0.5 h, 2 h, and 8 h for following the reaction. For organic 
phase, n-hexadecane (100 µL) were separated after centrifugation, diluted with 900 µL 
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n-hexane (containing 2 mM benzyl alcohol as internal standard), and subjected to 
normal phase HPLC analysis for quantifying the olefin substrates 1a–22a and possible 
epoxide intermediate. For aqueous phase, supernatants (100 µL) were separated after 
centrifugation, diluted with 400 µL water and 500 µL acetonitrile (containing 2 mM 
benzyl alcohol as internal standard), and then used for reverse phase HPLC analysis of 
the diol products 1c–22c. The remaining aqueous phase (about 1 mL) after 8 h in the 
flask was subjected to centrifugation to remove the cells, followed by extraction with 
ethyl acetate and dry over Na2SO4. After evaporation, the residue was dissolved in 2 
mL solvent (hexane: IPA = 9:1) for chiral HPLC analysis of the ee and/or de of the diol 
products 1c–22c. 
4.2.6 General Procedure for Preparation of (1S)-Vicinal Diols by Enantioselective 
Dihydroxylation of Aryl Olefins with Resting Cells of E. coli (SSP1) 
Freshly prepared E. coli (SSP1) cells were resuspended to a cell density of 20 
g cdw/L in KP buffer (200 mM, pH 8.0) containing glucose (2%, w/v) to 45 mL system 
in a shaking flask (250 mL with tri-baffle). 5 mL n-hexadecane containing 2.50 mmol 
substrate (0.260 g 1a, 0.305 g 2a, 0.295 g 5a, 0.346 g 9a, and 0.335 g 12a) was added 
to the reaction system to form a second phase (50 mM substrate concentration based 
on total reaction volume). The reaction mixture was shaken at 250 rpm and 30 oC, and 
the reaction was monitored by TLC. After 5–8 h, the substrate disappeared totally, and 
the reaction mixture was then saturated with NaCl. After centrifugation, the aqueous 
phase was collected and washed with 10 mL n-hexane. The aqueous phase was then 
extracted with ethyl acetate three times (3 × 50 mL), and all the organic phase were 
combined. After drying over Na2SO4, the solvents were removed by evaporation. The 
crude diol products were purified by flash chromatography on a silica gel column with 
n-hexane: ethyl acetate (2–1:1) as eluent (Rf ≈ 0.3 for all diol products). 
4.2.7 General Procedure for Preparation of (1R)-Vicinal Diols by Enantioselective 
Dihydroxylation with Resting Cells of E. coli (SST1) 
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Freshly prepared E. coli (SST1) cells were resuspended to a cell density of 20 
g cdw/L in KP buffer (200 mM, pH 8.0) containing glucose (2%, w/v) to 45 mL system 
in a shaking flask (250 mL with tri-baffle). 5 mL n-hexadecane containing 2.50 mmol 
substrate (0.260 g 1a, 0.305 g 2a, 0.346 g 9a, 0.295 g 16a, and 0.295 g 17a) was added 
to the reaction system in the flask. The reaction mixture was shaken at 250 rpm and 30 
oC. The reaction was monitored by TLC. After 5–8 h, the substrate disappeared totally. 
The reaction mixture was then saturated with NaCl. After centrifugation, the aqueous 
phase was collected and then washed with 10 mL n-hexane. The aqueous phase was 
extracted with ethyl acetate three times (3 × 50 mL), and all the organic phase were 
combined. After drying over Na2SO4, the solvents were removed by evaporation. The 
crude diol products were then purified by flash chromatography on a silica gel column 
with n-hexane: ethyl acetate (2–1:1) (Rf ≈ 0.3 for all diol products). 
4.2.8 Enantioselective Dihydroxylation of Styrene 1a with Growing Cells of E. coli 
(SST1) in a Bioreactor 
E. coli (SST1) was cultured in 2 mL LB medium containing kanamycin (50 
mg/L) at 37 oC for 7–10 h, and then inoculated into 100 mL M9 medium containing 
glucose (30 g/L), yeast extract (5 g/L), and kanamycin (50 mg/L). The cells were grown 
at 30 oC for 12 h to reach an OD600 of 15. All culture was transferred into 900 mL 
sterilized modified Riesenberg medium with 15 g/L glucose as carbon source in a 3 L 
fermentor (Sartorius). The cells were grown in the fermentor at 30 oC for 12 h to reach 
an OD600 of 15–18. During the batch growth, the pH value was maintained at 7.0 by 
adding 30% phosphoric acid or 25% ammonia solution based on pH sensing, and the 
stirring rate was kept constant at 1000 rpm, and aeration rate was kept constant at 1 
L/min. At the end of batch growth (12 h), PO2 started to increase, indicating glucose 
depletion. Fed-batch growth was started by feeding a solution containing 730 g/L 
glucose and 19.6 g/L MgSO4·7H2O. The feeding rate was stepwise increased: 6.5 mL/h 
for 1 h, 8 mL/h for 1 h, 10 mL/h for 1h, 13 mL/h for 1 h, then kept at 16 mL/h until the 
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end of reaction. Stirring rate was stepwise increased: 1200 rpm for 2 h, 1500 rpm for 
2h, then kept at 2000 rpm until the end of reaction. Aeration rate was stepwise increased: 
1.2 L/min for 2 h, 1.5 L/min for 2h, then kept at 2.0 L/min until the end of reaction. 
Antifoam PEG2000 (Fluka) was added when necessary. After fed-batch growth for 2 
h, IPTG (0.5 mM) was added to induce the expression of protein. After fed-batch 
growth for 5 h, the cell density reached 20 g cdw/L, and the biotransformation started 
by dropwise adding styrene 1a at the rate of 6 mL/h for 4 h, and then 3 mL/h for 
additional 1 h. The reaction was monitored by taking sample every hour for analyzing 
the formation of diol 1c by reverse phase HPLC. After 5 h reaction, 120 mM (R)-1-
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4.3 Results and Discussion    
4.3.1 Genetic Engineering of E. coli Coexpressing of SMO and SpEH for S-
Selective Dihydroxylation of Styrenes 
 SMO was chosen as the enzyme for epoxidation of olefins in the first step of 
the cascade, since it is a well-known enzyme for the epoxidation of styrenes to give 
(S)-epoxides in high ee.[138-152] In addition, the epoxidation of styrenes with 
recombinant E. coli expressing SMO has been developed as one of the most productive 
biocatalytic oxyfunctionalization processes.[152] EH from Sphingomonas sp. HXN-200 
(SpEH) was used as the enzyme for the hydrolysis of the epoxides in the second step 
of the cascade, because this EH is known to hydrolyze (S)-styrene oxides at the β 
position to give (S)-diols in high ee with the retention of configuration. [127, 128] The E. 
coli strain expressing SpEH was also developed as an efficient catalyst for the 
preparation of enantiopure epoxides by kinetic resolution (see Chapter 3).  
Scheme 4.3. Enantioselective dihydroxylation of styrene 1a with E. coli (SSP1) coexpressing 
SMO and SpEH to produce (S)-1c. 
  
To develop recombinant E. coli containing both SMO and SpEH as a simple 
and efficient catalyst system for the dihydroxylation of olefins (Scheme 4.3), the two 
coding sequences of SMO (styA and styB) were amplified from pSPZ10 plasmid,[149] 
and the gene of SpEH was amplified from the genome of the Sphingomonas sp. HXN-
200. To optimize the expression level of the three genes, we engineered three different 
expression cassettes on the commercially available plasmid pRSFduet (Figure 4.3a): 
SSP1, an artificial operon of styA, styB, and spEH controlled by one T7 promoter; 
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SSP2-1 and SSP2-2, where styA, styB, and spEH are under the control of two T7 
promoters. These plasmids were transformed into E. coli T7 expression cell to give E. 
coli (SSP1), E. coli (SSP2-1), and E. coli (SSP2-2), respectively. These strains were 
grown in TB medium, and IPTG was added to induce protein expression. As a result, 
all three strains were able to coexpress SMO (StyA and StyB) and SpEH, but at 
different levels. The strains were examined for biotransformation of 100 mM styrene 
1a in a two-liquid phase system consisting of potassium phosphate (KP) buffer and n-
hexadecane (1:1). E. coli (SSP1) showed the best results, producing 65 mM (S)-1-
phenylethane-1,2-diol 1c in 99% ee at 5 h (Figure 4.3a). Other two strains also gave 
(S)-1c, but in lower concentration. In comparison of other two strains, E. coli (SSP1) 
has higher ratio of SMO/SpEH, which is desirable for the cascade dihydroxylation, 
since the catalytic efficiency of SpEH (kcat/Km = 6.0 mM−1 s−1, Chapter 3) is higher than 
that of SMO (kcat/Km = 4.2 mM−1 s−1).[141] The superior of E. coli (SSP1) is also probably 
due to the more homogeneous expression of several genes in one operon. E. coli (SSP1) 
was selected for further development. 
 
Figure 4.3. a) Genetic constructions of and dihydroxylation with three different E. coli strains 
coexpressing SMO (StyA and StyB) and SpEH; b) Genetic constructions of and dihydroxylation 
with three different E. coli strains coexpressing SMO (StyA and StyB) and StEH. The 
dihydroxylation of 100 mM styrene 1a to diol 1c was performed with resting cells (10 g cdw/L) 
of the corresponding E. coli strain at 30 oC in a two-liquid phase system (n-hexadecane: KP 
buffer = 1:1). 
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4.3.2 Genetic Engineering of E. coli Coexpressing of SMO and StEH for R-
Selective Dihydroxylation of Styrenes 
Scheme 4.4. Enantioselective dihydroxylation of styrene 1a with E. coli (SST1) coexpressing 
SMO and StEH to produce (R)-1c. 
 
To develop a cascade biocatalysis for R-selective dihydroxylation of styrenes, 
the EH from Solanum tuberosum (StEH) was selected as the enzyme for the hydrolysis 
step, because StEH is known to hydrolyze (S)-styrene oxides to offer (R)-diols by 
opening at the α position (inversion of configuration).[333–336] The regioselectivity for 
the hydrolysis with StEH is complementary to that with SpEH. The gene of StEH was 
synthesized according to the reported potato cDNA sequence[334] with codon 
optimization for the expression in E. coli. Similar to the engineering of SMO and SpEH, 
three different expression cassettes of SMO and StEH were constructed, and three 
strains E. coli (SST1),  E. coli (SST2-1), and  E. coli (SST2-2) were obtained and 
evaluated for the dihydroxylation (Figure 4.3b). E. coli (SST1) gave a specific activity 
of 40 U/g cdw and produced 82 mM (R)-1-phenylethane-1,2-diol 1c in 96% ee at 5 h 
in the dihydroxylation of 100 mM styrene 1a at a cell density of 10 g cdw/L in the two-
liquid phase system. It is the best among the three strains. Thus, E. coli (SST1) was 
chosen for further development as a powerful catalyst for R-enantioselective 
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4.3.3 Cell Growth and Activity of E. coli (SSP1) and E. coli (SST1) 
 E. coli (SSP1) strain was grown easily in M9 medium with glucose as carbon 
source in a shaking flask, and SMO and SpEH were coexpressed by adding IPTG as 
inducer. The growth and activity of the cells were monitored by taking samples at 
different time points for measuring the optical density and dihydroxylation activity. As 
shown in Figure 4.4a, the cells reached a high density (5–6 g cdw/L; cdw: cell dry 
weight) at 13–16 h. High specific activities (70–80 U/g cdw) toward (S)-
dihydroxylation of styrene 1a were achieved at the late exponential growing phase (11–
13 h). In the SDS-PAGE of the cell free extract of the E. coli (SSP1) taken at 12 h 
(Figure 4.4c, lane 3), StyA, StyB, and SpEH are clearly visible.  
Figure 4.4. a-b) Cell growth and specific activity for dihydroxylation of the recombinant strains. 
a) E. coli (SSP1); b) E. coli (SST1). Cells were initially cultured at 37 oC, induced at 2 h by the 
addition of IPTG (0.5 mM), and then grown at 25 oC. The activities were based on 30 min 
dihydroxylation of 10 mM styrene 1a with resting cells (1 g cdw/L) in aqueous buffer. c) SDS-
PAGE, Lane 1: Protein Marker; Lane 2: Cell-free extract of E. coli (SST1) coexpressing SMO 
and StEH taken at 12 h; Lane 3: Cell-free extract of E. coli (SSP1) coexpressing SMO and SpEH 
taken at 12 h. 
E. coli (SST1) showed a similar cell growth curve and reached high cell density 
(5–6 g cdw/L) at 13–16 h (Figure 4.4b).  Good specific activities (40–50 U/g cdw) for 
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R-dihydroxylation of styrene 1a were also achieved at the late exponential growing 
phase (12–14 h). The SDS-PAGE of the cell free extract of the E. coli (SST1) taken at 
12 h (Figure 4.4c, lane 2) also clearly demonstrated the expressing of StyA, StyB, and 
StEH in E. coli (SST1). 
4.3.4 S-selective trans-Dihydroxylation of Terminal Aryl Olefins with Resting 
Cells of E. coli (SSP1)  
Scheme 4.5. Enantioselective dihydroxylation of aryl olefins 1a–15a with E. coli (SSP1) 
coexpressing SMO and SpEH to produce (S)-vicinal diols (S)-1c–15c. 
To explore the synthetic potential of E. coli (SSP1), the resting cells of the 
strain were employed for the dihydroxylation of 20 mM styrene 1a and substituted 
styrenes 2a–15a (Scheme 4.5) in a two-liquid phase system containing KP buffer and 
n-hexadecane (1:1). The n-hexadecane phase acts as a reservoir of the substrate and 
possible epoxide intermediate to reduce their inhibition effect on the enzymes. As listed 
in Table 4.3, (S)-vicinal diols 1c–15c were produced in high ee from 1a–15a by the 
one-pot cascade epoxidation and hydrolysis with resting cells of E. coli (SSP1). 
Importantly, many vicinal diols, such as (S)-1c–4c, (S)-7c–10c, (S)-12c, and (S)-13c, 
were produced in excellent ee (>97.5%). Other vicinal diols, including (S)-5c, (S)-11c, 
and (S)-14c, were obtained in high ee (92.2–93.9%). The configurations of 1c–15c were 
established by comparing bioproducts with the standard diols that were either 
commercially available or prepared via Sharpless asymmetric dihydroxylation (Figure 
S2.1-S2.15, Appendix II). The high S-enantioselectivity of dihydroxylation is due to 
the high S-enantioselectivity of SMO-catalyzed epoxidation of styrenes and the high 
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regioselectivity of SpEH-catalyzed hydrolysis of (S)-epoxides at the β position. Only 
two diols, (S)-6c and (S)-15c, were produced in moderate ee (83.2% and 65.7%), 
possibly due to the autohydrolysis of unstable epoxide 6b or the reduced 
regioselectivity of SpEH in hydrolysis of epoxide 15b.  
Most of the dihydroxylations gave high conversion and high yield. (S)-Vicinal 
diols 1c, 8c, 9c, 11c, 12c, and 13c were obtained in 91–>99% yields, (S)-2c and (S)-5c 
were formed in 86–88% yields, and (S)-3c, (S)-6c, and (S)-10c were produced in 67–
73% yields. This confirmed that SMO and SpEH coexpressed in the E. coli cells are 
very active for the cascade biocatalysis. The specific activity for these S-
dihydroxylations is 11–55 U/g cdw, with the exception for the S-dihydroxylation of 
10a (8 U/g cdw). In the previous reported tandem biocatalysts system, (S)-epoxide 1b 
accumulated as the intermediate in the early stage of the biotransformation.[247] Due to 
the high activity of SpEH in E. coli (SSP1), there was no epoxide accumulated during 
the cascade biocatalysis with resting cells of E. coli (SSP1). The time curve of 
dihydroxylation of 9a was a representative example (Figure 4.5), which clearly 
evidenced this point. In comparison with the previous reported tandem biocatalysts (20 
mM 1a was converted in 21 h with 2.5 g cdw/L of E. coli cells expressing SMO and 
20 g protein/L of cell free extract containing SpEH),[247] the use of resting cells of E. 
coli (SSP1) coexpressing SMO and SpEH provides a much simpler catalyst and much 
higher catalytic efficiency: 20 mM 1a was converted to (S)-1c in only 2 h with 10 g 
cdw/L of E. coli (SSP1) cells.  
The S-dihydroxylations of 4a, 7a, 14a, and 15a with resting cells of E. coli 
(SSP1) gave lower yields (25–34%). This is mainly due to the low epoxidation activity 
of SMO towards these substrates, which have either a strong electron-withdrawing 
group or an ortho-substitution.[143-145] 
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Table 4.3. Enantioselective dihydroxylation of aryl olefins 1a–15a with resting cells of E. coli 
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a The reactions were performed with substrates 1a–15a (20 mM in organic phase) and resting 
cells (10 g cdw/L) in a two-liquid phase system consisting of KP buffer (200 mM, pH 8.0, 2% 
glucose) and n-hexadecane (1:1) at 30 oC for 8 h. b Activity is the specific activity determined 
for initial 30 min. c Conversion is the consumption of starting substrate, determined by normal 
phase HPLC analysis of the remaining substrate in the n-hexadecane phase. Error limit: 3% of 
the state values. d Yield is the analytical yield of the formation of diol product, determined by 
reverse phase HPLC analysis of the product in the aqueous phase. Error limit: 3% of the state 
values. e ee value was determined by chiral HPLC analysis. Error limit: 0.2% of the state values. 
f Yield is slightly higher than conversion due to the error limit in the measurement of yield and 
conversion.  
 
Figure 4.5. Typical time course of enantioselective dihydroxylation of 3-chlorostyrene 9a to 
(S)-1-(3-chlorophenyl)-1,2-ethanediol 9c with resting cells of E. coli (SSP1). The 
dihydroxylation was performed with resting cells (10 g cdw/L) in a two-liquid phase system (n-
hexadecane: KP buffer = 1:1). 
4.3.5 R-selective trans-Dihydroxylation of Terminal Aryl Olefins with Resting 
Cells of E. coli (SST1)  
 To explore the synthetic potential of another strain, E. coli (SST1), the resting 
cells of the strain were used for the R-dihydroxylation of 20 mM olefins 1a–15a 
(Scheme 4.6) in the same two-liquid phase system as described above. The results are 
listed in Table 4.3, and (R)-vicinal diols (R)-1c–15c were produced from 1a–15a by 
the one-pot cascade epoxidation and hydrolysis with resting cells of E. coli (SST1). 
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Many (R)-vicinal diols, such as (R)-1c–4c, (R)-8c, (R)-9c, and (R)-11c, were produced 
in excellent ee (94.2–98.2%). The diols (R)-5c–7c, (R)-10c, (R)-12c, and (R)-15c were 
also formed in high ee (84.2–89.9%). The high R-enantioselectivity of dihydroxylation 
is the combined result of high S-enantioselectivity of SMO-catalyzed epoxidation of 
styrenes and the high regioselectivity of StEH-catalyzed hydrolysis of (S)-epoxides at 
the α position. Only (R)-13c and (R)-14c were obtained in low ee (68.1% and 36.9%). 
The low enantioselectivity was probably caused by the hindrance of the ortho-
substitution in epoxides 13b–14b for the hydrolysis at the α position with StEH.  
Scheme 4.6. Enantioselective dihydroxylation of aryl olefins 1a–15a with E. coli (SST1) 
coexpressing SMO and StEH to produce (R)-vicinal diols (R)-1c–15c. 
Most of the R-dihydroxylations with the resting cells of E. coli (SST1) also 
gave high conversion and high yield. (R)-Vicinal diols 1c, 2c, 3c, 8c, 9c, 11c, and 12c 
were obtained in 90–>99% yields, (R)-4c, (R)-5c, (R)-10c and (R)-13c were formed in 
85-89% yields, and (R)-6c was produced in 65% yield. This confirmed also that SMO 
and StEH coexpressed in the E. coli cells are very active for the cascade biocatalysis. 
The specific activity for these R-dihydroxylations is 15–43 U/g cdw, with the exception 
for the R-dihydroxylations of 4a, 10a, and 11a (6–9 U/g cdw). Due to the high activity 
of StEH in E. coli (SST1), no epoxide was accumulated in the dihydroxylations of 1a-
12a. Accumulation of epoxide was observed only in the dihydroxylation of ortho-
substituted olefins 13a–15a. Here, the resting cells of E. coli (SST1) coexpressing 
SMO and StEH were developed as a simple and efficient catalyst for the synthesis of 
these (R)-vicinal diols via dihydroxylation, being the first biocatalytic system for the 
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R-enantioselective dihydroxylations of styrenes. Clearly, E. coli (SSP1) and E. coli 
(SST1) are excellent cascade biocatalysts with complementary enantioselectivity for 
the dihydroxylation of styrene and its derivatives. It is the first example to achieve the 
reversal of overall enantioselectivity of cascade biocatalysis by changing the 
regioselectivity in an individual reaction step. The concept can be applied to solve the 
problem of lacking mirror-image enzymes in biocatalysis, in addition to the discovery 
and development of enantiocomplementary enzymes.[337]  
The R-dihydroxylations of 7a, 14a, and 15a with resting cells of E. coli (SST1) 
gave lower yields (10–19%). This is similar to the cases with E. coli (SSP1) and due to 
the low activity of SMO. 
 
4.3.6 Asymmetric trans-Dihydroxylation of Nonterminal Aryl Olefins with 
Resting Cells of E. coli (SSP1) and E. coli (SST1) 
Scheme 4.7. Enantioselective trans-dihydroxylation of nonterminal aryl olefins 16a and 17a 
with E. coli (SSP1) (SMO & SpEH) to produce vicinal diols (1S, 2R)-16c and (1S, 2S)-16c, 
and with E. coli (SST1) (SMO & StEH) to produce vicinal diols (1R, 2S)-16c and (1R, 2R)-
16c, respectively. 
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To prepare vicinal diols with two chiral centres and evidently distinguish our 
trans-dihydroxylation with Sharpless cis-dihydroxylation, we tested the 
dihydroxylation of nonterminal olefin substrates 16a and 17a with our catalysts 
(Scheme 4.7). The trans-dihydroxylation was also performed in a two-phase system 
with resting cells as catalysts.  As shown in Table 4.4, trans-dihydroxylation of 16a 
and 17a with E. coli (SST1) gave (1R, 2S)-16c and (1R, 2R)-16c in excellent ee (>98%) 
and de (≥98%), respectively. The configuration of 16c was established by comparing 
bioproducts with the standard diols that were prepared via Sharpless asymmetric 
dihydroxylation (Figure S2.16-S2.17, Appendix II). The yields (96% and 89%) and the 
specific activities (15 and 20 U/g cdw) were also high. On the other hand, trans-
dihydroxylation of β-methyl styrenes 16a and 17a with E. coli (SSP1) afforded (1S, 
2R)-16c in 94.2% ee and 91.8% de and (1S, 2S)-16c in 85.6% ee and >99% de, 
respectively. The regioselectivity and the yield for the hydrolysis were decreased 
possibly as a result of the steric hindrance of a β-methyl group in the epoxide 
intermediate to the hydrolysis at the β position with SpEH. Nevertheless, the product 
ee and de were still quite high. The great achievement here was the production of all 
four stereoisomers of 1-phenyl-1,2-propanediol 16c in high ee and de by the trans-
dihydroxylation of trans-alkene 16a and cis-alkene 17a with the two complementary 
biocatalysts, respectively. In comparison, the elegant Sharpless dihydroxylation has 
difficulty in transforming cis-alkene such as 17a with high selectivity.[315] 
4.3.7 Asymmetric trans-Dihydroxylation of Cyclic Aryl Olefins with Resting Cells 
of E. coli (SSP1) and E. coli (SST1)  
Scheme 4.8. Enantioselective trans-dihydroxylation of aryl cyclic olefins 18a and 19a with E. 
coli (SSP1) (SMO & SpEH) or E. coli (SST1) (SMO & StEH) to produce vicinal diols (1R, 
2R)-18c and (1R, 2R)-19c. 
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The trans-dihydroxylation of cyclic aryl olefins 18a and 19a (Scheme 4.8) was 
performed with resting cells of E. coli (SSP1) and E. coli (SST1).  As shown in Table 
4.4, E. coli (SSP1) gave (1R, 2R)-18c and (1R, 2R)-19c in very high ee (>96%), de 
(>98%), and yield (73-80%) from 18a and 19a, respectively. The configurations of 
18c–19c were established by comparing bioproducts with the standard diols that were 
commercially available (Figure S2.18-S2.19, Appendix II). The unexpected change of 
the enantioselectivity of the dihydroxylation was possibly caused by the change of the 
regioselectivity of SpEH in E. coli (SSP1) to the cyclic epoxides 18b and 19b. On the 
other hand, E. coli (SST1) also produced (1R, 2R)-18c and (1R, 2R)-19c in very high 
ee (>96%), de (>98%), and yield (67-71%) from 18a and 19a, respectively. These 
results demonstrated once again the unique potential of E. coli (SSP1) and E. coli 
(SST1) in asymmetric trans-dihydroxylation of cis-alkenes. In comparison, Sharpless 
dihydroxylation has difficulty with cis-alkenes as starting materials and could not 
produce trans-vicinal diols (1R, 2R)-18c and (1R, 2R)-19c from cis-alkenes 18a and 
19a.[315] 
Table 4.4. Enantioselective trans-dihydroxylation of nonterminal aryl olefins 16a, 17a and aryl 
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a-e same to table 4.3. f de value was determined by chiral HPLC analysis. Error limit: 0.2% of 
the state values. g Error limit: 0.5% of the state values. 
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4.3.8 Asymmetric trans-Dihydroxylation of Other Aryl Olefins with Resting Cells 
of E. coli (SSP1) and E. coli (SST1)  
 
Scheme 4.9. Enantioselective dihydroxylation of aryl olefins 20a–22a with E. coli (SSP1) 
(expressing SMO and SpEH) or E. coli (SST1) (expressing SMO and StEH) to produce 
vicinal diols (R)-20c, (S)-21c, and (S)-22c. 
 
We further tested E. coli (SSP1) and E. coli (SST1) for the dihydroxylation of 
substituted olefins (20a–22a) (Scheme 4.9, Table 4.5) in a two-liquid phase system 
with the resting cells as catalysts. With two methyl groups on the β carbon, 20a could 
not be converted to (S)-20c in high ee by E. coli (SSP1) due to the huge steric hindrance 
at the β position for the hydrolysis with SpEH.  On the other hand, dihydroxylation of 
20a with E. coli (SST1) gave (R)-20c in 98.2% ee and 83% yields. In contrary, 
dihydroxylation of 21a and 22a with E. coli (SSP1) afforded (S)-21c in 94.5% ee and 
(S)-22c in 97.6% ee, respectively. But dihydroxylation of 21a and 22a with E. coli 
(SST1) failed to produce (R)-21c and (R)-22c, which is probably due to the poor α-
regioselectivity of StEH to the corresponding epoxide intermediates. The 
configurations of 20c–22c were established by comparing bioproducts with the 
standard diols that were prepared via Sharpless asymmetric dihydroxylation (Figure 
S2.20-2.22, Appendix II). 
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Table 4.5. Enantioselective dihydroxylation of aryl olefins 20a–22a with resting cells of E. coli 
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a-f same to table 4.3.  
4.3.9 Preparation of 10 Vicinal Diols with Resting Cells of E. coli (SSP1) or E. coli 
(SST1)  
 To further demonstrate the synthetic potential of trans-dihydroxylation via 
cascade biocatalysis, we carried out the preparation of 10 valuable vicinal diols from 7 
aryl olefins 1a, 2a, 5a, 9a, 12a, 16a, 17a on 50 mL scale with the resting cells of E. 
coli (SSP1) or E. coli (SST1). The syntheses were performed at substrate concentration 
of 50 mM (based on total reaction volume) in a modified two-phase system containing 
45 mL aqueous KP buffer and 5 mL n-hexadecane. The reactions were monitored by 
TLC by checking the disappearance of substrates. After 5–8 h, the reactions were 
stopped, and the products were separated and purified by flash chromatogram. All 10 
useful and valuable vicinal diols (S)-1c, (S)-2c, (S)-5c, (S)-9c, (S)-12c, (R)-1c, (R)-2c, 
(R)-9c, (1R,2S)-16c, and (1R,2R)-16c were obtained in high ee (92.4–98.6%), de (de ≥ 
98%, if applicable), and good isolated yield (70.6–85.5%) (Table 4.6). The 
dihydroxylation via cascade biocatalysis gave around 0.3 g of product/g of cells. In the 
representative procedure of Sharpless asymmetric dihydroxylation,[315] 1.4 g AD-mix-
α was used for the dihydroxylation of 1 mmol of olefin, corresponding to about 0.1 g 
of product/g of catalyst. In our cascade biocatalysis for trans-dihydroxylation of olefins, 
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whole cells are used as the less expensive and greener catalyst, molecular oxygen is 
used as the less expensive and green oxidant, and water is used for the epoxide 
hydrolysis. The green and efficient cascade biocatalysis provides practical syntheses of 
the useful and valuable vicinal aryl diols in high ee and high yield. 
 
Table 4.6. Preparation of (R)- or (S)- vicinal diols in high ee by enantioselective dihydroxylation 
of aryl alkenes with resting cells of E. coli (SSP1) or E. coli (SST1).  
a The reactions were performed with substrates (50 mM based on total volume) and resting cells 
(20 g cdw/L) in a two-liquid phase system (50 mL) consisting of KP buffer (200 mM, pH 8.0, 
2% glucose) and n-hexadecane (9:1) at 30 oC. b ee value was determined by chiral HPLC 
analysis. Error limit: 0.2% of the state values. c de value was determined by chiral HPLC 
analysis. Error limit: 0.2% of the state values. d n.a.: not applicable. e Error limit: 0.5% of the 










Isolated Yield     








1a E. coli (SSP1) 5 (S)-1c 0.295    85.5 96.3 n.a.d 0.30 
1a E. coli (SST1) 5 (R)-1c 0.289    83.8 95.8 n.a. 0.29 
2a E. coli (SSP1) 6 (S)-2c 0.299    76.7 96.7 n.a. 0.30 
2a E. coli (SST1) 5 (R)-2c 0.325    80.7 96.7 n.a. 0.33 
5a E. coli (SSP1) 8 (S)-5c 0.279    73.4 92.4 n.a. 0.28 
9a E. coli (SSP1) 8 (S)-9c 0.326    75.6 96.5 n.a. 0.33 
9a E. coli (SST1) 8 (R)-9c 0.304    70.6 96.3 n.a. 0.30 
12a E. coli (SSP1) 6 (S)-12c 0.358    85.3 96.8 n.a. 0.36 
16a E. coli (SST1) 7 (1R,2S)-16c 0.313    82.3 >98e 98.2 0.31 
17a E. coli (SST1) 8 (1R,2R)-16c 0.300    78.8 98.6 >99 0.30 
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Table 4.7. Physical properties, 1H NMR analysis, and optical rotations of chiral vicinal diols 
prepared by using E. coli (SSP1) or E. coli (SST1).  
Prod. Appea
rance 
1H NMR chemical shift a [α]D b Lit. [α]D 
(S)-1c White 
solid 
7.23–7.38 (m, 5H, ArH), 4.79–4.82 (m, 1H), 3.62–











7.26–7.37 (m, 5H, ArH), 4.76–4.79 (dd, J = 8.4, 
3.2 Hz, 1H), 3.70–3.74 (dd, J = 11.6, 3.2 Hz, 1H), 
3.60–3.65 (dd, J = 11.6, 8.4 Hz, 1H), 3.05–3.20 











7.26–7.34 (m, 2H, ArH), 7.01–7.06 (t, J = 8.8, 2H, 
ArH), 4.77–4.80 (dd, J = 8.4, 3.2 Hz, 1H), 3.70–
3.74 (dd, J = 11.2, 3.2 Hz, 1H), 3.58–3.63 (dd, J = 











7.26–7.34 (m, 2H, ArH), 7.01–7.06 (t, J = 8.4, 2H, 
ArH), 4.77–4.80 (dd, J = 8.4, 3.6 Hz, 1H), 3.70–
3.74 (dd, J = 11.2, 3.2 Hz, 1H), 3.58–3.63 (dd, J = 











7.14–7.26 (m, 4H, ArH), 4.74–4.77 (dd, J = 8.0, 
3.2 Hz, 1H), 3.68–3.72 (dd, J = 11.2, 3.2 Hz, 1H), 
3.61–3.65 (dd, J = 11.6, 8.4 Hz, 1H), 2.95–3.08 












7.14–7.22 (m, 4H, ArH), 4.71–4.74 (dd, J = 8.0, 
3.6 Hz, 1H), 3.67–3.71 (dd, J = 11.2, 3.2 Hz, 1H), 













7.23–7.39 (m, 4H, ArH), 4.79–4.82 (dd, J = 8.0, 
3.2 Hz, 1H), 3.75–3.79 (dd, J = 11.2, 3.2 Hz, 1H), 













6.84–7.19 (m, 4H, ArH), 4.69–4.73 (dd, J = 8.0, 
4.0 Hz, 1H), 3.73 (s, 3H), 3.66–3.70 (dd, J = 11.6, 
3.6 Hz, 1H), 3.56–3.60 (dd, J = 11.6, 8.0 Hz, 1H), 

















7.29–7.43 (m, 5H, ArH), 4.69–4.70 (d, J = 4.4 Hz, 
1H), 4.01–4.07 (m, 1H), 2.17 (s, 2H, OH), 1.10–














7.26–7.38 (m, 5H, ArH), 4.35–4.37 (d, J = 7.2 Hz, 
1H), 3.82–3.89 (quint, J = 6.4 Hz, 1H), 2.52 (s, 









a1H NMR was determined in CDCl3 with TMS as internal standard using a 400 MHz Bruker 
NMR system (spectral see Appendix II). bOptical rotation was determined using a Jasco 
polarimeter DIP-1000.  
 
4.3.10 Synthesis of (R)-1-Phenyl-1,2-ethanediol with Growing Cells in Fermentor 
We further explored the potential of using growing cells of the recombinant E. 
coli strain for the dihydroxylation of aryl olefins. Dihydroxylation of styrene 1a with 
E. coli (SST1) was chosen as a model reaction. To avoid the possible environmental 
concerns and reduce the additional cost, the organic phase (n-hexadecane) was not 
applied in the growing cell experiment. Instead, styrene 1a was fed directly and slowly 
to the reaction mixture to alleviate the toxicity of styrene.  
E. coli (SST1) was grown in a fermentor overnight to a cell density of 7 g 
cdw/L, glucose was fed, and IPTG was added to induce the enzyme expression. After 
5 h growth, the cell density reached 20 g cdw/L, and styrene 1a was fed to start the 
dihydroxylation. After 5 h biotransformation with the growing cells, 120 mM (16.6 g/L) 
(R)-1-phenyl-1,2-ethanediol 1c was produced in 96.2% ee with an average volumetric 
productivity of 3.3 g/L/h for the reaction period. The enantioselectivity of the 
dihydroxylation with growing cells was the same as that with resting cells. Thus, the 
cascade biocatalysis for enantioselective dihydroxylation can be performed with either 
growing cells or resting cells as catalysts, it can also be carried out in either aqueous 
phase or a two-phase system, and it can be easily scaled up by using a fermentor.  The 
use of growing cells as the catalyst may further improve the product titer and 
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volumetric productivity. Further optimization of the process could make the cascade 




E. coli (SSP1) cells coexpressing styrene monooxygenase (SMO) and epoxide 
hydrolase SpEH were developed as a green and efficient biocatalyst for S-
enantioselective dihydroxylation of aryl olefins via intracellular cascade epoxidation 
and hydrolysis. The S-enantioselectivity was generated by SMO-catalyzed S-selective 
epoxidation and SpEH-catalyzed regioselective hydrolytic opening of the (S)-epoxide 
at the β position. Dihydroxylation of terminal aryl olefins 1a–15a with resting cells of 
E. coli (SSP1) offered (S)-vicinal diols 1c–15c in high ee (97.5-98.6% for 10 diols; 
92.2–93.9% for 3 diols) and high yield (91%-99% for 6 diols; 86-88% for 2 diols; 67-
73% for 3 diols).  
Combining SMO and epoxide hydrolase StEH showing an α opening of aryl 
epoxides for the cascade biocatalysis gave rise to R-enantioselective dihydroxylation 
of aryl olefins. E. coli (SST1) coexpressing SMO and StEH was also engineered as a 
green and efficient biocatalyst for R-dihydroxylation of aryl olefins, being 
complementary to E. coli (SSP1). Dihydroxylation of terminal aryl olefins 1a–15a with 
resting cells of E. coli (SST1) afforded (R)-vicinal diols 1c–15c in high ee (94.2–98.2% 
for 7 diols; 84.2-89.9% for 6 diols) and high yield (90-99% for 7 diols; 85-89% for 4 
diols; 65% for 1 diol). To the best of our knowledge, it is the first report of reversing 
the overall enantioselectivity of cascade biocatalysis by changing the regioselectivity 
in an individual reaction step, which will help to solve the problem of lacking mirror-
image enzymes in biocatalysis. 
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E. coli (SSP1) and E. coli (SST1) catalyzed the trans-dihydroxylation of either 
trans-aryl olefin 16a or cis-aryl olefin 17a with excellent and complementary 
stereoselectivity, giving each of the four stereoisomers of 1-phenyl-1,2-propanediol 
16c in high ee and de, respectively. Both strains catalyzed the trans-dihydroxylation of 
aryl cyclic olefins 18a and 19a to afford the same trans-cyclic diols (1R, 2R)-18c and 
(1R, 2R)-19c, respectively, in excellent ee and de. This type of cascade biocatalysis 
provides a complementary tool to Sharpless dihydroxylation, accepting cis-alkene and 
offering enantioselective trans-dihydroxylation. 
Preparative dihydroxylations with the resting cells of E. coli (SSP1) or E. coli 
(SST1) were successfully demonstrated to prepare five (1S)-vicinal diols and five (1R)-
vicinal diols in high ee (92.4–98.6%) with high isolated yield (70.6–85.5%). Growing 
cells of E. coli (SST1) were also proven to be a good catalyst for the enantioselective 
dihydroxylation of styrene 1a to produce 120 mM (16.6 g/L) (R)-1-phenyl-1,2-
ethanediol 1c (96.2% ee) in a bioreactor (1 L).  
The cascade biocatalysis for dihydroxylation of olefins reported here utilizes 
molecular oxygen as an inexpensive and green oxidant and water as a simple reagent, 
thus being sustainable.  The developed catalysts show a relatively broad substrate range 
for aryl olefins, high and complementary enantioselectivity, high activity and yield, 
thus being useful for the production of several useful and valuable enantiopure vicinal 
diols and deserving further development for potential industrial application. The 
reported concept and methodology on engineering efficient, enantioselective, and 
enantiocomplementary catalysts could be extended to the development of new 
biocatalysts for enantioselective trans-dihydroxylation of other types of olefins by 
combining other monooxygenases and EHs. Furthermore, this epoxidation-hydrolysis 
cascade could be utilized to build more complex biocatalytic cascades to achieve even 
more challenging transformations (See Chapter 5).  
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5 MODULAR CASCADE BIOCATALYSIS: ASYMMETRIC 
OXY- AND AMINO-FUNCTIONALIZATION OF ARYL 
ALKENES AND UTILIZATION OF BIO-BASED 
PHENYLALANINE  
 
Figure 5.1. Asymmetric oxy- and amino-functionalization of alkenes to chiral hydroxy acids, 
amino alcohols, and amino acids, with recombinant E. coli containing different modules.  
 
5.1 Introduction 
Terminal alkenes are ideal starting materials for organic synthesis because they 
are manufactured on very large scales from petroleum feedstock. Regio- and enantio- 
selective functionalization of alkenes via various chemicals transformations with 
appropriate catalysts provides a facile access to a wide range of bulk and specialty 
chemicals. Many advances of selective alkene functionalization with chemical catalysts 
were recently reported, such as palladium-catalyzed selective oxidation,[341, 342] iron-
catalyzed regioselective hydrosilylation,[343] rhodium-catalyzed stereoselective 
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aziridination,[344] ruthenium-catalysed alkoxycarbonylation,[345] and photoredox 
catalyzed regioselective hydrohalogenation.[346] On the other hand, nature provides 
enzymes as promising alternative catalysts for various types of selective chemical 
transformations in mild conditions with green and easily available reagents, such as 
oxygen, ammonia, and glucose.[16-27] Regarding to functionalization of alkenes, a 
number of enzymatic transformations were reported: epoxidation with monooxygenase 
or peroxidase,[129, 169, 170, 347] dihydroxylation with dioxygenase,[316, 317] hydration with 
hydratase or decarboxylase,[348-351] and more recently created cyclopropanation with 
engineered P450 monooxygenase.[87, 88]  
However, one-step transformation with either chemo- or bio-catalysts is 
limited in accessible chemical space. A possible solution is performing multiple 
catalyzed reactions in one pot concurrently, namely, cascade/tandem catalysis, which 
enables facile access to more diverse structures in new ways.[232-234] Recent 
breakthroughs in cascade selective functionalization of alkenes include anti-
Markovnikov hydration via oxidation-hydrolysis-reduction with palladium-acid-
ruthenium catalysis,[352] enantioselective diboration-cross-coupling with platinum-
palladium catalysis,[353] and selective metathesis-epoxidation with ruthenium-P450 
monooxygenase catalysis.[354] In comparison with cascade chemocatalysis or cascade 
hybrid catalysis,[355, 356] cascade biocatalysis could maintain the green and inexpensive 
advantages of enzymes (e.g. without involving toxic and precious metals) and it is also 
easy to achieve because of natural compatibility of enzymes.[34-40] Over the years, a 
variety types of non-natural biocatalytic cascades have been developed.[235-281] 
Nevertheless, no cascade biocatalysis was reported for enantioselective 
functionalization of hydrocarbons (alkanes and alkenes), except for the epoxidation-
hydrolysis cascade (Chapter 4) we developed for asymmetric trans-dihydroxylation of 
alkenes,[247, 248] which could be achieved via similar one-step cis-dihydroxylation with 
Sharpless method[315] or dioxygenase.[316, 317]  
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Scheme 5.1. Cascade biocatalysis for one-pot conversion of terminal alkene to chiral α-
hydroxyl acid, 1,2-amino alcohol, and α-amino acid. 
To address this significant gap, we are interested in developing novel and 
efficient cascade biocatalysis for oxy- and amino-functionalization of terminal alkene 
to produce chiral α-hydroxyl acid, 1,2-amino alcohol, and α-amino acid in a highly 
regio- and enantio-selective manner (Figure 5.1, Scheme 5.1). These three 
transformations are very useful but significantly challenging in chemistry. Enantiopure 
α-hydroxyl acid,[357] 1,2-amino alcohol,[358] and α-amino acid[359, 360] are three very 
important groups of chiral chemicals with broad applications, such as building blocks 
for bioactive compounds and chiral ligands/auxiliaries for asymmetric synthesis. The 
transformation of terminal alkene to hydroxyl acid or amino acid represents unequal 
oxidation of the two alkene carbons to one low (0) and one high (+3) oxidation states, 
which is very challenging in traditional chemistry, because weak oxidants (e.g. OsO4) 
oxidize both carbons to low oxidation states (0, +1), while strong oxidants (e.g. O3) 
usually cleave the double bond and oxidize both carbons to high oxidation states (+2, 
+3).[361] Further providing enantioselectivity poses additional challenge. On the other 
hand, the transformation of alkene to 1,2-amino alcohol could be achieved with 
Sharpless asymmetric aminohydroxylation (oxyamination),[362, 363] but chemical 
aminohydroxylation methods are still difficult to simultaneously control both regio- 
and enantio-selectivity excellently, and unable to use inexpensive ammonia as nitrogen 
source for synthesizing primary amine.[364] Herein, the cascade biocatalysis developed 
in this thesis represents a novel one-pot synthetic route and provides a unique approach 
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for green and efficient production of  chiral α-hydroxyl acids, 1,2-amino alcohols, and 
α-amino acids.    
 
5.2 Experimental Section 
5.2.1 Chemicals, Strains, and Materials 
The chemicals, strains, and materials which have been used in Chapter 3 and 
Chapter 4 were not listed here. Please refer to section 3.2.1 and 4.2.1 for detail.  
All the chemicals and solvents were directly purchased from the commercial 
suppliers and used without further purification. Chemicals from Sigma-Aldrich: 
mandelic acid (≥99%), (R)-(−)-mandelic acid (≥99%), 3-fluoromandelic acid (98%), 
(R)-4-fluoromandelic acid (98%), 3-chloromandelic acid (98%), (R)-3-chloromandelic 
acid (97%), (R)-4-chloromandelic acid (98%), 3-methylmandelic acid (97%), 2-amino-
1-phenylethanol (98%), (R)-(−)-2-amino-1-phenylethanol (97%), phenylglyoxylic acid 
(97%), L-phenylglycine (99%), trans-cinnamic acid (≥99%), L-alanine (≥99%),L-
glutamic acid monosodium salt monohydrate (≥98%). Chemicals from Alfa Aesar: (S)-
(+)-mandelic acid (≥99%), 4-chloromandelic acid (98%), 4-fluoromandelic acid (98%), 
(R)-(−)-4-methylmandelic acid (98%), D-phenylglycine (99%). Chemicals from TCI: 
2-fluoromandelicAcid (>98%).   
1 L M9 medium containing: 8.5 g Na2HPO4•2H2O, 3.0 g KH2PO4, 0.5 g NaCl, 
1.0 g NH4Cl, 2 mL MgSO4 solution (1M), 1 mL CaCl2 solution (0.1M), 1 mL 1000X 
MT solution (8.3 g/L FeCl3•6H2O, 0.84 g/L ZnCl2, 0.13 g/L CuCl2•2H2O, 0.1 g/L 
CoCl2•2H2O, 0.1 g/L H3BO3, 0.016 g/L MnCl2•4H2O, adding EDTA to dissolve), 20 
g/L glucose, and 6 g/L yeast extract.  
Other biochemicals and strains are the same to Chapter 3 and Chapter 4. 
5.2.2 Analytical Methods 
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The concentration of many substrates, intermediates, and products from 
biotransformations was determined using a Shimadzu prominence reverse phase HPLC 
system with an Agilent Poroshell 120 SB-C18 column (150 × 4.6 mm, 2.7 µm) and UV 
detection at 210 nm. Conditions: 70% water (with 0.1% TFA): 30% acetonitrile, flow 
rate: 0.5 mL min−1. The following is the retention times: phenylglycine (3.2 min), 
phenylalanine (3.4 min), phenylethanol amine (3.4 min), phenylethane diol (4.5 min), 
mandelic acid (4.9 min), hydroxy(phenyl)acetaldehyde (6.0 min), phenylglyoxylic acid 
(6.2 min), benzyl alcohol (internal standard, 7.3 min). The concentration of styrene 
substrates was quantified using a Shimadzu prominence normal phase HPLC system 
with an Agilent Zorbax Rx-SIL column (150 × 4.6 mm, 5 µm) and UV detection at 210 
nm. Condition: 10% IPA: 90% n-hexane, flow rate: 1.0 mL min−1. The retention times 
for most of the styrenes are from 1 to 2 min.  
The ee values of mandelic acids were determined by chiral HPLC using a 
Shimadzu prominence HPLC system (normal phase) and UV detection at 210 nm with 
a Daicel AS-H, or IA-3 chiral column (250 × 4.6 mm, 5µm) with 10% IPA: 90% n-
Hex (containing 0.1% TFA) at 0.5 mL min−1. Retention times for mandelic acid using 
IA-3 column: (S)-mandelic acid (21.5 min), (R)-mandelic acid (23.5 min). Retention 
times for 3-chloromandelic acid using AS-H column: (S)-3-chloromandelic acid (21.2 
min), (R)-3-chloromandelic acid (19.5 min). Retention times for 3-methylmandelic 
acid using AS-H column: (S)-3-methylmandelic acid (20.8 min), (R)-3-
methylmandelic acid (19.8 min). 
5.2.3 Genetic Engineering of Module 1, Module 2, Module 3, Module 4, and 
Module 0 
Construction of Module 1 (styA-styB-spEH): Module 1 is the same construct 
of previous SSP1, an operon of styA, styB, and spEH genes (see Chapter 4). R-M1 
represents the recombinant plasmid pRSFduet (Novagen) containing Module 1. To 
sub-cloning of this operon to other plasmids, primers StyA-BspHI-F and SpEH-XhoI-
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R (see Table 5.1 for a full list of primers) were used to amplify the Module 1 from R-
M1 with Phusion DNA polymerase according to the instruction. The PCR product was 
subjected to double digestion with BspHI and XhoI (FastDigest, Thermo Scientific). 
And the other three vectors, pACYCduet, pCDFduet, and pETduet (Novagen) were 
also subjected to digestion with NcoI and XhoI. Then ligation of digested PCR product 
and vectors was performed with T4 DNA ligase (Thermo Scientific), and then the 
ligation products were used for transformation (heat shock) of chemical competent E. 
coli cells (T7 Express strain, New England Biolabs). The sub-cloning of Module 1 to 
pACYCduet, pCDFduet, and pETduet gave A-M1, C-M1, and E-M1, respectively.  
Construction of Module 2 (alkJ-aldh): The alkJ gene was amplified from the 
OCT megaplasmid from Pseudomonas putida GPo1[186, 187] using primers AlkJ-
BamHI-F and AlkJ-BglII-R (Table 5.1) and Phusion DNA polymerase. The PCR 
product were double digested with BamHI and BglII, and then ligated to same digested 
pRSFduet with T4 DNA ligase. The ligation product was transformed (heat shock) into 
E. coli T7 Expression competent cells to give pRSF-AlkJ. On the other hand, the aldh 
gene was amplified from the genome of E. coli K12 MG 1655 using primers EcALDH-
BglII-RBS-F and EcALDH-XhoI-R (Table 5.1). The PCR product was double digested 
with BglII and XhoI, and then ligated to same digested pRSF-AlkJ with T4 DNA ligase. 
The ligation product was transformed (heat shock) into E. coli T7 Expression 
competent cells to give Module 2 on pRSFduet plasmid, namely R-M2. Similar to 
Module 1, Module 2 was also sub-cloning to other three vectors by the following 
procedures. Module 2 operon was amplified with primers AlkJ-BamHI-F and 
EcALDH-XhoI-R (Table 5.1), digested with BamHI and XhoI, and then ligated to 
double digested pACYCduet, pCDFduet, and pETduet. The transformation of these 
products gave A-M2, C-M2, and E-M2, respectively.  
Table 5.1. Primers (DNA oligos) used for construction of Module 0-4.  
Name Sequence 













TTACGCCAGGCCACGAGCTTTCAG     
AlaDH-EcoRI-RBS-F ACTGGAATTCTAAGGAGATATATA 
ATGATCATAGGGGTTCCTAAAGAGAT   
AlaDH-XhoI-R ACTGCTCGAGTTAAGCACCCGCCACAGATGATTCA       
HMO-BspHI-F ACTGTCATGATGCGTGAACCGCTGACGCTGGATG   
HMO-EcoRI-R ACTGGAATTCTTAGCCGTGAGAACGATCGCGATGC     
IlvE-EcoRI-RBS-F ACTGGAATTCTAAGGAGATATATA 
ATGACCACGAAGAAAGCTGATTACA   
IlvE-BglII-R ACTGAGATCTTTATTGATTAACTTGATCTAACCAGCCC    
GluDH-BglII-RBS-F ACTGAGATCTTAAGGAGATATATA 
ATGGATCAGACATATTCTCTGGAGTC    
GluDH-KpnI-R ACTGGGTACCTTAAATCACACCCTGCGCCAGCATC     
KatE-KpnI-RBS-F ACTGGGTACCTAAGGAGATATATA 
ATGTCGCAACATAACGAAAAGAACC   












Construction of Module 3 (alkJ-cvωTA-aladh): The cvωTA gene was first 
synthesized and codon optimized for E. coli according to the published gene 
sequence[208] (see Appendix III for the synthesized DNA sequence, Genscript). Using 
this synthesized DNA as template, the gene was amplified using primers CvTA-BglII-
RBS-F and CvTA-XhoI-EcoRI-R (Table 5.1) and Phusion DNA polymerase. The PCR 
product was double digested with BglII and XhoI, and then ligated to pRSF-AlkJ 
(digested with BglII and XhoI) with T4 DNA ligase. The ligation product was 
transformed (heat shock) into E. coli T7 Expression competent cells to give pRSF-
AlkJ-CvTA. On the other hand, aladh gene was amplified from the genome of Bacillus 
subtilis str.168 using primers AlaDH-EcoRI-RBS-F and AlaDH-XhoI-R (Table 5.1). 
The PCR product was double digested with EcoRI and XhoI, and then ligated to pRSF-
AlkJ-CvTA (digested with EcoRI and XhoI). The ligation product was transformed 
(heat shock) into E. coli T7 Expression competent cells to give Module 3 on pRSFduet 
plasmid, namely R-M3. Similarly, Module 3 was also sub-cloned to other three vectors 
by the following procedures. Module 3 operon was amplified with primers AlkJ-
BamHI-F and AlaDH-XhoI-R (Table 5.1), digested with BamHI and XhoI, and then 
ligated to double digested pACYCduet, pCDFduet, and pETduet. The transformation 
of these products gave A-M3, C-M3, and E-M3, respectively. 
Construction of Module 4 (hmo-ilvE-gludh-katE): The hmo gene was first 
synthesized and codon optimized for E. coli according to the published gene 
sequence[194] (see Appendix III for the synthesized DNA sequence, Genscript). Using 
this synthesized DNA as template, the gene was amplified using primers HMO-BspHI-
F and HMO-EcoRI-R (Table 5.1). The PCR product was double digested with BspHI 
and EcoRI, and then ligated to pRSF (digested with NcoI and EcoRI) with T4 DNA 
ligase. The ligation product was transformed (heat shock) into E. coli T7 Expression 
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competent cells to give pRSF-HMO. Next, ilvE gene was amplified from the genome 
of E. coli K12 MG 1655 using primers IlvE-EcoRI-RBS-F and IlvE-BglII-R (Table 
5.1). The PCR product was digested with EcoRI and BglII, ligated to pRSF-HMO 
(digested with EcoRI and BglII), and then transformed (heat shock) into E. coli T7 
Expression competent cells to yield pRSF-HMO-IlvE. Similarly, gludh gene was 
amplified from the genome of E. coli K12 MG 1655 using primers GluDH-BglII-RBS-
F and GluDH-KpnI-R (Table 5.1). The PCR product was digested with BglII and KpnI, 
ligated to pRSF-HMO-IlvE (digested with BglII and KpnI), and then transformed into 
E. coli competent cells to offer pRSF-HMO-IlvE-GluDH. In the last step, ketE gene 
was amplified from the genome of E. coli K12 MG 1655 using primers KatE-KpnI-
RBS-F and KatE-XhoI-R (Table 5.1). The PCR product was digested with KpnI and 
XhoI, ligated to pRSF-HMO-IlvE-GluDH (digested with KpnI and XhoI), and then 
transformed into E. coli competent cells to offer pRSF-HMO-IlvE-GluDH-KatE 
(Module 4 on pRSF, R-M4). Similarly, Module 4 was also sub-cloned to other three 
vectors by first amplified with primers HMO-BspHI-F and KatE-XhoI-R (Table 5.1), 
digested with BspHI and XhoI, and then ligated to double digested pACYCduet, 
pCDFduet, and pETduet. The transformation of these products gave A-M4, C-M4, and 
E-M4, respectively. 
Construction of Module 0 (ohbA-padA-pal): The ohbA and padA genes were 
first synthesized and codon optimized for E. coli according to the published gene 
sequence from Aspergillus niger[394, 396] (see Appendix III for the synthesized DNA 
sequence, Genscript). Using the synthesized DNA as template, the ohbA gene was 
amplified using primers AnOhbA-BspHI-F and AnOhbA-EcoRI-R (Table 5.1). The 
PCR product was double digested with BspHI and EcoRI, ligated to pRSF (digested 
with NcoI and EcoRI) with T4 DNA ligase, and then transformed into E. coli competent 
cells to give pRSF-AnOhbA. Next, padA gene was amplified using primers AnPAD-
EcoRI-RBS-F and AnPAD-PstI-R (Table 5.1). The PCR product was digested with 
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EcoRI and PstI, ligated to pRSF-OhbA (digested with EcoRI and PstI), and then 
transformed into E. coli T7 Expression competent cells to yield pRSF-AnOhbA-
AnPAD. On the other hand, the pal gene was amplified from a cDNA library of 
Arabidopsis thaliana (ATCC 77500) using primers AtPAL-NdeI-F and AtPAL-XhoI-
R (Table 5.1). The PCR product was double digested with NdeI and XhoI, and then 
ligated to pRSF-AnOhbA-AnPAD (digested with NdeI and XhoI) with T4 DNA ligase. 
The ligation product was transformed into E. coli competent cells to offer pRSF-
AnOhbA-AnPAD-AtPAL (Module 0 on pRSF, R-M0). Module 0 was also sub-cloned 
to pACYCduet, pCDFduet, and pETduet to give A-M0, C-M0, and E-M0, respectively. 
For the sub-cloning, Module 0 was first amplified with primers AnOhbA-BspHI-F and 
AtPAL-XhoI-R (Table 5.1), digested with BspHI and XhoI, ligated to double digested 
pACYCduet, pCDFduet, and pETduet, and then transformed into E. coli competent 
cells.    
5.2.4 Engineering of E. coli Strains Containing Multiple Modules 
 Table 5.2 listed all the 50 E. coli strains and the containing modules. These 
strains were engineered with the following procedures.   
 Engineering of strains 1-12 containing Module 1 and Module 2: Four E. coli 
strains containing A-M2, C-M2, E-M2, and R-M2 were grown in 1 mL LB media 
containing appropriate antibiotic (50 mg/L chloramphenicol, 50 mg/L streptomycin, 
100 mg/L ampicillin, or 50 mg/L kanamycin) at 37 oC for overnight. Then 100 µL 
culture was inoculated into 5 mL fresh LB media containing appropriate antibiotic at 
37 oC until OD600 reached 0.5 (about 2 h). Then the cells were harvested by 
centrifugation (2500 g, 10 min, 4 oC) and resuspended in 1 mL cold CaCl2 solution (0.1 
M) on ice. The cell suspension was kept on ice and shaken at 90 rpm for 2 h, and then 
harvested by centrifugation (2500 g, 8 min, 4 oC) and resuspended in 0.2-0.5 mL cold 
CaCl2 solution (0.1 M) to obtain the competent cells of E. coli containing A-M2, C-
M2, E-M2, and R-M2, respectively. 0.5 µL of plasmid A-M1, C-M1, E-M1, and R-M1 
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(100-500 ng/µL) was transformed into the competent cells according to standard heat 
shock procedure (on ice for 30 min, 42 oC for 90 sec, ice for 5 min, recovery at 37 oC 
for 45 min). The recombinant cells were spread on LB agar plates with two appropriate 
antibiotics. The 12 combinatorial transformation leaded to strains 1-12.  
Engineering of strains 13-24 containing Module 1 and Module 3: Similarly, 
the competent cells of E. coli containing A-M3, C-M3, E-M3, and R-M3 were first 
prepared according to above procedure, and plasmid A-M1, C-M1, E-M1, and R-M1 
were transformed into the competent cells. The 12 combinatorial transformation 
afforded strains 13-24.   
 Engineering of strains 25-32 containing Module 1, Module 2, and Module 4: 
The competent cells of E. coli strain 2, 3, 5, 12 were first prepared according to above 
procedure, and plasmid A-M4, C-M4, E-M4, and R-M4 were transformed into the 
competent cells. The 8 combinatorial transformation yielded strains 25-32. 
 Engineering of strains 33-40 containing Module 0, Module 1, and Module 2: 
The competent cells of E. coli strain 2, 3, 5, 12 were used for transformation of plasmid 
A-M0, C-M0, E-M0, and R-M0. The 8 combinatorial transformation gave strains 33-
40. 
 Engineering of strains 41-46 containing Module 0, Module 1, and Module 3: 
The competent cells of E. coli strain 13, 17, 24 were first prepared according to above 
procedure, and plasmid A-M0, C-M0, E-M0, and R-M0 were transformed into the 
competent cells. The 6 combinatorial transformation offered strains 41-46. 
 Engineering of strains 47-50 containing Module 0, Module 1, Module 2, and 
Module 4: The competent cells of E. coli strain 26, 27 were first prepared according to 
above procedure, and plasmid C-M0, and E-M0 were transformed into the competent 
cells to give strain 48, 49, respectively. On the other hand, the competent cells of E. 
coli strains 33, 40 were first prepared according to above procedure, and plasmid R-
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M4, and A-M4 were transformed into the competent cells to give strains 47, 50, 
respectively. 
Table 5.2. E. coli strains 1-50 and the containing modules.  
Strain No. Module 0 Module 1 Module 2 Module 3 Module 4 
1  A-M1 C-M2   
2  A-M1 E-M2   
3  A-M1 R-M2   
4  C-M1 A-M2   
5  C-M1 E-M2   
6  C-M1 R-M2   
7  E-M1 A-M2   
8  E-M1 C-M2   
9  E-M1 R-M2   
10  R-M1 A-M2   
11  R-M1 C-M2   
12  R-M1 E-M2   
13  A-M1  C-M3  
14  A-M1  E-M3  
15  A-M1  R-M3  
16  C-M1  A-M3  
17  C-M1  E-M3  
18  C-M1  R-M3  
19  E-M1  A-M3  
20  E-M1  C-M3  
21  E-M1  R-M3  
22  R-M1  A-M3  
23  R-M1  C-M3  
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24  R-M1  E-M3  
25  A-M1 E-M2  C-M4 
26  A-M1 E-M2  R-M4 
27  A-M1 R-M2  C-M4 
28  A-M1 R-M2  E-M4 
29  C-M1 E-M2  A-M4 
30  C-M1 E-M2  R-M4 
31  R-M1 E-M2  A-M4 
32  R-M1 E-M2  C-M4 
33 A-M0 C-M1 E-M2   
34 A-M0 R-M1 E-M2   
35 C-M0 A-M1 E-M2   
36 C-M0 A-M1 R-M2   
37 C-M0 R-M1 E-M2   
38 E-M0 A-M1 R-M2   
39 R-M0 A-M1 E-M2   
40 R-M0 C-M1 E-M2   
41 A-M0 C-M1  E-M3  
42 A-M0 R-M1  E-M3  
43 C-M0 A-M1  E-M3  
44 C-M0 R-M1  E-M3  
45 R-M0 A-M1  E-M3  
46 R-M0 C-M1  E-M3  
47 A-M0 C-M1 E-M2  R-M4 
48 C-M0 A-M1 E-M2  R-M4 
49 E-M0 A-M1 R-M2  C-M4 
50 R-M0 C-M1 E-M2  A-M4 
 
 Chapter 5. Cascade Biocatalysis for Oxy- and Amino-Functionalization  
123 
 
5.2.5 General Procedure to Culture Recombinant E. coli Strains   
Recombinant E. coli strain was cultured in 1 mL LB medium containing 
appropriate antibiotic at 37 oC for 7-10 h, and then inoculated into 25 mL M9 medium 
containing glucose (20 g/L), yeast extract (6 g/L), and appropriate antibiotic in a 125 
mL tri-baffled flask. The cells were grown at 37 oC 300 rpm for 1.5-2 h to reach an 
OD600 of 0.6, and then IPTG (0.5 mM) was added to induce the expression of enzymes. 
The cells continued to grow for 12-13 h at 22 oC to reach late exponential phase. The 
cells were harvested by centrifugation (2500 g, 10 min), and the cell pellets were 
resuspended. The resting cells were used as catalysts for biotransformation.  
5.2.6 General Procedure for Biotransformation with Resting E. coli Cells  
 Freshly prepared E. coli cells were resuspended to a cell density of 10 g cdw/L 
in KP buffer (200 mM, pH 8.0) containing 0.5-2%, w/v glucose (optional: 50-200 mM 
NH3:NH4Cl 1:10) to 2 mL system in a shaking flask (100 mL). A 2 mL n-hexadecane 
containing 20-100 mM styrene was added to the reaction system to form a second phase. 
For biotransformation of phenylalanine, the substrate was directly added in the aqueous 
phase (KP buffer) and a 2 mL pure n-hexadecane was added. The reaction mixture was 
shaken at 300 rpm and 30 oC for 24 h. 150 µL aliquots of each phase were taken out at 
the specified times (mainly 6 h, 10 h, and 24 h) for the following reaction. For organic 
phase, n-hexadecane (100 µL) were separated after centrifugation, diluted with 900 µL 
n-hexane (containing 2 mM benzyl alcohol as internal standard), and subjected to 
normal phase HPLC or GC analysis for quantifying styrene and possible epoxide 
intermediate. For aqueous phase, supernatants (100 µL) were separated after 
centrifugation, diluted with 400 µL water (containing 0.5% TFA) and 500 µL 
acetonitrile (containing 2 mM benzyl alcohol as internal standard), and then used for 
reverse phase HPLC analysis of the hydrophilic products. 
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5.3 Results and Discussion    
5.3.1 Design of Synthetic Routes and Modular Transformations  
Figure 5.2. Design of four independent modular transformations. Module 1: terminal alkene to 
1,2-diol; Module 2: 1,2-diol to α-hydroxy acid; Module 3: 1,2-diol to 1,2-amino alcohol; 
Module 4: α-hydroxy acid to α-amino acid.   
To realize the biocatalytic cascades, we first designed four independent 
modular transformations (each containing 2-4 reactions) based on biocatalytic 
retrosynthesis analysis[365] (Figure 5.2). Module 1 is an epoxidation-hydrolysis 
transformation of terminal alkene to chiral 1,2-diol with epoxidase and epoxide 
hydrolase (EH). Module 2 is a double terminal oxidation of 1,2-diol to chiral α-hydroxy 
acid with alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). 
Module 3 is a terminal oxidation-reductive amination of 1,2-diol to chiral 1,2-amino 
alcohol with ADH, ω-transaminase (ω-TA), and alanine dehydrogenase (AlaDH, to 
regenerate the direct amine donor). Module 4 is a sub-terminal oxidation-reductive 
amination of α-hydroxy acid to chiral α-amino acid with hydroxy acid oxidase (HO), 
α-transaminase (α-TA), glutamate dehydrogenase (GluDH, to regenerate the direct 
amine donor), and catalase (CAT, to degrade H2O2). These modular transformations 
were designed following some principles of chemistry: a) each module utilizes a stable 
input (substrate) and gives a stable output (product), because alkene, diol, amino 
alcohol, hydroxy acid, and amino acid are stable chemicals in general; b) keep the 
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unstable or toxic intermediate inside the modules to minimize accumulation and side 
reactions, because epoxide, hydroxy aldehyde, and keto acid are generally reactive and 
toxic compounds.  
Scheme 5.2. General synthetic routes of terminal alkene to chiral α-hydroxyl acid, 1,2-amino 
alcohol, and α-amino acids by assembly of different modular transformations.  
By assembly of different modules in one cell, terminal alkene can be converted 
to chiral α-hydroxy acid (Module 1 + Module 2), chiral 1,2-amino alcohol (Module 1 
+ Module 3), and chiral α-amino acid (Module 1 + Module 2 + Module 4), as draw in 
Scheme 5.2. In addition, the modular approach provides convenience in adjusting and 
turning the expression level of multiple proteins, which is a key issue in complex 
biosystems, such as cascade biocatalysis, synthetic biology,[366-368] and metabolic 
engineering.[369-371]  
To prove the concept, we chose the cascade transformation of styrene and its 
substituted derivatives to the corresponding chiral (S)-mandelic acids, (S)-
phenylethanol amines, and (S)-phenylglycines as the target (Scheme 5.3).   
Scheme 5.3. Targeted cascade transformation of styrenes to corresponding chiral (S)-mandelic 
acids, (S)-phenylethanol amines, and (S)-phenylglycines, with recombinant E. coli strains 
coexpressing multiple enzymes on multiple modules.   
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5.3.2 Genetic Construction and Functional Test of Module 1 
Figure 5.3. Cascade transformation and genetic construction of Module 1. 
Module 1 requires the transformation of styrene to (S)-phenylethane diol 
(PED). Previously, we had engineered E. coli coexpressing styrene monooxygenase 
(SMO) and SpEH from Sphingomonas sp. HXN-200 to do the same chemistry and 
produce (S)-PEDs in high ee and good yield without accumulation of epoxides (Chapter 
4). Thus, the genetic construction of an artificial operon containing styA, styB, and 
spEH was used as Module 1 in this project (Figure 5.3). The expression of two enzymes 
was examined by a SDS-PAGE analysis, and both StyA and SpEH were clearly visible 
(Figure 5.4, lane M1), while the size of StyB is too small to show on this gel. To 
facilitate further assembling multiple modules and optimizing expression, the Module 
1 was sub-cloned into four different but compatible plasmids (pACYCduet, pCDFduet, 
pETduet, and pRSFduet) to give A-M1, C-M1, E-M1, and R-M1.    
Figure 5.4. SDS-PAGE analysis of whole-cell protein of 5 E. coli strains containing Module 1-
5, respectively. Arrows indicate the expressed enzymes. C: control; M: Marker; M0: Module 0 
(up to down: AtPAL, AnOhbA); M1: Module 1 (StyA, SpEH); M2: (AlkJ, EcALDH); M3: 
(AlkJ, CvωTA, AlaDH); M4: (CAT, GluDH, HMO, EcαTA).     
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5.3.3 Genetic Construction and Functional Test of Module 2 
 Module 2 is a terminal oxidation of (S)-phenylethane diol to (S)-mandelic acid 
by ADH and ALDH (Figure 5.5). To find a highly regioselective ADH, we screened 
many commercial ADHs, cloned ADHs, and wild type strains in our group for 
oxidation of racemic phenylethane diol. As can be seen in Table 5.3, most enzymes did 
not show significant activity in oxidation of (S)-phenylethane diol, and some enzymes 
showed sub-terminal oxidation activity or both sub-terminal and terminal oxidation 
activities. Only three wild type strains, namely Gluconobacter oxydans 621H,  
Pseudomonas putida GPo1, and Sphingomonas sp. HXN-200, clearly oxidized diol to 
mandelaldehyde and mandelic acid without forming ketones. Furthermore, 
Pseudomonas putida GPo1 and Sphingomonas sp. HXN-200 showed S-selective 
preference in oxidation, producing (S)-mandelic acid with (R)-diol leftover, while 
Gluconobacter oxydans 621H exhibited R-selective preference.     
Table 5.3. Summary of screened ADHs and some strains for oxidation of phenylethane diol. 
aThe commercial enzymes are from Sigma-Aldrich in isolated forms (liquid or lyophilized 
power). bThe recombinant enzymes were over expressed in E. coli: Sc from Saccharomyces 
Function Source Enzymes/Strains 
No 
activity 
Commerciala PpAO, DrADH, TbADH, ScADH,  
Recombinantb  ScADH1, ScADH2, ScADH7, EcYdbC, EcYbdR, 
EcHcaB, PfNahB, BlADH, AcBADH, BsIoIG, BsSCD, 




Commercial PlADH, LkADH, 




Commercial HLADH,  
Recombinant  BsBDHA,[372] BsGubt 
Terminal 
oxidation 
Strains Gluconobacter oxydans 621H,  Pseudomonas putida GPo1, 
Sphingomonas sp. HXN-200 
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cerevisiae, Ec from Escherichia coli, Pf from Pseudomonas fluorescens, Bl from 
Brevibacterium linens, Ac from Acinetobacter calcoaceticus, Bs from Bacillus subtilis, Sp from 
Sphingomonas sp. HXN-200. 
Figure 5.5. Cascade transformation and genetic construction of Module 2. 
To identify the responsible ADHs in these wild type strains, we grew the strains 
with different carbon source and test their oxidation activity. For Pseudomonas putida 
GPo1 and Sphingomonas sp. HXN-200, the cells growing on alkane (n-octane) showed 
significant oxidation activity, while the cells growing on glucose or LB media did not 
give substantial activity. This phenomenon hinted that the diol oxidation is probably 
related to alkane metabolism. Since the alkane degradation pathway in Pseudomonas 
putida GPo1 has been well studied,[186, 187] the most straightforward hypothesis is that 
the ADH for oxidation terminal alkanol is responsible for terminal oxidation of diol. 
We successfully cloned the AlkJ, a membrane-associated non-canonical ADH for 
terminal alkanol oxidation in Pseudomonas putida GPo1.[189] E. coli expressing this 
AlkJ efficiently oxidized phenylethane diol to mandelaldehyde and mandelic acid with 
the same S-selectivity. In order to fully convert mandelaldehyde to mandelic acid, we 
further cloned an ALDH, phenylacetaldehyde dehydrogenase (aldh), from E. coli 
itself.[373] This EcALDH exhibited some substrate promiscuity, accepting α-hydroxy 
aldehyde (mandelaldehyde). The AlkJ and EcALDH were engineered into one non-
natural operon as Module 2 (Figure 5.5). The E. coli containing Module 2 coexpressed 
AlkJ and EcALDH very well (Figure 5.4, lane M2) and catalyzed highly regioselective 
terminal oxidation of 50 mM racemic phenylethane diol to 26 mM (S)-mandelic acid 
in 18 h without accumulation of mandelaldehyde, leaving 24 mM (R)-phenylehtane 
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diol (Figure 5.6). The high enantioselectivity enables other applications in future, such 
as oxidative resolution of diols. The Module 2 was also sub-cloned to four plasmids to 
give A-M2, C-M2, E-M2, and R-M2, similarly.    
Figure 5.6. Cascade oxidation of 50 mM racemic phenylethane diol (PED) to mandelic acid 
(MA) with 10 g cdw/L resting cells of E. coli expressing AlkJ and EcALDH (Module 2). 
 
5.3.4 Genetic Construction and Functional Test of Module 3 
Figure 5.7. Cascade transformation and genetic construction of Module 3. 
Module 3 is a cascade transformation including oxidation terminal alcohol to 
aldehyde and reductive amination of aldehyde to amine. As AlkJ catalyzed the highly 
regioselective oxidation of (S)-phenylehtane diol to (S)-mandelaldehyde in Module 2, 
it is also used as the first enzyme in Module 3. For the second step reductive amination, 
we cloned and tested the ω-TA from Chromobacterium violaceum (CvωTA), which 
had been reported with very broad substrate scope.[208] An E. coli strain was engineered 
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using 200 mM L-alanine as amine donor gave 22 mM desired (S)-phenylethanol amine 
(55% yield), with 13 mM (S)-mandelaldehyde (intermediate) and 5 mM (S)-mandelic 
acid (byproduct) remained in the system (Figure 5.8a). Clearly, the transamination is a 
reversible reaction and difficult to fully convert aldehyde to amine. In order to increase 
the yield of amine and utilize easily available ammonia as amine donor, we employed 
L-alanine dehydrogenase (AlaDH) from Bacillus subtilis to regenerate L-alanine from 
pyruvate using ammonia, which together with ω-TA have been developed as a formal 
amination system in vitro.[210] An E. coli strain was engineered to coexpress AlkJ, 
CvωTA, and AlaDH by construction of a non-natural operon (Module 3, Figure 5.7, 
protein expression see Figure 5.4, lane M3). By using this strain, biotransformation of 
40 mM (S)-phenylehtane diol was significantly improved to afford 32 mM (S)-
phenylethanol amine (80% yield) with 200 mM ammonia without external L-alanine 
(Figure 5.8b). This is the first in vivo formal amination with coexpressed ω-TA and 
AlaDH. Similarly, the Module 3 was sub-cloned to four plasmids to give A-M3, C-M3, 
E-M3, and R-M3.        
Figure 5.8. Cascade transformation of 40 mM (S)-phenylethane diol (PED) to (S)-
phenylethanol amine (PEA) with a) E. coli expressing AlkJ and CvωTA and 200 mM L-
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5.3.5 Genetic Construction and Functional Test of Module 4 
 Figure 5.9. Cascade transformation and genetic construction of Module 4. 
Module 4 requires a cascade transformation of (S)-mandelic acid to (S)-
phenylglycine via oxidation and reductive amination. Two different enzymes were 
known to oxidize (S)-mandelic acid to phenylglyoxylic acid: (S)-mandelate 
dehydrogenase (MDH) in the mandelic acid degradation pathway of Pseudomonas 
putida ATCC 12633,[374, 375] and hydroxymandelate oxidase (HMO) in the vancomycin 
biosynthesis pathway of Streptomyces coelicolor A3(2).[194, 195] Both enzymes were 
successfully cloned and over expressed in E. coli, and the corresponding whole cells 
were evaluated for oxidation of 50 mM (S)-mandelic acid to phenylglyoxylic acid 
(Figure 5.10). Clearly, HMO showed higher activity and fully converted 50 mM 
substrates in 24 h. Thus, HMO was chosen for the Module 4.    
Figure 5.10. Oxidation of 50 mM (S)-mandelic acid (MA) to phenylglyoxylic acid (PGA) with 
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The second reaction in Module 4 is enantioselective amination of 
phenylglyoxylic acid to L-phenylglycine. Although the transformation has been 
achieved with some commercial amino acid dehydrogenases in isolated form without 
sequence information,[376] we cloned and tested the phenylalanine dehydrogenase from 
Rhodococcus[377, 378] but the biotransformation result is not good (data not shown here). 
Thus, we focused on another type of enzyme, α-transaminase (α-TA), for amination of 
phenylglyoxylic acid. Four different α-TAs were cloned and tested: L-phenylglycine 
transaminase (LpgAT) from Streptomyces pristinaespiralis,[379] branch chain amino 
acid transaminase (IlvE) from E. coli,[380] aromatic amino acid transaminase (TyrB) 
from E. coli,[381] and aromatic amino acid transaminase (Aro8) from Saccharomyces 
cerevisiae.[382] The E. coli cells expressing these α-TAs were examined for amination 
of 50 mM phenylglyoxylic acid with 200 mM glutamate as amino donor. As can be 
seen in Figure 5.11a, all the cells converted phenylglyoxylic acid, though incompletely, 
and the best two are EcIlvE and ScAro8. Obviously, the transamination is a reversible 
reaction and difficult to complete in this reaction condition. To increase the yield using 
easily available ammonia as amine donor, we cloned glutamate dehydrogenase (GluDH) 
from E. coli to regenerate glutamate (direct amine donor) using ammonia. GluDH was 
successfully expressed alone and together with EcIlvE or ScAro8. We evaluated the 
corresponding E. coli strains for amination of 50 mM phenylglyoxylic acid with 200 
mM ammonia (Figure 5.11b). E. coli coexpressing EcIlvE and GluDH was found to be 
the best biocatalyst for complete amination of the phenylglyoxylic acid in 9 h.     
 To construct Module 4, we first combined HMO, EcIlvE, and GluDH together 
as an operon. Because HMO is a H2O2 generating oxidase, we further integrated a 
catalase, KatE, from E. coli,[383] and found that it improved the oxidation of 
phenylglyoxylic acid of HMO (data not shown here). Thus Module 4 containing four 
enzymes was constructed (Figure 5.9), and the four enzymes were clearly coexpressed 
in E. coli containing Module 4 (Figure 5.4, lane M4). Cascade transformation was 
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optimized to convert 45 mM (S)-mandelic acid to 42.5 mM (S)-phenylglycine (95% 
yield) within 32 h (Figure 5.12). Similarly, the Module 4 was also sub-cloned to four 
plasmids to give A-M4, C-M4, E-M4, and R-M4, to facilitate further assembly.  
Figure 5.11. Amination of 50 mM phenylglyoxylic acid (PGA) with a) E. coli expressing α-TA 
and 200 mM glutamate, b) E. coli expressing α-TA and/or GluDH and 200 mM NH3.   
Figure 5.12. Cascade transformation of 45 mM (S)-mandelic acid (MA) to (S)-phenylglycine 
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5.3.6 Assembly and Optimization of Module 1 and Module 2 for Cascade 
Transformation of Styrenes to (S)-Mandelic Acids  
 
Scheme 5.4. Cascade transformation of styrene to chiral (S)-mandelic acid with recombinant E. 
coli coexpressing multiple enzymes on Module 1 and Module 2.   
5.3.6.1 Combinatorial Assembly and Cascade Biotransformation with 12 Strains 
To achieve efficient cascade transformation of styrene to chiral (S)-mandelic 
acid with one recombinant E. coli strain (Scheme 5.4), the Module 1 and Module 2 
were assembled together in E. coli cells. To explore the optimal combination of Module 
1 and 2, four different Module 1 plasmids (A-M1, C-M1, E-M1, & R-M1) and four 
Module 2 plasmids (A-M2, C-M2, E-M2, & R-M2) were combinatorially transformed 
into E. coli to obtain different E. coli strains 1-12, each coexpressing the four enzymes, 
SMO, SpEH, AlkJ, and EcALDH. The number of strain is 12 not 16, because plasmids 
with the same backbone (e.g. A-M1 and A-M2) are not compatible with each other due 
to the same ori and antibiotic resistance marker. The E. coli strains 1-12 were easily 
grown in M9-glucose medium with the protein expression, and then harvested as 
resting cells for biotransformation. The strains were individually evaluated for 
transformation of 100 mM styrene in a two-liquid-phase system (1:1 KP buffer and n-
hexadecane) containing 0.5% glucose (to regenerate NADH for SMO via cell 
metabolism). As can be seen in Figure 5.13, all the 12 strains were able to convert 
styrene to (S)-mandelic acid, but in different yields. The best three strains (strains 2, 3, 
5) produced 71-83 mM (S)-mandelic acid in 24 h with small amount of diol 
intermediate, while the worst three strains (strains 4, 7, 9) only produced 21-26 mM 
(S)-mandelic acid in 24 h with 59-70 mM diol accumulated. To investigate the possible 
reasons for the different performance, we conducted a SDS-PAGE analysis of the 
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whole-cell protein of the 12 strains. As showed in Figure 5.14, the four enzymes were 
well separated and clearly visible. Good strains (strains 2, 3, 5) exhibited a relatively 
balanced expression of the four enzymes, whereas bad strains (strains 4, 7, 9) clearly 
expressed much more SMO and SpEH (Module 1) but much less AlkJ and EcALDH 
(Module 2), and this also explained the significant accumulation of intermediate diol 
in these three strains. On the other hand, strains 1 and 12 expressed relatively more 
AlkJ and EcALDH than SMO and SpEH, which leaded to < 3 mM diol left in 20 h. We 
demonstrated that the expression level of enzymes significantly influences in vivo 
cascade biocatalysis. Modularization of enzymes provides a basic to optimize cascade 
biocatalysis via adjusting the expression of modules by using different plasmids (as we 
have done here), different inducers, or promoters and other sequences.[384-386]               
Figure 5.13. Cascade transformation of 100 mM styrene to (S)-mandelic acid (MA) via (S)-
phenylethane diol (PED) with different E. coli strains 1-12 containing Module 1 and 2, 
coexpressing SMO, SpEH, AlkJ, and EcALDH. Values are average of three independent results.  
Figure 5.14. SDS-PAGE analysis of whole-cell protein of E. coli strains 1-12 containing 
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5.3.6.2 Biotransformation of Substituted Styrenes with the Best Strain  
The best E. coli strain 3 containing A-M1 and R-M2 was employed to further 
explore the substrate scope and characterize the cascade transformation. We tested the 
transformation of a set of substituted styrenes (20 mM) in the same KP buffer: n-
hexadecane two phase system with resting cells of E. coli (strain 3). As listed in Table 
5.4, some simple substituted styrenes (fluoro-, chloro-, and methyl-) were also 
converted to the corresponding substituted (S)-mandelic acids in excellent ee of ≥97% 
and high yield of 72-98%, within 12 h. Apparently, all the four enzymes, SMO, SpEH, 
AlkJ, and EcALDH, exhibited some substrate promiscuity (accept substrate with some 
variations) and kept the required selectivity (enantioselectivity of SMO, 
regioselectivity of SpEH and AlkJ). The result demonstrated the synthetic potential of 
our biocatalytic cascade in multi-step oxyfunctionalization of alkenes to produce 
various chiral mandelic acids with diverse possible applications. We are currently 
testing the cascade to convert other alkenes (e.g. aliphatic) to other valuable chiral α-
hydroxy acids.    
5.3.6.3 Cascade Biotransformation at Higher Concentration 
To examine the efficiency of the catalysis system, the resting cells of E. coli 
(strain 3) were applied to transform styrene at higher concentration (120 mM) in 
shaking flasks. As shown in Figure 5.15, 94 mM (14.2 g/L) (S)-mandelic acid was 
produced with 15 g cdw/L E. coli (strain 3) in 22 h, which corresponds to 78% yield 
from styrene. On the other hand, other chemicals, including unreacted substrate styrene, 
intermediate diol, and byproduct phenylacetic acid, were maintained in low amount (≤ 
10 mM). Since the chemical property of (S)-mandelic acid is rather different with those 
of the other chemicals, separation and further purification could be easy to obtain 
relative pure (S)-mandelic acid solid. The cascade biocatalysis converting styrenes to 
(S)-mandelic acids represents a significant advance in biocatalytic asymmetric 
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oxyfunctionalization, deserving further scaling up in fermentor with growing cells in 
high density.    
   
Table 5.4. Cascade transformation of (substituted) styrenes to corresponding (S)-mandelic 
acids with E. coli (strain 3) coexpressing four enzymes. 
a The reactions were performed with substrates (20 mM in organic phase) and resting cells of E. 
coli (strain 3) (10 g cdw/L) in a two-liquid phase system consisting of KP buffer (200 mM, pH 
8.0, 0.5% glucose) and n-hexadecane (1:1) at 30 oC for 12 h. b Consumption of styrene (STY) 
was determined by normal phase HPLC analysis. c Amount of phenylethane diols (PED) and 
mandelic acids (MA) was determined by reverse phase HPLC analysis. d The ee value was 
determined by chiral HPLC analysis. e Other lost was calculated from the other values, mainly 
caused by byproduct formation and substrate evaporation. f No determined because of temporary 
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Figure 5.15. Time course of transformation of 120 mM styrene (STY) to (S)-mandelic acid 
(MA) with E. coli strain 3 (15 g cdw/L). (S)-phenylethane diol (PED) is intermediate and 
phenylacetic acid (PAA) is byproduct.    
 
5.3.7 Assembly and Optimization of Module 1 and Module 3 for Cascade 
Transformation of Styrene to (S)-Phenylethanol Amine  
 
Scheme 5.5. Cascade transformation of styrene to chiral (S)-phenylethanol amine with 
recombinant E. coli coexpressing multiple enzymes on Module 1 and Module 3.    
5.3.7.1 Optimization of Reaction Conditions for the Cascade Biotransformation  
To achieve formal asymmetric aminohydroxylation of styrene to chiral (S)-
phenylethanol amine (Scheme 5.5), Module 1 (formal dihydroxylation) and Module 3 
(alcohol to amine) need to be combined together. Similarly, combinatorial assembly of 
Module 1 plasmids (A-M1, C-M1, E-M1, & R-M1) and Module 3 plasmids (A-M3, C-
M3, E-M3, & R-M3) leaded to E. coli strains 13-24, each coexpressing the five 
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more complex, we first optimized the cascade reaction by applying different amount of 
glucose and ammonia. Biotransformation of 50 mM styrene was performed with resting 
cells of E. coli strains 15 and 17 (two representative strains coexpressing five enzymes) 
with 0.5-2% glucose and 100-400 mM ammonia. The result (Figure 5.16) indicated 
that the best condition is 2% glucose with 200 mM ammonia for both strains. Too much 
ammonia might be toxic to the cells and inhibit enzymatic reactions.  
Figure 5.16. Cascade transformation of 50 mM styrene to (S)-phenylethanol amine (PEA) with 
various amount of glucose and ammonia using a) E. coli strain 15, b) E. coli strain 17.  
5.3.7.2 Cascade Biotransformation with 12 Strains 
Using the optimal condition, all the E. coli strains 13-24 were individually 
evaluated for cascade transformation of 50 mM styrene, resulting in very different 
amount of (S)-phenylethanol amine in 10 h (Figure 5.17). The best three E. coli strains 
14, 17, 24 gave 22-27 mM desired amino alcohol product in 44-54% yield, yet with 
significant amount of (S)-phenylethane diol, (S)-mandelaldehyde, and (S)-mandelic 
acid accumulated in the system. We also suspected that styrene was not fully converted 
in some cases. Nevertheless, chiral (S)-phenylethanol amine was still produced in 
reasonable yield, and more importantly in excellent ee, which proved the very high 
enantioselectivity and regioselectivity of the cascade transformation. To the best of our 
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SDS-PAGE analysis was also performed to examine the expression of five enzymes, 
SMO, SpEH, AlkJ, CvωTA, and AlaDH (Figure 5.18). Strong expression of AlkJ and 
CvωTA (Module 3) was observed for the best three strains 14, 17, 24, while strong 
expression of SMO and SpEH (Module 1) often leaded to substantial accumulation of 
intermediate phenylethane diol (strains 16, 18-22). This suggested that the bottleneck 
of the cascade is terminal oxidation and amination. The current system would be 
improved by further optimization of reaction conditions or screening/engineering of 
better enzymes for terminal oxidation of diol and transamination of α-hydroxy 
aldehyde.                 
Figure 5.17. Cascade transformation of 50 mM styrene to (S)-phenylethanol amine (PEA) 
with different E. coli strains 13-24 containing Module 1 and 3, coexpressing SMO, SpEH, AlkJ, 
CvωTA, and AlaDH. Values are average of three independent results.    
Figure 5.18. SDS-PAGE analysis of whole-cell protein of E. coli strains 13-24 containing 
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5.3.8 Assembly and Optimization of Module 1, Module 2, and Module 4 for 
Cascade Transformation of Styrene to (S)-Phenylglycine  
 Scheme 5.6. Cascade transformation of styrene to chiral (S)-phenylglycine with recombinant 
E. coli coexpressing multiple enzymes on Module 1, Module 2, and Module 4.   
To achieve more challenging asymmetric oxy- and amino-functionalization of 
alkene to chiral α-amino acid, three modular transformations need to be combined 
together, including Module 1 (dihydroxylation), Module 2 (terminal oxidation), and 
Module 4 (sub-terminal amination) (Scheme 5.6). Based on the results of styrene to 
(S)-mandelic acid (section 5.3.6), we selected the best four strains, E. coli strains 2, 3, 
5, 12, containing both Module 1 and Module 2 as parental stains for further assembly 
with Module 4. Module 4 on four different plasmids (A-M4, C-M4, E-M4, & R-M4) 
was transformed into E. coli strains 2, 3, 5, 12 to give E. coli strains 25-32, each 
containing Module 1, Module 2, and Module 4 on different plasmids. The E. coli strains 
25-32 were individually evaluated for cascade transformation of 50 mM styrene to (S)-
phenylglycine. As shown in Figure 5.19, strains 25, 26, 27 successfully produced >40 
mM (S)-phenylglycine (>80% yield) in 24 h. Other intermediates including 
phenylethane diol, mandelic acid, and phenylglyoxylic acid, only accounted for <5 mM 
in total with these three best strains. This is a significant achievement: >80% product 
yield from initial substrate with six selective enzymatic transformations and two 
assistant steps. The transformation of styrene to (S)-phenylethanol amine and (S)-
phenylglycine is the first two biocatalytic examples to achieve simultaneously amino- 
and oxy-functionalization of hydrocarbons. A SDS-PAGE analysis was performed for 
the whole-cell protein of all the eight strains (data not shown here). However, since the 
four proteins (GluDH, StyA, HMO, and SpEH) are very close in size, we could not 
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achieve acceptable resolution on normal SDS-PAGE now. Gradient gel may be applied 
in future.   
Figure 5.19. Cascade transformation of 50 mM styrene to (S)-phenylglycine (PG) with different 
E. coli strains 25-32 containing Module 1, 2, and 4, coexpressing SMO, SpEH, AlkJ, EcALDH, 
HMO, EcIlvE, GluDH, and CAT. Values are average of three independent results.   
 
5.3.9 Extend the Cascade to Start from Phenylalanine with Module 0 
 Although terminal alkene is an excellent starting material for organic synthesis, 
it derives from dwindling petroleum feedstock which is unsustainable from a 
prospective point of view. Thus, we are interested in extending our biocatalytic 
cascades to directly using sustainable bioresource as starting material. Recently, 
progress in metabolic engineering and synthetic biology enables production of more 
and more basic biochemicals, e.g. amino acids, from renewable bioresource via 
fermentation process.[55-58] Such basic biochemicals will be available in large quantity 
at low price in the near future, which are similar to basic petrochemicals (e.g. alkenes) 
today, but being greener and more sustainable. To extend the biocatalytic cascades to 
basic biochemicals, we designed an additional Module 0 to connect styrene to L-
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Scheme 5.7. Synthetic routes of L-phenylalanine to chiral mandelic acid, phenylethanol amine, 
and phenylglycine by assembly of different modular transformations. 
Figure 5.20. Cascade transformation and genetic construction of Module 0. 
5.3.9.1 Cloning and Testing PAL and PAD Individually  
The transformation of L-phenylalanine to styrene requires removing an amino 
group and a carboxyl group and forming a C=C double bond (Figure 5.20). Two 
enzymes were employed for the transformation: phenylalanine lyase (PAL) to convert 
L-phenylalanine to trans-cinnamic acid, and phenylacrylic acid decarboxylase (PAD) 
to convert cinnamic acid to styrene. PAL belongs to amino acid ammonia lyase which 
catalyzes reversible hydroamination of unsaturated acid to amino acid,[387, 388] and it is 
the first committed enzyme for phenylpropanoids biosynthesis in plants.[389] To find an 
efficient PAL, several PALs were cloned and expressed in E. coli, including AtPAL 
from plant Arabidopsis thaliana,[390] AvPAL from cyanobacterium Anabaena 
variabilis,[391] and RtPAL from yeast Rhodosporidium toruloides.[392] The 
corresponding E. coli cells expressing these PALs were examined for conversion of 20 
mM L-phenylalanine to cinnamic acid. As clearly shown in Figure 5.21a, AtPAL 
outperformed other two PALs and produced 9 mM cinnamic acid in 5 h. On the other 
hand, PAD is less studied and only exists in certain yeast and fungus for degradation 
of some acrylic acids. We initially cloned the padA gene from Saccharomyces 
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cerevisiae[393] and Aspergillus niger,[394] but both of them did not show decarboxylation 
activity in recombinant E. coli. Two close related genes, fdc from S. cerevisiae[395] and 
ohbA from A. niger,[396] were then cloned but showed a low decarboxylation activity in 
E. coli (Figure 5.21b). Because the padA and fdc/ohbA genes were found to function 
collaboratively in native organisms,[395, 396] we tested coexpression of padA and ohbA 
gene in E. coli, and much higher decarboxylation activity was obtained (Figure 5.22b). 
Thus, AnPadA and AnOhbA are the two components of AnPAD.  
Figure 5.21. a) Conversion of 20 mM L-phenylalanine to cinnamic acid (Cin) with E. coli (1 g 
cdw/L) expressing different PAL; b) Conversion of 20 mM cinnamic acid (Cin) into styrene 
(Sty) with E. coli (1 g cdw/L) expressing different PAD component.  
5.3.9.2 Genetic Construction and Functional Test of Module 0 
To achieve cascade transformation of L-phenylalanine to styrene, the AtPAL 
and AnPAD were genetically constructed together as an expression cassette (Module 
0). E. coli cells well-coexpressed these two enzymes (Figure 5.4, lane M0) and 
efficiently converted 50 mM L-phenylalanine into quantitative amount of styrene in an 
n-hexadecane: KP buffer two-phase system in 5 h (Figure 5.22). Obviously, the 
irreversible decarboxylation by AnPAD drove the reversible PAL-catalyzed reaction 
to complete. Although the same reactions have been published for production of 
styrene from glucose,[397] the decarboxylation was catalyzed by ScFDC, which is much 
less active than the two component AnPAD (Figure 5.21b). Similarly, the Module 0 
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Figure 5.22. Cascade transformation of 50 mM L-phenylalanine to styrene with E. coli (5 g 
cdw/L) coexpressing AtPAL and AnPAD (Module 0).  
5.3.10 Assembly and Optimization of Module 0, Module 1, and Module 2 for 
Cascade Transformation of L-Phenylalanine to (S)-Mandelic Acid  
Scheme 5.8. Cascade transformation of L-phenylalanine to chiral (S)-mandelic acid with 
recombinant E. coli coexpressing multiple enzymes on Module 0, Module 1, and Module 2.   
 Now, the transformation of L-phenylalanine to styrene could be coupled with 
the following oxy- and amino-functionalization of styrene by assembling the Module 
0 with appropriate Module 1-4 in one E. coli strain. To produce (S)-mandelic acid from 
L-phenylalanine, Module 0, Module 1, and Module 2 need to be combined together. 
We selected four best strains, E. coli strains 2, 3, 5, 12, containing both Module 1 and 
Module 2 as parental strains for further assembly with Module 0. Module 0 on four 
different plasmids (A-M0, C-M0, E-M0, & R-M0) was transformed into E. coli strains 
2, 3, 5, 12 to give E. coli strains 33-40, each containing Module 0, Module 1, and 
Module 2 on different plasmids. The E. coli strains 33-40 were studied for cascade 
transformation of 100 mM L-phenylalanine to (S)-mandelic acid in a two-liquid-phase 
system. To our delight, four out of eight strains efficiently produced >80 mM (S)-
mandelic acid (Figure 5.23), representing >80% yield over six steps from L-
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phenylalanine in a similar setup. As a result, the strain 33 and strain 40 produced 138-
140 mM (21 g/L) (S)-mandelic acid in 24 h (Figure 5.25), giving a very high yield of 
92-93%. The protein expressing profile was examined by SDS-PAGE analysis, which 
showed the relative balanced expression of the six enzymes in the best strain 33 and 40 
(Figure 5.24). Without a doubt, such a highly efficient multistep reaction clearly 
demonstrated the potential of cascade biocatalysis, deserving further research and 
future industrial implementation. During the culturing of strains 33-40, we observed 
the production of (S)-mandelic acid (12-110 mg/L) in the cell culture broth, which 
evidenced the synthesis from endogenous L-phenylalanine, providing a novel and 
potential synthetic pathway for fermentative production of (S)-mandelic acid from 
glucose in the future.[398]       
Figure 5.23. Cascade transformation of 100 mM L-phenylalanine to (S)-mandelic acid (MA) 
with different E. coli strains 33-40 containing Module 0, 1, and 2, coexpressing AtPAL, AnPAD, 
SMO, SpEH, AlkJ, and EcALDH. Values are average of three independent results.    
Figure 5.24. SDS-PAGE analysis of whole-cell protein of E. coli strains 33-40 containing 
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Figure 5.25. Production of (S)-mandelic acid from 150 mM L-phenylalanine with E. coli strains 
33, 35, 37, 40 (15 g cdw/L), each containing Module 0, 1, and 2.   
   
5.3.11 Assembly and Optimization of Module 0, Module 1, and Module 3 for 
Cascade Transformation of L-Phenylalanine to (S)-Phenylethanol Amine  
Scheme 5.9. Cascade transformation of L-phenylalanine to chiral (S)-phenylethanol amine with 
recombinant E. coli coexpressing multiple enzymes on Module 0, Module 1, and Module 3. 
To produce (S)-phenylethanol amine from L-phenylalanine, Module 0 needs 
to be assembled with Module 1 and Module 3. Similarly to the above, the three best 
strains, strains 13, 17, 24, containing Module 1 and Module 3, were chosen as parental 
strains for combining with Module 0 on four different plasmids (A-M0, C-M0, E-M0, 
& R-M0). As a result, six different strains, strains 41-46, were obtained for 
coexpressing enzymes on the three modules. Initial screening found that strain 43 
produced 7 mM (S)-phenylethanol amine from 50 mM L-phenylalanine in 24 h without 
optimization of reaction conditions. We are currently investigating the possible reasons 
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and suggested the first de novo biosynthetic pathway from glucose via phenylalanine 
to this useful biogenic amine in enantiopure form.  
 
5.3.12 Assembly and Optimization of Module 0, Module 1, Module 2, and Module 
4 for Cascade Transformation of L-Phenylalanine to (S)-Phenylglycine  
Scheme 5.10. Cascade transformation of L-phenylalanine to chiral (S)-phenylglycine with 
recombinant E. coli coexpressing multiple enzymes on Module 0, Module 1, Module 2, and 
Module 4. 
 The assembly of Module 0, Module 1, Module 2, and Module 4, could achieve 
production of (S)-phenylglycine from L-phenylalanine (Scheme 5.10). Module 0 on 
two plasmids (C-M0, E-M0) were transformed into the two best strains (strain 26, 27) 
containing Module 1, 2, and 4, to give strains 48, 49, respectively. On the other hand, 
Module 4 on two plasmids (R-M4, A-M4) were transformed into the two best strains 
(strains 33, 40) containing Module 0, 1, and 2, to offer strains 47, 50, respectively. Each 
of these four strains (strains 47-50) holds the four modules on four different plasmids 
and could be induced to coexpress ten enzymes, AtPAL, AnPAD, SMO, SpEH, AlkJ, 
EcALDH, HMO, EcIlvE, GluDH, and CAT. A set of experiment was performed to test 
them for converting 50 mM L-phenylalanine in the two-liquid phase system. 
Preliminary results showed that strain 48 and strain 49 produced 22 mM and 17 mM 
(S)-phenylglycine, respectively, in 24 h. The cascade biocatalysis successful 
demonstrated the production of non-proteinogenic (S)-phenylglycine from L-
phenylalanine by assembly of four different modules in E. coli, and it also suggested a 
new de nove biosynthetic pathway to produce chiral phenylglycine from simple 
renewable bioresource, e.g. glucose.[399, 400]   




Novel and efficient one-pot multi-step cascade biocatalysis for asymmetric 
oxy- and amino-functionalization of terminal aryl alkene to produce chiral α-hydroxy 
acid, 1,2-amino alcohol, and α-amino acid was developed by using a modular approach. 
The following modules were designed, constructed, and verified to give the desired 
transformation: (1) monooxygenase-epoxide hydrolase for asymmetric 
dihydroxylation of alkene to chiral 1,2-diol; (2) alcohol dehydrogenase-aldehyde 
dehydrogenase for terminal oxidation of chiral diol to chiral α-hydroxy acid; (3) alcohol 
dehydrogenase-ω-transaminase for terminal amination of 1,2-diol to 1,2-amino alcohol; 
(4) hydroxy acid oxidase-α-transaminase for sub-terminal amination of α-hydroxy acid 
to α-amino acid. Assembly of different modules in E. coli enabled cascade 
transformation of styrene to (S)-mandelic acid (Module 1 + 2), (S)-phenylethanolamine 
(Module 1 + 3), and (S)-phenylglycine (Module 1 + 2 + 4), respectively, with single 
whole-cell biocatalyst. Importantly, the expression level of multiple enzymes was 
adjustable by changing the plasmid backbone of different modules, and the expression 
was optimized to achieve efficient cascade catalysis. As a result of strain and reaction 
optimization, (S)-mandelic acid, (S)-phenylethanolamine, and (S)-phenylglycine were 
produced in high yield and excellent enantiopurity from styrene, respectively. In this 
work, we harnessed cascade biocatalysis to achieve asymmetric one-pot multi-step 
oxy- and amino-functionalization of hydrocarbons, which is useful but challenging in 
chemistry: the transformation of styrene to (S)-phenylethanolamine represents the first 
biocatalytic method for asymmetric aminohydroxylation, and the one-pot 
transformation of styrene to (S)-mandelic acid and (S)-phenylglycine is reported for the 
first time, without any known chemical counterparts. From a biochemical point of view, 
the cascade transformation is also a new artificial pathway, with no known natural 
equivalents. Other terminal alkenes could also be converted to other chiral α-hydroxy 
acids, 1,2-amino alcohols, and α-amino acids via the same biocatalytic cascade by 
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using these or other similar enzymes. The modular approach could be generally applied 
to other biocatalytic cascades to improve efficiency. Furthermore, we extended the 
cascade biocatalysis to start from L-phenylalanine with one additional module 0 
(ammonia lyase-decarboxylase). By combining different modules in E. coli, bio-based 
L-phenylalanine was converted to enantiopure (S)-mandelic acid (Module 0 + 1 + 2), 
(S)-phenylethanolamine (Module 0 + 1 + 3), and (S)-phenylglycine (Module 0 + 1 + 2 
+ 4), respectively. This provides the opportunity to produce these useful and valuable 
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6 CONCLUSIONS AND RECOMMENDATIONS 
6.1 Overall Conclusions 
Biocatalysis is an emerging tool for production of high value added 
enantiopure fine chemicals and pharmaceutical intermediates in a green and efficient 
way. However, many biocatalytic reactions are still not efficient enough for practical 
application, due to the lack of highly active enzymes. Novel enzymes need to be 
discovered/engineered, and productive and cost-effective biotransformation needs to 
be developed. Another current limitation in biocatalysis is that most of industrial 
biotransformations are mainly based on one-step biocatalysis, which requires tedious 
intermediate recovery and purification for traditional multistep synthesis. Several types 
of cascade biocatalysis have been recently reported to overcome the limitation, yet 
most of them are still suffering from low productivity, limited substrate scope, and no 
access to multiple enantiomers. Furthermore, new type of cascades are demanded to 
achieve green and efficient one-pot multistep synthesis of various chiral fine chemicals.  
One potential but currently inefficient biotransformation is enantioselective 
hydrolysis of epoxide with epoxide hydrolase (EH). To address this gap, we 
successfully identified and cloned a unique SpEH from Sphingomonas sp. HXN-200 
based on genome sequencing for enantioselective hydrolysis of racemic and meso-
epoxides to prepare the corresponding (S)-epoxides and (R, R)-vicinal diols, 
respectively. The engineered E. coli (SpEH) highly expressed SpEH and gave 172 folds 
higher cell-based activity for the hydrolysis of styrene oxide than that of Sphingomonas 
sp. HXN-200. Kinetic resolution of several selected racemic styrene oxides with the 
resting cells of E. coli (SpEH) produced the corresponding (S)-styrene oxides in 98.0-
99.5% ee and 35.1-46.5% yield, representing the highest R-enantioselectivity for some 
styrene oxides among all the known EHs. Hydrolysis of three cyclic meso-epoxides 
afforded the corresponding (R, R)-vicinal diols in 86-93% ee and 90-99% yield. These 
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biotransformations showed high cell-based specific activities (0.28–4.3 U/mg cdw), 
product concentration, product/cells ratio, and cell-based productivity. 
Biotransformation at even higher substrate concentration produced (S)-styrene oxide in 
430 mM (51 g/Lorg) and (1R, 2R)-cyclohexene diol in 500 mM (58 g/L). The production 
of 500 mM (1R, 2R)-cyclohexene diol stands for the first report of EH-catalyzed 
hydrolysis of meso-epoxide in elevated concentration (>30 g/L). We also performed 
gram-scale preparation of three enantiopure epoxides and three vicinal diols in high ee. 
In comparison with the industrial standard, Jacobsen’s Co(salen) catalyst, for 
hydrolysis of styrene oxide, E. coli (SpEH) showed similar product/catalyst ratio, but 
higher catalyst-based specific productivity. Clearly, the E. coli (SpEH) cells are highly 
active and easily available biocatalysts for the practical production of these useful and 
valuable enantiopure epoxides and vicinal diols.  
To address the second gap of cascade biocatalysis, we developed an 
intracellular epoxidation-hydrolysis cascade for efficient asymmetric trans-
dihydroxylation of aryl olefins to produce chiral vicinal diols by combining styrene 
monooxygenase (SMO) and epoxide hydrolase. E. coli (SSP1) was engineered to 
coexpress SMO and SpEH for efficient S-enantioselective dihydroxylation. 
Biotransformation of 15 terminal aryl olefins with E. coli (SSP1) produced the 
corresponding 15 (S)-vicinal diols in high ee (most ee 92-99%) and high yield (most 
yield > 67%). On the other hand, to achieve R-enantioselective dihydroxylation, E. coli 
(SST1) was engineered to coexpress SMO and the epoxide hydrolase from Solanum 
tuberosum (StEH, regioselective-complementary to SpEH). Transformations of 15 
terminal aryl olefins with E. coli (SST1) gave corresponding 15 (R)-vicinal diols, in 
high ee (most ee 84-99%) and good yield (most yield > 65%). In addition, E. coli (SSP1) 
and E. coli (SST1) catalyzed the trans-dihydroxylation of cis and trans β-methyl 
styrenes with excellent and complementary stereoselectivity, giving each of the four 
stereoisomers of 1-phenyl-1,2-propanediol in high ee and de, respectively. Clearly, E. 
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coli (SSP1) and E. coli (SST1) are a unique pair of biocatalysts with complementary 
enantioselectivity, providing access to multiple enantiomers of products in high 
enantiopurity. The reversing of overall enantioselectivity by changing one-step 
regioselectivity could be a general strategy for elegant control of stereochemistry in 
cascade catalysis. Preparation of five (1S)-diols and five (1R)-diols was also 
demonstrated, and the process was easily scaled up by using growing cells in a 
bioreactor. The cascade biocatalysis utilizes molecular oxygen, water, and glucose as 
inexpensive stoichiometric reagents without involving any toxic metals. Thus it 
provides a green and useful synthetic tool to produce chiral vicinal diols, 
complementary to Sharpless cis-dihydroxylation.  
With the above dihydroxylation, we developed very novel one-pot multi-step 
cascade biocatalysis for asymmetric oxy- and amino-functionalization of aryl alkenes 
to produce useful chiral hydroxy acids, amino alcohols, and amino acids. To achieve 
these challenging transformations, several enzymatic modules were designed, 
constructed, and validated to give the desired reactions: (1) SMO-SpEH for converting 
alkene to chiral 1,2-diol; (2) alcohol dehydrogenase-aldehyde dehydrogenase for 
converting 1,2-diol to chiral α-hydroxy acid; (3) alcohol dehydrogenase-ω-
transaminase for converting 1,2-diol to 1,2-amino alcohol; (4) hydroxy acid oxidase-
α-transaminase for converting α-hydroxy acid to chiral α-amino acid. Assembly of 
different modules in E. coli enabled cascade transformation of styrene to (S)-mandelic 
acid (Module 1 + 2), (S)-phenylethanolamine (Module 1 + 3), and (S)-phenylglycine 
(Module 1 + 2 + 4), respectively, with single whole-cell biocatalyst. As a result of strain 
and reaction optimization, (S)-mandelic acid, (S)-phenylethanolamine, and (S)-
phenylglycine were produced in high yield and excellent enantiopurity from styrene, 
respectively. In this work, we harnessed cascade biocatalysis to achieve asymmetric 
one-pot multi-step oxy- and amino-functionalization of hydrocarbons, which is useful 
but challenging in chemistry: the transformation of styrene to (S)-phenylethanolamine 
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represents the first biocatalytic method for asymmetric aminohydroxylation, and the 
one-pot transformation of styrene to (S)-mandelic acid and (S)-phenylglycine is 
reported for the first time, without any known chemical counterparts. From a 
biochemical point of view, the cascade transformation is also a new artificial pathway, 
with no known natural equivalents. It demonstrated the power of retrosynthetic analysis 
and modular approach in designing and building of non-natural biocatalytic cascades 
(synthetic pathways). Furthermore, we extended the cascade biocatalysis to start from 
L-phenylalanine with one additional module 0 (ammonia lyase-decarboxylase). By 
combining different modules in E. coli, bio-based L-phenylalanine was converted to 
enantiopure (S)-mandelic acid (Module 0 + 1 + 2), (S)-phenylethanolamine (Module 0 
+ 1 + 3), and (S)-phenylglycine (Module 0 + 1 + 2 + 4), respectively. This provides the 
opportunity to produce these useful and valuable enantiopure chemicals from 
renewable feedstock.  
To sum up the three parts, we developed several novel recombinant whole-cell 
biocatalysts and the corresponding processes for green and efficient production of 
various important chiral chemicals, including epoxide, diol, hydroxyl acid, amino 
alcohol, and amino acid, in high enantiopurity, from cheap and easily available racemic 
and meso-epoxide, prochiral alkene, or bio-based amino acid. 
 
6.2 Recommendations for Future Work 
 The further developments would focus on the following directions.  
6.2.1 Solving the Structure of SpEH and Protein Engineering   
 The newly identified SpEH has shown high enantioselectivity and high activity 
in hydrolysis of several racemic and meso-epoxides. To find out the reason for the 
enantioselectivity and activity at a molecular level, the 3-D structure of SpEH should 
be obtained to study the molecular interaction between substrate and enzymes. We had 
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applied homology modeling to get the structure of SpEH based on the most related 
structure of AnEH (PDB: 3g02A),[116] yet the resulting structure is unreliable (data not 
shown here), mainly because of the low similarity of 30% between SpEH and AnEH 
(refer to Figure 3.2). Thus, it is demanded to crystalize the SpEH and solve the 3-D 
structure to study the structure-function relationship. Furthermore, structure-guided 
protein engineering will be performed to improve SpEH properties. Although protein 
engineering of other EHs has been published to enhance the enantioselectivity[115, 116, 
122] and activity[401, 402] in hydrolysis of racemic epoxides, there is no report on 
engineering of EH towards hydrolysis of meso-epoxides. Thus, it will be interesting to 
engineer SpEH for even more practical hydrolysis of many meso-epoxides.   
6.2.2 Extending Substrate and Product Scope of the Cascade Biocatalysis   
Scheme 6.1. Expended scope of the cascade biocatalysis for terminal alkenes to chiral α-
hydroxy acids, 1,2-amino alcohols, and α-amino acids.  
In the cascade biocatalysis for asymmetric oxy- and amino-functionalization 
of aryl alkenes, we had demonstrated the conversion of styrene to (S)-mandelic acid, 
(S)-phenylethanolamine, and (S)-phenylglycine. Obviously, some substituted styrenes 
could also be transformed into the corresponding substituted (S)-mandelic acids, (S)-
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phenylethanolamines, and (S)-phenylglycines (Scheme 6.1a). Due to the time 
limitation, only the production of several substituted (S)-mandelic acids was reported 
in this thesis. On the other hand, the other enantiomer of the products, (R)-mandelic 
acids, (R)-phenylethanolamines, and (R)-phenylglycines, are very useful chiral 
chemicals as well (Scheme 6.1b). For example, (R)-phenylglycine is the key 
intermediate for manufacturing widely-used Ampicillin and Cefalexin.[238] The 
transformation of styrenes to these (R)-chemicals requires several (R)-selective 
enzymes (ADH, α-TA), and we have obtained some preliminary results on these 
enzymes. Besides the styrene type of substrates, the cascade biocatalysis could also 
convert other aromatic or even aliphatic alkenes (Scheme 6.1c, 6.1d) into the 
corresponding chiral α-hydroxy acids, 1,2-amino alcohols, and α-amino acids by using 
the same or other enzymes with similar functions. Some of these products are key chiral 
building blocks for pharmaceuticals, e.g. (R)-2-amino-4-phenylbutyric acid (L-
homophenylalanine) for several angiotensin-converting enzyme (ACE) inhibitors[403] 
and anti-cancer drug Carfilzomib.[404]       
6.2.3 Protein Engineering of Individual Enzymes to Improve Cascade Biocatalysis 
 During the development of cascade biocatalysis to produce (S)-mandelic acid, 
(S)-phenylethanolamine, and (S)-phenylglycine, we had identified the possible 
bottleneck enzymes. For example, the amination of (S)-mandelaldehyde to (S)-
phenylethanolamine with CvωTA is not efficient, resulting in significant amount of 
(S)-mandelaldehyde and (S)-mandelic acid remained (refer to section 5.3.7). We 
suspected that CvωTA is either not stable or not active enough under the reaction 
condition. Since the structure of CvωTA has been solved recently,[405] protein 
engineering could be possible to solve this problem. On the other hand, HMO-catalyzed 
oxidation of (S)-mandelic acid is probably the bottleneck of producing (S)-
phenylglycine. We noticed that the native substrate for HMO is hydroxymandelic acid, 
and this hydroxy group on the benzene ring might contribute to substrate binding to 
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HMO. If the amino acid residue for this binding can be identified and mutated, the 
mutated HMO could exhibit higher activity towards (S)-mandelic acid. There are other 
targets for protein engineering in the cascade biocatalysis, such as AlkJ, and enzymes 
for production of other products in section 6.2.2. Clearly, protein engineering has 
become a versatile tool in biocatalysis, and combining of protein engineering with 
cascade biocatalysis, metabolic engineering, and synthetic biology will enable efficient 
bio-production of various chemicals.    
6.2.4 Development of Efficient Bioprocesses for Oxy- and Amino-
Functionalization of Alkenes 
 Most of the biotransformations in this thesis were performed in shaking flasks 
with resting cells. In order to further improve the productivity and demonstrate the 
feasibility for future industrial implementation, the biotransformation should be scaled 
up in bioreactor (≥ 1 L) and catalyzed with growing cells. Furthermore, downstream 
processes should be developed as well. In this thesis, we had achieved some initial 
results for dihydroxylation using bioreactor and growing cells (section 4.3.10), but the 
more commercially potential transformation of styrene to (S)-mandelic acid and (S)-
phenylglycine has not been performed in bioreactor. In the desired scenario, the 
recombinant E. coli strain is first grown in fermentor with the well-developed high-
cell-density cultivation technology.[220-222] The protein expression is induced at a certain 
time during the growth. When the cells reach high density (e.g. 30-50 g cdw/L), styrene 
will be directly fed into the fermentor to start the biotransformation. Obviously, the 
feeding strategy of styrene is crucial for a highly productive process: the accumulation 
of styrene (e.g. > 1 mM) will be very toxic to the growing cells, while under-supply of 
styrene will lead to unsatisfied volumetric productivity. Furthermore, in situ product 
recovery/removal technology[406, 407] could be applied to reduce product inhibition. 
With all these efforts, we expect to produce (S)-mandelic acid and (S)-phenylglycine 
in 30-50 g/L in fermentor with high density of growing cells (representing a 2-5 folds 
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improvement of the results in shaking flask with less cells, section 5.3.6). This is 
essential for future commercialization.  
6.2.5 Metabolic Engineering to Produce Chiral Chemicals from Glucose  
Scheme 6.2. Novel pathway from glucose to (S)-mandelic acid, (S)-phenylethanolamine, and 
(S)-phenylglycine.  
We had demonstrated the conversion of L-phenylalanine to (S)-mandelic acid, 
(S)-phenylethanolamine, and (S)-phenylglycine, respectively, with multiple modular 
transformations in E. coli (sections 5.3.10-12). Phenylalanine was one of the most 
popular targets of metabolic engineering during the last decade, and it could be 
produced at the concentration of > 50 g/L using recombinant strains (Corynebacterium 
glutamicum or E. coli) in optimized fermentation.[408-411] Thus, the downstream 
transformation of phenylalanine could be introduced into the phenylalanine producer 
to achieve directly fermentative production of (S)-mandelic acid, (S)-
phenylethanolamine, and (S)-phenylglycine from glucose. Even though bio-production 
of mandelic acid and phenylglycine in small concentration (≤1 g/L) has been reported 
with another pathway,[398-400] it depends on a difficult hydroxymandelate synthase.[194] 
In comparison, our pathway would probably be more efficient, since (S)-mandelic acid 
has been produced at 21 g/L from phenylalanine (sections 5.3.10). Therefore, it is an 
opportunity to develop new strains and efficient bioprocesses to produce these valuable 
chiral chemicals from renewable glucose via a novel pathway.  
6.2.6 Cascade Biocatalysis for Formal anti-Markovnikov Hydration and 
Hydroamination of Aryl Alkenes 
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 Anti-Markovnikov additions are one group of regioselective reactions for 
direct functionalization of alkenes to various useful chemicals, with huge potential for 
industrial applications.[412, 413] Two of the most important additions are anti-
Markovnikov adding water to produce terminal alcohols (hydration) and adding 
ammonia to produce terminal amines (hydroamination), which together was named as 
one of 10 challenges for industrial catalysis.[414] Formal anti-Markovnikov hydration 
was traditionally achieved by two-step hydroboration-oxidation reaction,[415] and 
recently realized by oxidation-hydrolysis-reduction using Pd-Acid-Ru triple relay 
catalysis.[352] Regioselective hydroamination of alkenes was reported by mainly 
transition-metal-mediated and organocatalytic photoredox approaches.[416-418] However, 
many of these methods are still problematic: transitional metals, borane reagents, chiral 
ligands are expensive and toxic in general. And it is very challenging for 
hydroamination directly using ammonia. On the other hand, nature provides hydratases 
for hydration of C=C double bonds,[348-351] yet there is no enzyme for hydration of non-
activated C=C double bonds with distinct anti-Markovnikov selectivity. 
Hydroamination of C=C bonds could be achieved with ammonia lyases and 
aminomutases,[387, 388] but none of them could convert non-activated C=C double bonds.  
Scheme 6.3. Novel cascade biocatalysis to achieve formal anti-Markovnikov hydration and 
hydroamination of styrenes.   
To address this significant gap, we are developing novel biocatalytic 
epoxidation-isomerization-reduction and epoxidation-isomerization-amination for 
formal anti-Markovnikov hydration and hydroamination of non-activated alkenes, 
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respectively (Scheme 6.3). The key step is isomerization of epoxide into aldehyde by 
styrene oxide isomerase (SOI). The transformations are very green, only consuming 
stoichiometric amount of oxygen, glucose, and ammonia. We have obtained very 
promising preliminary results recently, and more experiments are on-going.  
6.2.7 Structure-based in silico Analysis and Synthetic Biology Tools for Design 
and Engineer Biocatalysis Systems 
For future development of biocatalysis field, I believe two very important 
technologies could play a very important role: 1) Structure-based in silico analysis for 
development of biocatalysis with a single enzyme; and 2) Synthetic biology tools for 
engineering of biocatalysis system with multiple enzymes.  
Enzyme function is determined by its 3-D structure. Thus in silico analysis of 
enzyme structures could provide much valuable insights for engineering enzymes with 
various improved features, such as high chemo-, regio-, and enantioselectivity, good 
stability, and expanded substrate scopes. Furthermore, in silico analysis of structure 
could also shed light on understanding of enzyme catalytic mechanisms, which will 
facilitate the development of new types of reactions.  
Recently, many synthetic biology tools have been developed for quick and 
precise engineering of complex biological systems, and they are also applicable for 
engineering of novel and efficient cascade biocatalysis systems. Examples of these 
tools includes: advanced genetic cloning with Gibson’s method[419] and DNA 
assembler[420]; advanced genomic engineering with multiplex automated genome 
engineering (MAGE)[421] and CRISPR/Cas technology[422]; and balancing multiple 
protein expression with promoter engineering[423] and engineering of other non-coding 
sequences[424, 425]. With these powerful tools, more novel and efficient whole-cell 
biocatalysts will be developed in the near future.         
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Appendix I: Supporting Information for Chapter 3 
 











































Figure S1.1. Chiral HPLC chromatogram of racemic 1 and product (S)-1 (Column: Daicel AS-H (250 
× 4.6 mm, 5µm); eluent: 10% IPA: 90% n-hexane; flow rate: 1.0 mL min−1).        
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Figure S1.2. Chiral HPLC chromatogram of racemic 2 and product (S)-2 (Column: Daicel AS-H (250 
× 4.6 mm, 5µm); eluent: 0% IPA: 100% n-hexane; flow rate: 0.5 mL min−1). 
 
 








































Figure S1.3. Chiral HPLC chromatogram of racemic 3 and product (S)-3 (Column: Daicel AS-H (250 














































Figure S1.4. Chiral HPLC chromatogram of racemic 4 and product (S)-4 (Column: Daicel AS-H (250 

















































Figure S1.5. Chiral HPLC chromatogram of racemic 5 and product (S)-5 (Column: Daicel AS-H (250 


















































Figure S1.6. Chiral HPLC chromatogram of racemic 6 and product (S)-6 (Column: Daicel AS-H (250 

















































Figure S1.7. Chiral HPLC chromatogram of racemic 7 and product (S)-7 (Column: Daicel AS-H (250 














































Figure S1.8. Chiral HPLC chromatogram of racemic 8 and product (−)-8 (Column: Daicel OB-H 





















































Figure S1.9. Chiral HPLC chromatogram of product (3R, 4R)-14 (Column: Daicel AS-H (250 × 4.6 


































































Figure S1.10. Chiral GC chromatogram of trans-12 and product (1R, 2R)-12 (Column: Macherey-
Nagel Lipodex-E (25 m × 0.25 mm); temperature: 100 oC constant; pressure: 11.093 psi).   
 
 
(1R, 2R)-12 (1S, 2S)-12 









Figure S1.11. Chiral GC chromatogram of trans-13, product (1R, 2R)-13, and product (1R, 2R)-13 
after crystallization (Column: Macherey-Nagel Lipodex-E (25 m × 0.25 mm); temperature: 100 oC 
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Figure S2.1. Chiral HPLC chromatograms of diol 1c. a) racemic 1c; b) (S)-1c standard; c) (S)-1c 
produced by E. coli (SSP1); d) (R)-1c produced by E. coli (SST1). (Daicel Chiralpak AS-H (250 × 4.6 
mm, 5µm) column, mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 
25 oC, UV detection at 210 nm)  
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Figure S2.2. Chiral HPLC chromatograms of diol 2c. a) racemic 2c; b) (S)-2c produced by E. coli 
(SSP1); c) (R)-2c produced by E. coli (SST1); d) (S)-2c produced by AD-mix-α; e) (R)-2c produced by 
AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm) 
 


































































































































Figure S2.3. Chiral HPLC chromatograms of diol 3c. a) racemic 3c; b) (S)-3c produced by E. coli 
(SSP1); c) (R)-3c produced by E. coli (SST1); d) (S)-3c produced by AD-mix-α; e) (R)-3c produced by 
AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)   
 



















































































































































Figure S2.4. Chiral HPLC chromatograms of diol 4c. a) racemic 4c; b) (S)-4c produced by E. coli 
(SSP1); c) (R)-4c produced by E. coli (SST1); d) (S)-4c produced by AD-mix-α; e) (R)-4c produced by 
AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-











































































































































Figure S2.5. Chiral HPLC chromatograms of diol 5c. a) racemic 5c; b) (S)-5c produced by E. coli 
(SSP1); c) (R)-5c produced by E. coli (SST1); d) (S)-5c produced by AD-mix-α; e) (R)-5c produced by 
AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm) 
 
 










































































































































Figure S2.6. Chiral HPLC chromatograms of diol 6c. a) racemic 6c; b) (S)-6c produced by E. coli 
(SSP1); c) (R)-6c produced by E. coli (SST1); d) (S)-6c produced by AD-mix-α; e) (R)-6c produced by 
AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm) 
 
 

















































































































































Figure S2.7. Chiral HPLC chromatograms of diol 7c. a) racemic 7c; b) (S)-7c produced by E. coli 
(SSP1); c) (R)-7c produced by E. coli (SST1); d) (S)-7c produced by AD-mix-α; e) (R)-7c produced by 
AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-































































































































Figure S2.8. Chiral HPLC chromatograms of diol 8c. a) racemic 8c; b) (S)-8c produced by E. coli 
(SSP1); c) (R)-8c produced by E. coli (SST1); d) (S)-8c produced by AD-mix-α; e) (R)-8c produced by 
AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm) 
 
 






































































































































Figure S2.9. Chiral HPLC chromatograms of diol 9c. a) racemic 9c; b) (S)-9c produced by E. coli 
(SSP1); c) (R)-9c produced by E. coli (SST1); d) (S)-9c produced by AD-mix-α; e) (R)-9c produced by 
AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm) 
 



















































































































































Figure S2.10. Chiral HPLC chromatograms of diol 10c. a) racemic 10c; b) (S)-10c produced by E. coli 
(SSP1); c) (R)-10c produced by E. coli (SST1); d) (S)-10c produced by AD-mix-α; e) (R)-10c produced 
by AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)   
 
 













































































































































Figure S2.11. Chiral HPLC chromatograms of diol 11c. a) racemic 11c; b) (S)-11c produced by E. coli 
(SSP1); c) (R)-11c produced by E. coli (SST1); d) (S)-11c produced by AD-mix-α; e) (R)-11c produced 
by AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)   
 
 



























































































































Figure S2.12. Chiral HPLC chromatograms of diol 12c. a) racemic 12c; b) (S)-12c produced by E. coli 
(SSP1); c) (R)-12c produced by E. coli (SST1); d) (S)-12c produced by AD-mix-α; e) (R)-12c produced 
by AD-mix-β. (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)    
 
 










































































































































Figure S2.13. Chiral HPLC chromatograms of diol 13c. a) racemic 13c; b) (S)-13c produced by E. coli 
(SSP1); c) (R)-13c produced by E. coli (SST1); d) (S)-13c produced by AD-mix-α; e) (R)-13c produced 
by AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-



































































































































Figure S2.14. Chiral HPLC chromatograms of diol 14c. a) racemic 14c; b) (S)-14c standard; c) (S)-14c 
produced by E. coli (SSP1); d) (R)-14c produced by E. coli (SST1). (Daicel Chiralpak AS-H (250 × 4.6 
mm, 5µm) column, mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 










































































































Figure S2.15. Chiral HPLC chromatograms of diol 15c. a) racemic 15c; b) (S)-15c produced by E. coli 
(SSP1); c) (R)-15c produced by E. coli (SST1); d) (S)-15c produced by AD-mix-α; e) (R)-15c produced 
by AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)   
 
 




























































































































Figure S2.16. Chiral HPLC chromatograms of diol 16c. a) racemic 16c (mixture of trans and cis); b) 
(1S, 2R)-16c produced by E. coli (SSP1) from 16a; c) (1R, 2S)-16c  produced by E. coli (SST1) from 
16a; d) (1S, 2R)-16c produced by AD-mix-α from 17a (low ee); e) (1R, 2S)-16c produced by AD-mix-
β from 17a (low ee). (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) column, mobile phase 5% IPA: 95% 
n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)  
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Figure S2.17. Chiral HPLC chromatograms of diol 16c (continue). a) racemic 16c (mixture of trans 
and cis); b) (1S, 2S)-16c produced by E. coli (SSP1) from 17a; c) (1R, 2R)-16c  produced by E. coli 
(SST1) from 17a; d) (1S, 2S)-16c produced by AD-mix-α from 16a; e) (1R, 2R)-16c produced by AD-
mix-β from 16a. (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) column, mobile phase 5% IPA: 95% n-



















































































































































Figure S2.18. Chiral HPLC chromatograms of diol 18c. a) racemic 18c (mixture of cis and trans); b) 
trans-18c strandard; c) (1R, 2R)-18c strandard; d) 18c (mixture of cis and trans) produced by styrene 
monooxygenase and undergo autohydrolysis; e) (1R, 2R)-18c produced by E. coli (SSP1); f) (1R, 2R)-
18c  produced by E. coli (SST1). (Daicel Chiralpak OB-H (250 × 4.6 mm, 5µm) column, mobile phase 
10% IPA: 90% n-hexane, flow rate 0.5 mL min−1, oven temperature 25 oC, UV detection at 210 nm)  
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Figure S2.19. Chiral HPLC chromatograms of diol 19c. a) racemic 19c (mainly trans, some cis); b) 
(1R, 2R)-19c strandard; c) (1S, 2S)-19c strandard; d) (1R, 2R)-19c produced by E. coli (SSP1); e) (1R, 
2R)-19c  produced by E. coli (SST1). (Daicel Chiralpak OB-H (250 × 4.6 mm, 5µm) column, mobile 
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Figure S2.20. Chiral HPLC chromatograms of diol 20c. a) racemic 20c; b) (S)-20c produced by E. coli 
(SSP1) (low ee); c) (R)-20c produced by E. coli (SST1); d) (S)-20c produced by AD-mix-α; e) (R)-20c 
produced by AD-mix-β. (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) column, mobile phase 10% IPA: 



































































































































Figure S2.21. Chiral HPLC chromatograms of diol 21c. a) racemic 21c; b) (S)-21c produced by E. coli 
(SSP1); c) (S)-21c produced by E. coli (SST1); d) (S)-21c produced by AD-mix-α; e) (R)-21c produced 
by AD-mix-β. (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)   
 
 




































































































































Figure S2.22. Chiral HPLC chromatograms of diol 22c. a) racemic 22c; b) (S)-22c produced by E. coli 
(SSP1); c) (S)-22c produced by E. coli (SST1); d) (S)-22c produced by AD-mix-α; e) (R)-22c produced 
by AD-mix-β.  (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, mobile phase 10% IPA: 90% n-
hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection at 210 nm)  
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Figure S2.23-S2.32. 1H NMR Spectra and Chiral HPLC Chromatograms of Prepared Diols  
 
Figure S2.23. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (S)-1c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm). 



























Figure S2.24. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (R)-1c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm).  
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Figure S2.25. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (S)-2c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm).  



























Figure S2.26. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (R)-2c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm).  






























Figure S2.27. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (S)-5c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm).  
































Figure S2.28. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (S)-9c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm).  




































Figure S2.29. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (R)-9c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak AS-H (250 × 4.6 mm, 5µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm).  
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Figure S2.30. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (S)-12c. a) 1H 
NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) column, 
mobile phase 10% IPA: 90% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV detection 
at 210 nm. thod C). 




























Figure S2.31. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (1R, 2S)-16c. a) 
1H NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) 
column, mobile phase 5% IPA: 95% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV 
detection at 210 nm).  
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Figure S2.32. 1H NMR spectrum and Chiral HPLC chromatogram of prepared product (1R, 2R)-16c. 
a) 1H NMR (400 MHz, CDCl3, TMS); b) Chiral HPLC (Daicel Chiralpak IA-3 (250 × 4.6 mm, 3µm) 
column, mobile phase 5% IPA: 95% n-hexane, flow rate 1.0 mL min−1, oven temperature 25 oC, UV 
detection at 210 nm).  
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